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Abstract 
Heart failure (HF) is a pernicious medical syndrome which is growing in prevalence as the 
global population ages, while outcomes in acute heart failure (AHF) remain dire, with 
mortality approximating 10-30% at 1-year post hospital admission. Clearly delineating AHF 
subcategories may aid in the assessment and treatment of patients, allowing clinicians to 
better elucidate the underlying mechanisms, whilst better prognostication may help 
physicians to appropriately escalate therapies in AHF. 
This thesis presents data from the Mitral Regurgitation in Acute Heart Failure (MRAHF) 
study. This thesis hypothesised that myocardial deformation imaging in standard clinical 
conditions was both feasible and would demonstrates substantial differences in global 
longitudinal strain and strain rate values between heart failure subcategories, and that a novel 
prognostic tool for AHF could be produced using only data available upon admission.  
When compared to the EuroHeart Survey II (EHSII) cohort, a large prospective observational 
cohort of AHF, the MRAHF cohort is older (79.0 years ± 11.5 versus 69.9 years ± 12.5, 
p<0.00001), with reduced rates of hypertension (55.0% vs 62.5%, p <0.005), ischaemic heart 
disease (37.8% vs 53.6%, p<0.00001) and COPD  (14.3% vs 19.3%, p<0.05), but with 
similar in-hospital mortality outcomes (4.9% vs 6.7%, p<0.15). 
Peak systolic strain (PSS) varied significantly and substantially between the AHF 
subcategories - HFrEF, HFmrEF and HFpEF – in all cardiac regions assessed in the 
echocardiographic 4, 2 and 3 chamber views using standard clinical frame rates. The 
difference was most clearly seen when assessing global longitudinal peak systolic strain 
(GLS) where median GLS was - -6.62% (-4.41 – -8.83), -9.03% (-6.28 – -11.78) and -13.12% 
(-10.02 – -16.22) in HFrEF, HFmrEF and HFpEF respectively, p<0.0001 between all 
subgroups. The above was also seen for peak systolic strain rate (PSSR), where PSSR varied 
substantially and significantly between subcategories in all myocardial regions assessed. This 
difference was most marked for global longitudinal peak systolic strain rate (GLSR);               
-0.48 S-1 (-0.34 – -0.62), -0.66 S-1 (-0.49 – -0.83) and -0.87 S-1 (-0.70 – -1.04) respectively, 
p<0.00001 between all groups. These data demonstrate the feasibility and potential utility of 
stratifying AHF patients according to less load-dependent measures of systolic function such 
as GLS and GLSR. 
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Using demographic and biochemical data collected at the point of patient admission for AHF, 
a prognostic risk scoring system was created using binary logistic regression methods. Each 
variable was assigned one point in the score, and total scores were grouped together to 
produced low risk (0-2) medium risk (3-4) and high risk (≥5) groups. Significantly different 
6-month mortality rates were seen between risk groups - 4.9%, 25.3% and 49.2% 
respectively, p<0.0001. The C-index for this risk score was 0.746 (0.695 – 0.798) indicating a 
test with fair predictive accuracy. 
A further prognostic model was created which included echocardiographic variables. In this 
model age ≥80 was assigned two points due to an odds ratio approximately double that of the 
other variables. All other variables were assigned one point and the total score were grouped 
together to produce low risk (0-3), medium risk (4-5) and high risk (6-10). Significantly 
different 6-month mortality rates were seen between risk groups – 4.7%, 23.7% and 54.2% 
respectively, p<0.0001. The C-index for this risk score was 0.804 (0.758-0.849) indicating a 
test with good predictive accuracy. These data demonstrate the feasibility of producing and 
using such a risk scoring tool at the point of admission to hospital. 
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Original Findings 
This section will outline the original findings of this thesis to demonstrate that the work is 
both substantial and original. 
Chapter two outlines the methods and materials required in the development of, and 
completion of the MRAHF trial, a prospective observational cohort study. This has not 
previously been reported in publication. 
Chapter four reports new findings in relation to global longitudinal strain (GLS) and global 
longitudinal strain rate (GLSR) in acute heart failure (AHF). It demonstrates that statistically 
discriminatory global longitudinal peak systolic strain (PSS) and peak systolic strain rate 
(PSSR) values can be determined in an AHF population in standard clinical settings with 
standard frame rates. It demonstrates that PSS and PSSR values in the three current HF 
subcategories of HF with reduced ejection fraction (HFrEF), HF with mid-range ejection 
fraction (HFmrEF) and HF with preserved ejection fraction (HFpEF) are substantially and 
significantly different. These data are the first reported regarding the discriminatory value of 
GLSR in standard clinical settings, and the first large dataset in AHF reporting GLS and 
GLSR variation between the above subgroups which also includes patients with AHF of an 
ischaemic aetiology. 
In addition, observational data reported in this chapter show that GLS and GLSR values in 
patients recruited in < 2 days from their inpatient admission are statistically similar when 
compared to those recruited ≥ 2 days from their admission date. This is not seen with left 
ventricular ejection fraction (LVEF) which is statistically and quite substantially higher in 
those recruited and assessed in < 2 days compared with those recruited ≥ 2 days after 
admission. These data suggest that GLS and GLSR may be more stable markers of contractile 
function in the acute phase of an admission compared to LVEF. This finding is compatible 
with known data regarding the relative load-independency of GLS and particularly GLSR in 
comparison to LVEF but this has not previously been described in the AHF population. 
Chapter five outlines the production and testing of a novel prognostic tool to be used to 
predict risk of 6-month mortality at admission for patients with AHF. This is produced using 
a binary logistic regression method standardly seen in other commonly used risk-scoring 
algorithms. It is the first risk-scoring tool in AHF that is applicable without recourse to either 
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a computer or online calculator that can offer prognostic information solely with data 
gathered upon admission, thus rendering it easier to use than current prognostic models 
available in AHF. The model is shown to have similar or greater predictive accuracy when 
compared to other commonly applied prognostic models in AHF. 
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Chapter One: Introduction to the literature, current 
understanding and statement of hypotheses 
1.1 Chapter introduction 
This chapter reviews current literature regarding heart failure (HF) and is divided into three 
sections. The first describes the current understanding of the natural history of HF, the second 
describes the and reviews the literature regarding the main foci of this study, novel 
subclassifications of HF and prognostication in HF, while the last identifies the current 
deficits in knowledge and describes the purpose, proposed hypothesis and structure of the 
thesis. 
1.2 Heart Failure  
HF is a complex medical syndrome in which the heart fails to fill at low enough pressures to 
avoid pulmonary congestion and/or fails to provide adequate cardiac output to sustain the 
metabolic requirements of the body.  
Clinically it is defined by the European Society of Cardiology (ESC) as a combination of 
signs and symptoms of HF (see Table 1.1), objective evidence of cardiac dysfunction and, in 
unclear cases, clinical response to standard HF therapy (Ponikowski, P., Voors et al. 2016).   
This clinical syndrome can be caused by a range of underlying pathologies but is typically a 
result of disorders of the pericardium, myocardium, endocardium, heart valves, the great 
vessels or cellular metabolism (Yancy, Jessup et al. 2013). 
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Symptoms Signs 
Typical More Specific 
Breathlessness 
Orthopnoea 
Paroxysmal nocturnal dyspnoea 
Reduced exercise tolerance 
Fatigue 
Ankle swelling 
Elevated jugular venous pressure 
Hepatojugular reflux 
Third heart sound (gallop rhythm) 
Laterally displaced apical impulse 
Less Typical Less Specific 
Nocturnal cough 
Wheezing 
Bloated feeling 
Loss of appetite 
Confusion (particularly in the elderly) 
Depression 
Palpitations 
Dizziness 
Syncope 
Bendopnoea 
Weight gain (>2 kg/week) 
Weight loss (in advanced HF) 
Cachexia 
Cardiac murmur 
Peripheral oedema (ankle, sacral, scrotal) 
Pulmonary crepitations 
Clinical signs of pleural effusion 
Tachycardia 
Irregular pulse 
Tachypnoea 
Cheyne-Stokes respiration 
Hepatomegaly 
Ascites 
Cold extremities 
Oliguria 
Aberrations of pulse pressure 
Table 1.1 – Symptoms and signs typical of heart failure – adapted from 2016 ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure 
(Ponikowski, P., Voors et al. 2016). 
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1.2.1 Subclassification 
HF can be subclassified in a variety of ways. With regards to time course, HF can be 
described either as chronic (CHF) or acute (AHF). The former is often considered 
synonymous with clinically stable disease, while the latter typically refers to episodes where 
there is an exacerbation of HF symptoms which requires either medical attention or hospital 
admission. Use of the term ‘stable’ is not without controversy as clinically stable HF is 
known to progress over time, but it is a term often used to delineate those patients typically 
treated in the community from those requiring acute inpatient or intensive management.  
Episodes of AHF can occur due to either decompensations of known disease or a de novo 
expression of HF. Decompensations of known disease are slightly more common, but in the 
EuroHeart Failure Survey II de novo disease still represented approximately 40% of AHF 
cases (Nieminen, Brutsaert et al. 2006). 
HF can be categorised according to metabolic requirements as either high or low output. 
High-output HF typically refers to conditions in which increased metabolic demand is unable 
to be met by increases in cardiac output, typically diseases such as thyrotoxicosis, sepsis and 
systemic arterio-venous fistulae (Mehta, Dubrey 2009). Therapy in this group is normally 
focussed on amelioration of the underlying pathology (Mehta, Dubrey 2009). In comparison, 
low-output HF occurs when the heart fails to provide adequate metabolic support due to sub-
optimal cardiac output. 
When considering symptomatic severity, the two most commonly used categorisation tools 
are the American College of Cardiology/American Heart Association (ACC/AHA) and New 
York Heart Association (NYHA) classifications. These are commonly used in clinical 
practice as symptomatic severity correlates with patient outcomes (Ammar, Jacobsen et al. 
2007, Ahmed, Aronow et al. 2006, Gradman, Deedwania et al. 1989). 
The NYHA classification of HF has been used since 1928, with multiple subsequent revisions 
and updates (New York Heart Association 1964). The NYHA classification ascribes a 
functional class depending upon the extent to which the patient’s reported symptoms impact 
on functional status. Class I is attributed to patients with minimal symptomatic interference, 
while class IV refers to patients with maximal functional impairment – a more complete 
description can be seen in Table 1.2. 
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The ACC/AHA classification was introduced in 1994 and differs in three main ways from the 
NYHA functional classification. Firstly, it uses information regarding underlying cardiac 
structural abnormalities to discriminate between patients, secondly, it contains a category for 
patients at risk of developing HF, and thirdly patients cannot move backwards through its 
classes if functional status improves, unlike in the NYHA classification. A full description is 
given in Table 1.3. 
NYHA 
Class 
Functional impairment 
I No limitation of physical activity. Ordinary physical activity does not cause 
undue fatigue, palpitations or dyspnoea. 
II Slight limitation of physical activity. Patients are comfortable at rest but 
ordinary levels of physical activity lead to fatigue, palpitations or 
dyspnoea. 
III Marked limitation of physical activity. Patients are comfortable at rest but 
less than ordinary levels of physical activity cause fatigue, palpitations or 
dyspnoea. 
IV Symptomatic at rest. Patients experience fatigue, palpitations or dyspnoea 
in the absence of activity. Patients are unable to perform any physical 
activity without discomfort. If activity is performed, discomfort increases.  
Table 1.2 – New York Heart Association functional classification of heart failure – 
adapted from the NYHA Nomenclature and criteria for diagnosis of disease of the heart 
and blood vessels (New York Heart Association 1964). 
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ACC/AHA 
Class 
Description 
A Patients at high risk of developing HF because of the presence of 
conditions that are strongly associated with the development of HF. 
B Patients who have developed structural heart disease that is strongly 
associated with the development of HF but who have never shown signs or 
symptoms of HF. 
C Patients who have current or prior symptoms of HF associated with 
underlying structural heart disease. 
D Patients with advanced structural heart disease and marked symptoms of 
HF at rest despite maximal medical therapy and who require specialized 
interventions. 
Table 1.3 – ACC/AHA clinical classification of heart failure – adapted from 2013 
ACCF/AHA guidelines for the management of heart failure (Yancy, Jessup et al. 2013). 
 
HF can also be discussed in terms of right ventricular (RV) versus left ventricular (LV) 
failure, related to sub-optimal systolic or diastolic function of the affected side. LV systolic 
function is commonly discussed in terms of LV ejection fraction (LVEF), a parameter 
derived from either echocardiographic or magnetic resonance imaging while RV systolic 
function is difficult to measure in a similar manner given its non-geometric shape. Commonly 
used markers of RV systolic function include fractional area change (RVFAC) and tricuspid 
annular plane systolic excursion (TAPSE) while systolic pulmonary artery pressure (SPAP) is 
an important marker of RV afterload.  
While the LV and RV are distinct in terms of their embryological origins (Anderson, Brown 
et al. 2018), there are similarities in terms of response to adverse loading and failure, with 
foetal gene reactivation seen bilaterally as an adaptive response (Lowes, Minobe et al. 1997, 
Schiano, Vietri et al. 2015). They also demonstrate similar molecular reorganisation in the 
setting of hypertrophy (Unverferth, Fetters et al. 1983), and are functionally interdependent; 
they share myocardial fibres which encircle both ventricles, share the pericardial space and 
alteration in contractility of either ventricle markedly affects the function of the other 
(Friedberg, Redington 2014). Given the interdependence, it is perhaps not 
pathophysiologically accurate to discuss failure in terms of unilaterality due to the extent to 
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which each ventricle affects contralateral function, and thus global output (Friedberg, 
Redington 2014).  
They are also markedly different in terms of morphology, where there are differences in the 
macro and micro architectures of the left and right ventricles. The LV is substantially thicker 
with myocyte and myofibril orientation changing at different depths within the ventricular 
wall. In comparison, the right ventricle is much thinner and has a largely trabeculated apex, 
better adapted to deal with increases in volume than increases in pressure. The difference in 
muscle density is an adaptation to account for the different pressures against which the two 
ventricles must generate force, substantially lower in the pulmonary circulation compared to 
the systemic circulation (Scatteia, Baritussio et al. 2017).  
The LV approximates a conical shape that is classically described as having three layers; the 
subendocardium, the mid-wall and subepicardium. The subepicardium consists of myocytes 
organised in a left-handed helix which ultimately allows for torsion of the cardiac apex 
relative to the base. The mid-wall region contains largely circumferential myocytes which 
allow for contraction in radial direction. The subendocardium contains fibres organised in a 
right-handed helix as well as longitudinal fibres. While these layers are described here as 
distinct, myocytes are largely similarly oriented to their neighbours and there is a gradual, 
rather than abrupt change in fibre direction between the three layers described above. These 
differently arranged fibres allow for deformation in longitudinal, circumferential and radial 
planes as well as causing torsion of the myocardium. Due to the larger radius of rotation of 
the subepicardium it provides greater torque than the subendocardium thus the rotation of the 
subepicardium is significantly expressed (Nakatani 2011). 
Below the macro-architecture, the myocytes are arranged into sheetlets. These banks of 
sheetlets are arranged obliquely to the plane of the local wall and are able to change their 
angle during the cardiac cycle  (Nielles-Vallespin, Khalique et al. 2017). This helps to 
significantly enhance localised contraction; ultimately the individual myocytes shorten by 
approximately 15% but the LV wall thickens radially by approximately 30-50%. It is thought 
that the substantial disparity demonstrated above is largely accounted for by myocyte sheetlet 
reorientation (Ghonim, Voges et al. 2017). 
In comparison to the relatively simple shape of the LV, the crescenteric RV wraps around the 
LV. In comparison to the thicker LV, the RV free wall is relatively thin except at the 
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interventricular septum where there is marked ventricular interdependence as described above 
due to sharing of subendocardial fibres in the septum. The interventricular septum contains 
helical fibres but this is the only section of the RV to do so, with longitudinal fibres 
predominating throughout the rest of the RV. As a result, contraction of the RV occurs 
primarily due to long-axis shortening as opposed to the helical twisting of the LV (Buckberg, 
Hoffman 2014). In the RV free wall myocardial fibre orientation is longitudinal in the 
endocardial layer and circumferential in the epicardium. Due to its relatively thin wall the RV 
is not considered to have a middle layer unlike the LV except in the right ventricular outflow 
tract (Ozawa, Funabashi et al. 2016).  
The terms ‘Right’ and ‘Left’ heart failure are often used to describe a particular pattern of 
symptoms which are typically ascribed to the dysfunction of each ventricle (see Table 1.4).  
‘Right-sided’ Heart Failure ‘Left-sided’ Heart Failure 
Symptoms 
Peripheral Oedema 
Abdominal Swelling 
Weight gain 
Fatigue 
Symptoms 
Dyspnoea 
Cough 
Pink frothy sputum 
Orthopnoea 
Paroxysmal Nocturnal Dyspnoea 
Signs 
Ascites 
Hepatomegaly 
Hepatic dysfunction – jaundice, 
coagulopathy, gynaecomastia 
Parasternal Heave 
Distended jugular vein 
Signs 
Rales 
Laterally displaced apex beat 
Cyanosis 
Table 1.4 – Signs & symptoms classically attributed to 'right sided’ versus ‘left sided’ heart 
failure (Field, Kudenchuk et al. 2012). 
 
Acute decompensations can be classified using the Forrester haemodynamic subsets (see 
Table 1.5), using intra-cardiac measurements to obtain pulmonary capillary wedge pressure 
(PCWP) and derive the Cardiac Index (CI) (Forrester, Diamond et al. 1976). These correlate 
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with typical clinical pictures as described in Table 1.5. These subclassifications are important 
given that ‘cold and wet’ patients have significantly raised mortality compared to other 
groups, and that these classifications improve the ability to prognosticate, even more than 
NYHA status (Nohria, Mielniczuk et al. 2005). 
Forrester Haemodynamic Subsets 
Subset Description 
I - Warm and Dry (normal) PCWP 15-18 mmHg and CI >2.2 L/min/m2 
II - Warm and Wet (congested) PCWP >18 mmHg and CI >2.2 L/min/m2 
III - Cold and Dry (hypoperfused) PCWP 15-18 mmHg and CI <2.2 L/min/m2 
IV - Cold and Wet (congested and 
hypoperfused) 
PCWP >18 mmHg and CI <2.2 L/min/m2 
Table 1.5 – Forrester Haemodynamic Subsets of heart failure – adapted from Acute 
Decompensated Heart Failure (Galdo, Riggs et al. 2013) CI – Cardiac index, PCWP – 
Pulmonary capillary wedge pressure. 
 
Current consensus guidelines largely subcategorise HF according to LV systolic function. 
Varied definitions of impaired systolic function exist, but the categories used are typically 
defined in terms of LVEF which describes the proportion of blood pumped from the LV in 
each cardiac cycle.  
Lower limits for normal, or ‘preserved’ LVEF have been proposed at 35% (Heart Failure 
Society of America 2010), 40% (McMurray, John JV, Adamopoulos et al. 2012) and, more 
recently 50% (Ponikowski, P., Voors et al. 2016). The selection of these values as categories 
denoting distinct pathology is relatively arbitrary as they are derived from the selection 
criteria of major interventional studies rather than specific pathophysiological criteria (Merit-
HF Study Group 1999, Poole-Wilson 1999, Packer, M., Fowler et al. 2002, Packer, Milton, 
Bristow et al. 1996, SOLVD Investigators* 1991). There are, however, consistent data 
available that patients with lower LVEF values fare worse than matched cohorts with higher 
LVEF in the context of a range of cardiovascular diseases including coronary arterial disease 
(Yeboah, Rodriguez et al. 2016), sudden death post myocardial infarction (Schulze Jr, Strauss 
et al. 1977, Ayesta, Martinez-Selles et al. 2018, Wellens, Schwartz et al. 2014) and HF 
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(Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) 2011, Vasan, Larson et al. 
1999),  
Rather than define a specific disease, these LVEF values have historically helped label a 
syndrome that can be ameliorated with pharmacological interventions. The failure of these 
therapies to ameliorate the course of disease in HF with EF >40% has led to suspicion that 
HF with preserved ejection fraction (HFpEF) represents an alternate underlying pathology 
and phenotype, borne out by significant differences between the groups in terms of response 
to therapy, but also demographics, comorbidities and cardiac geometry (Butler, Fonarow et 
al. 2014).  
Originally HF was only considered in patients with reductions in systolic function, though as 
early as1984 there was recognition of a HF syndrome with preserved markers of systolic 
function and evidence of diastolic abnormalities (Dougherty, Naccarelli et al. 1984). Until the 
mid-2010s patients have been commonly categorised as either HF with reduced ejection 
fraction (HFrEF) when LVEF is <50% or HFpEF when LVEF is ≥50%. Recently the 
ACC/AHA, and subsequently the ESC guidelines, introduced the novel intermediate category 
of HF with borderline ejection fraction and mid-range ejection fraction (HFmrEF) 
respectively, both describing a subgroup in whom LVEF is measured at 40-49% (Yancy, 
Jessup et al. 2013). To accommodate this extra group, the new criteria have reclassified 
HFrEF as LVEF <40% in both guidelines.  
The nature and validity of this new subgroup remains unclear. As described above, HFrEF 
and HFpEF patients have such clearly different demographics, underlying aetiologies, 
comorbidity profiles, ventricular remodelling patterns and response to therapies that it is clear 
that these represent two separate pathways which lead to a similar clinical syndrome, 
however data regarding the nature of the HFmrEF have not been so unequivocal.   
Re-examination of registry information and previous clinical trials has suggested that 
HFmrEF represents a substantial subgroup of patients, somewhere between 14-18% 
(Rickenbacher, Kaufmann, Maeder, Bernheim, Goetschalckx, Pfister, Pfisterer, Brunner‐La 
Rocca et al. 2017). Patients with HFmrEF are more typically female and older which is more 
consistent with the HFpEF cohort (Toma, Ezekowitz et al. 2014, Steinberg, Zhao et al. 2012), 
while their underlying aetiology is more commonly ischaemic which is comparable to the 
HFrEF cohort (Solomon, SD 2005, Rickenbacher, Kaufmann, Maeder, Bernheim, 
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Goetschalckx, Pfister, Pfisterer, Brunner‐La Rocca et al. 2017). In terms of ventricular 
remodelling, HFmrEF is commonly reported as demonstrating intermediate myocardial mass 
and phenotypically intermediate between the typical concentric remodelling seen in HFpEF 
and the eccentric hypertrophy seen in HFrEF (Rickenbacher, Kaufmann, Maeder, Bernheim, 
Goetschalckx, Pfister, Pfisterer, Brunner‐La Rocca et al. 2017, Pascual-Figal, Ferrero-
Gregori et al. 2017). As has been previously shown HFpEF has similarly deleterious but 
slightly improved mortality outcomes compared to HFrEF (Gottdiener, McClelland et al. 
2002). HFmrEF has been shown to act correspondingly with similar rates of survival, 
rehospitalisation and HF rehospitalisation to HFpEF (Lam, Gamble et al. 2018). As yet there 
is little data regarding the effect of treatment options on HFmrEF as will be discussed later 
but retrospective analysis of the CHARM-Preserved and TOPCAT studies suggest HFmrEF 
may benefit from similar treatment pathways (Pitt, Pfeffer et al. 2014, Yusuf, Pfeffer et al. 
2003), however these analyses are limited by the typical confounders of retrospective 
analysis and new RCTs focussing specifically on the HFmrEF subgroup are awaited. 
Some groups have postulated that it is an overlap phase prior to transition to HFrEF or 
HFpEF, indeed in one study 35% patients with HFmrEF were shown to transition to HFmrEF 
and HFpEF in an almost 1:1 ratio over 3 years of follow-up (Webb, Draper et al. 2018). The 
fact that patients can transition both ways suggests notable heterogeneity within the group. 
Others have focussed on the similarities in terms of typical aetiology and ischaemic burden in 
both HFrEF and HFmrEF, hypothesising that HFmrEF is an early or transition stage in 
HFrEF (Lam, Solomon 2014). 
The true nature of HFmrEF remains unclear. It does appear to be distinct in certain variables 
from HFrEF and HFpEF, acting differently enough from both to be clearly included in either. 
In fact, the paradigm of HF as defined by LVEF may be unhelpful in the long term, but what 
is clear is that further information regarding what is currently classified as HFmrEF will 
likely help us to understand and treat the underlying pathophysiology, and that further efforts 
to elucidate the underlying group characteristics and pathological mechanisms of the 
syndrome are both useful and necessary.  
1.2.2 Pathophysiology  
The symptomatic and pathological sequelae of heart failure arise either from a reduction in 
cardiac output leading to a failure to adequately provide metabolically active tissues with 
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required substrates for metabolism, or from congestion of the pulmonary vasculature as a 
result of impaired diastolic relaxation. 
Cardiac output (CO) per minute is defined as: 
Heart rate (HR) x stroke volume (SV) 
Any factor negatively affecting either of the above will diminish CO, leading to reduction of 
tissue perfusion and thus metabolic support for active tissues. SV can also be affected by a 
decrease or persistent excess of preload, decrease in effective contractility or increase in 
afterload, all of which lead to a consequent fall in CO.  
The body has several intrinsic compensatory mechanisms to counter reductions in cardiac 
output which include cardiac remodelling, the Frank-Starling mechanism and neurohormonal 
activation (Mann, Douglas L., Bristow 2005, LaCombe, Basit et al. 2019). 
Cardiac remodelling occurs due to abnormalities in ventricular loading. In HF ventricular 
pressures are typically raised, either due to impaired ejection fraction and increased volume 
loading, or due to failure of myocardial relaxation and increased ventricular pressure loading. 
In the setting of persistent raised ventricular wall stress, the cardiac myocytes hypertrophy as 
part of their adaptive physiological response (Heusch, Libby et al. 2014).  According to the 
Laplace-Young relationship, myocardial oxygen requirements are proportional to wall 
tension so when cardiac wall thickness increases due to hypertrophy and cavity radius is 
reduced, wall tension falls and myocardial oxygen demand is decreased. 
Persistent supraphysiological preload leads to dilation of the ventricle, causing a transition 
from a small hyperkinetic ventricle to a large compliant ventricle capable of producing large 
stroke volumes (Gaasch, Meyer 2008). Pressure stimulates dissolution of extramyocardial 
structural collagen via fibroblast activation, which allows rearrangement of myofibrils and 
chamber enlargement to accommodate for a larger fluid volume. This causes myocytes to 
increase in length but allows sarcomere length to return to normal from their distended state 
(Gaasch, Meyer 2008). This normalises contractility and thus physiological contractile 
reserve. Systolic wall stress returns to baseline, with normal preload, afterload and LVEF 
while stroke volume increases due to the large end-diastolic volume. Eventually this process 
becomes maladaptive; fibroblast proliferation, oxidative stress and extracellular matrix 
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deposition leads to apoptosis and fibrosis within the myocardium (Mentz, O'connor 2016), 
but the manner and timing of this transition is still poorly understood. 
The Frank-Starling Mechanism describes the process by which an increase in preload leads to 
increased myocardial contractility. Excess myocardial stretch leads to increased calcium 
sensitivity of myofibrils which increases actin-myosin cross bridge formation (Klabunde 
2011). The increased stretch also distends the sarcomere. Maximal sarcomeric force is 
generated at a sarcomere length of 2.2 μm; sarcomeric length under this figure (or 
theoretically over) leads to diminution of potential contractile force (Sonnenblick, Spiro et al. 
1963). This relationship is outlined in Figure 1.1 and is demonstrated by the theoretically 
parabolic nature of the length-force curves.  
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The sympathetic nervous system plays a vital role in control of cardiovascular output and 
helps to regulate cardiac rate, myocardial contractility and peripheral resistance while the 
parasympathetic system acts as a counterbalance through stimulation of the vagus nerve.  
One of the most effective mechanisms to improve cardiac output is to increase heart rate, as 
is seen during exercise.  
Reduction in cardiac output and subsequent reduction in aortic and carotid baroreceptor 
pressure leads to subsequent upregulation of the sympathetic response to improve systemic 
perfusion pressures. Peripheral beta-1 stimulation leads to activation of the renin-angiotensin-
aldosterone system (RAAS) which causes vasoconstriction and sodium retention with 
Figure 1.1 – The Frank-Starling relationship – Ventricular 
performance compared against ventricular end diastolic volume 
(EDV). 1 = Normal-rest; 2 = Normal-exercise; 3 = Heart failure-exercise; 
3’ = Heart failure; 4 = Fatal myocardial depression; A = normal at rest; 
B = normal walking; C = normal maximal exercise; D = heart failure at 
rest; E = heart failure while walking. The dashed lines are the descending 
limbs of the ventricular performance curves, which are rarely seen during 
life but show the level of ventricular performance if EDV could be 
elevated to very high levels. Taken from Harrison’s Principles of Internal 
Medicine (Fauci 1998). 
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subsequent osmolar pressure to retain water, all leading to an increase in mean arterial 
pressure (MAP). This initially compensatory mechanism becomes maladaptive over time but 
in a manner and rate which is not well delineated.  
Animal models have shown that when this response is prolonged it leads to apoptosis via the 
protein kinase A pathway (Communal, Singh et al. 1998) and induces isolated myocardial 
increases in levels of tumour necrosis factor alpha, interleukin 1-beta and interleukin-6 
(Murray, Prabhu et al. 2000). It also leads to a reduction in beta-1 receptor density and 
uncouples the beta-2 receptors from their downstream effector molecules. This pathway 
normally increases calcium influx leading to an increase in myocardial contractility and when 
affected pathologically this response is attenuated (Houser, Margulies 2003). These pathways 
contribute to the pathogenesis of heart failure and to pathological remodelling (Triposkiadis, 
Karayannis et al. 2009). 
The biochemical pathways described above are now routine targets for pharmacological 
agents used to preventing maladaptive remodelling; beta blockers (BB), angiotensin 
converting enzyme inhibitors (ACEi) and aldosterone inhibitors are now the mainstay of 
contemporary medical therapy in HF. These will be discussed in greater depth later in this 
chapter. 
1.2.3 Diagnosis 
The process by which HF is diagnosed has changed in accordance with the understanding of 
the disease. In with the absence of proven biomarkers and widespread access to 
echocardiography, the researchers from the Framingham study provided the first agreed 
clinical criteria for a HF diagnosis with minor and major criteria from clinical examination 
and history combined to form a diagnosis (McKee, Castelli et al. 1971). 
The Boston points-scoring criteria subsequently included chest radiography alongside the 
clinical assessment (Carlson, K. J., Lee et al. 1985), while later research studies included 
echocardiographic data as access to echocardiography became more widely available 
(Bangdiwala, Weiner et al. 1992). 
Current ESC and AHA guidelines recommend a combination of clinical history, 
biochemistry, electrocardiographic data and echocardiographic imaging to confirm or refute a 
diagnosis (Ponikowski, P., Voors et al. 2016). 
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Common signs and symptoms that raise clinical suspicion of HF have already been described 
in Table 1.1, the confirmatory tools required for the diagnosis of HF will be outlined below. 
1.2.3.1 Biochemistry 
Biochemical assessment of HF was revolutionised with the discovery of circulating 
natriuretic peptides (NP) (Sudoh, Kangawa et al. 1988, De Bold, Borenstein et al. 1981)and 
subsequent research into their potential utility in HF diagnosis (de Lemos, McGuire et al. 
2003).  Circulating A-type (ANP), B-type (BNP) and C-type (CNP) natriuretic peptides are 
primarily produced by the heart in response to increased myocardial stretch due to either 
volume or pressure overloading. Physiologically they cause a variety of effects within the 
renal, adrenal, cardiac and vascular tissues including decreased sodium reabsorption (Kalra, 
Anker et al. 2001), increased natriuresis (Kalra, Anker et al. 2001), reduced aldosterone 
secretion (Yoshimura, Yasue et al. 2001), increased release of cyclic guanosine 
monophosphate (GMP) and thus vascular dilation (Yoshimura, Yasue et al. 2001), while 
absence of NPs leads to cardiac fibrosis in experimental models (Tamura, Ogawa et al. 2000). 
These effects combine to reduce cardiac stress and aid return to normal haemodynamics. 
ANP and BNP levels have been well established as correlating with mortality and inversely 
correlating with LVEF (Harrison, Morrison et al. 2002, Koglin, Pehlivanli et al. 2001, 
Menezes Falcão, Pinto et al. 2004), as well correlating with clinical response to 
pharmacotherapy (Troughton, RW, Yandle et al. 2000, Richards, Doughty et al. 1999, 
Magnussen, Blankenberg 2018). Meta analyses have demonstrated the superiority of BNP 
versus ANP as a diagnostic tool (Doust, Glasziou et al. 2004), and BNP is now routinely used 
as a ‘rule out’ test, given its high negative predictive value (NPV). The ESC guidelines 
suggest a rule out diagnostic value of <100 pg/ml in the acute setting for which the NPV is 
94-98% (Ponikowski, P., Voors et al. 2016), while ACC/AHA guidelines also recommend 
the use of BNP but do not suggest particular discriminatory values (Yancy, Jessup et al. 
2013). 
N terminal pro-BNP (NT pro-BNP) is the aminoterminal portion of pro-BNP and has a longer 
circulating half-life than BNP with similar diagnostic and prognostic value to BNP (Mueller, 
Gegenhuber et al. 2005, Linssen, Jaarsma et al. 2018). The structure and production of both 
BNP and NT-pro BNP are outlined in Figure 1.2. 
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Both assays have been recommended as part of the screening process for patients with 
potential HF, however recent pharmacological developments may lead to increased use of 
NT-pro-BNP. Sacubitril-Valsartan is a novel angiotensin-receptor neprolysin inhibitor 
(ARNI) which has recently been shown to be superior to ACEi therapy (McMurray, John JV, 
Packer et al. 2014) and its use has been included in the 2016 ESC HF guidelines 
(Ponikowski, P., Voors et al. 2016). Its mechanism of action leads to decreased degradation 
of circulating BNP, ameliorating its physiological effect. This consequently has implications 
for the use of BNP as a diagnostic tool and for BNP-guided titration of therapy. The 
PARADIGM-HF trial demonstrated raised circulating BNP and cGMP levels in the 
Sacubitril-Valsartan treatment arm (McMurray, John JV, Packer et al. 2014), while NT-pro 
BNP levels were reduced, a finding mirrored in the PARAMOUNT trial (Solomon, Scott D., 
Zile et al. 2012). Use of BNP as a diagnostic or prognostic marker appears of diminished 
value in patients treated with ARNIs due to its pharmacodynamics, and a shift may be seen in 
either the current diagnostic screening levels or an increased use of NT-pro BNP given that it 
is not similarly affected. 
Figure 1.2 – Diagram illustrating the conversion of Pro-BNP to BNP and NT-pro-
BNP via the action of the enzyme Corin. Taken from B-type natriuretic peptides and 
echocardiographic measures of cardiac structure and function (Troughton, Richard W., 
Richards 2009). 
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Primary amongst other potential biochemical markers is suppression of tumorigenicity factor 
2 (ST2) - a member of the interleukin-1 receptor family with soluble and ligand isoforms. 
These are upregulated when cardiac myocytes are strained, leading to transduction of the 
antifibrotic and antihypertrophic effects of interleukin-33. Several studies have demonstrated 
their potential use as a diagnostic aid, though it is often noted that NT-pro BNP levels are a 
better diagnostic discriminator than ST2 levels, primarily due to the lack of specificity 
(Januzzi, James L., Peacock et al. 2007, Dieplinger, Mueller 2015). Januzzi et al. 
demonstrated that ST2 was a stronger prognostic marker than NT-pro-BNP at 1 and 4 years 
(Januzzi, J. L.,Jr, Rehman et al. 2010), and is equally prognostic in both HFpEF and HFrEF 
(Manzano-Fernández, Mueller et al. 2011). Not only is it strongly prognostic, but Pascual-
Figal et al. demonstrated that ST2 was a stronger classifier of mortality risk than other 
markers including BNP, NT-pro BNP and CRP (Pascual‐Figal, Manzano‐Fernández et al. 
2011). Serial measurement of ST2 has been shown to identify decompensated HF patients at 
risk of mortality, transplantation and hospitalisation (Manzano-Fernandez, Januzzi et al. 
2012) as well as act as a strong prognosticator in chronic HF (Anand, Rector et al. 2014). 
Much like BNP and NT-pro BNP, levels of ST2 have been shown to reduce with optimal 
medical therapy, while it has been suggested that raised ST2 levels may predict implantation 
of defibrillators and sudden death in HF (Pascual-Figal, Ordoñez-Llanos et al. 2009), as well 
as identifying patients most likely to benefit from aldosterone antagonists (Weir, Miller et al. 
2010). 
ST2 is now in recommended for use in risk stratification and prognostication by the 
ACC/AHA for both chronic and decompensated heart failure, and it appears likely that its use 
may become more widespread.  
Markers of myocardial damage, structural remodelling and oxidative stress have also been 
investigated for utility in HF diagnosis and prognostication but are currently used primarily in 
research (Takeishi 2014). BNP and its precursor NT-pro-BNP remain the most common 
biochemical diagnostic tool in the field of HF, but as suggested there may be increased use of 
ST2 in the future. 
1.2.3.2 Electrocardiography 
The 2016 ESC guidelines reference the electrocardiogram (ECG) as one of its essential initial 
investigations in the diagnosis of HF. A normal ECG can rule out HFrEF with 89% 
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sensitivity (Mant, Doust et al. 2009) and in patients with suspected HF the ECG can be 
particularly useful when considering the underlying aetiology of HF, for example the typical 
changes ST segment and T wave changes seen in ischaemic heart disease, or the evidence of 
a cardiac arrhythmia.  
Notably there is little to no data regarding the utility of ECGs in diagnosis of HFpEF or 
HFmrEF. Consensus statements suggest the use of ECG to aid diagnosis (Paulus, Tschope et 
al. 2007), while some data suggest more consistent appearance of ECG abnormalities such as 
left ventricular hypertrophy (McMurray, John JV, Carson et al. 2008), but there are little data 
which guide the clinician as to sensitivity or specificity in this patient group. 
The ESC guidelines also note that generalised ECG abnormalities show understandably low 
specificity (Thomas, Kelly et al. 2002, Davie, Francis et al. 1996, Kelder, Cramer et al. 
2011), but given its sensitivity and negative predictive value for HFrEF it remains a logical 
first-line test, and was a particularly useful discriminator for the necessity of an 
echocardiogram prior to the discovery of serum biomarkers. 
1.2.3.3 Chest X-ray 
In suspected HF patients, performing and assessing x-ray imaging of the chest is recognised 
as a useful test given that the largest proportion of HF patients presenting to hospital do so 
with signs and symptoms of systemic overload. In this setting a chest x-ray is particularly 
useful to rule out other causes of breathlessness (Ponikowski, Piotr, Jankowska 2015). 
Classical features of HF on chest X-ray include cephalization (the rostral diversion of blood 
within the lungs), interstitial oedema, costophrenic angle blunting and cardiomegaly 
(Radiology Masterclass , Fonseca, Mota et al. 2004) – the latter of which is defined as a 
cardiothoracic ratio in excess of 0.5 on a posterior-anterior chest radiograph (Gaillard 2015). 
Interstitial oedema can also be seen in acute respiratory distress syndrome (ARDS) which can 
cause diagnostic uncertainty. Features which are known to aid the clinician in distinguishing 
underlying aetiology are shown below in Table 1.6 and typical features of heart failure on 
chest X-ray can be seen in Figure 1.3. 
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 Cardiac Cause ARDS 
Heart Size Enlarged Normal 
Vascular Pedicle Normal or enlarged Normal or reduced 
Pulmonary blood flow 
distribution 
Inverted Balanced 
Peribronchial cuffs Common Not common 
Regional distribution 
of lung oedema 
Even Peripheral/Patchy 
Air bronchograms Not common Very common 
Pleural effusions Very common Not common 
Table 1.6 – Features aiding discrimination between Cardiac interstitial oedema and 
ARDS – Adapted from The radiologic distinction of cardiogenic and non-cardiogenic 
oedema (Milne, Pistolesi et al. 1985). 
 
Figure 1.3 – Chest radiograph demonstrating typical features of cardiac 
pulmonary congestion. This includes an enlarged cardiac shadow, enlarged 
vascular pedicle, inverted pulmonary blood distribution, peribronchial cuffing 
and small bilateral pleural effusions.  
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1.2.3.4 Echocardiography 
Transthoracic echocardiography (TTE) has developed from a tool that was able to indistinctly 
image the walls of the atria and ventricles as flat lines on an oscilloscope (Hertz, Edler 1954), 
to become the cornerstone of structural cardiology, able to create live three-dimensional 
images of the heart. It is the essential confirmatory tool in HF, being simultaneously portable, 
essentially devoid of risk to the patient and more widely available than other imaging 
modalities such as magnetic resonance imaging (MRI). TTE provides useful data regarding 
cardiac structure and function in almost all patients and is routinely preferred to 
transoesophageal echocardiography in part due to the risks inherent to the pharmacological 
sedation which is often required.  
Diagnosis of HF is made by assessing left ventricular systolic and diastolic function, as well 
as right ventricular function and pulmonary artery pressures. TTE enables assessment of 
haemodynamics and consideration of underlying aetiology and is able to detect valvular 
abnormalities, regional wall motion abnormalities and evidence of other specific pathologies. 
It is markedly inferior to MRI in terms of tissue characterisation but is the reference standard 
for diagnosis and assessment of heart failure. 
As noted earlier, one of the major criteria for diagnosing HF is based upon LVEF. This can 
be estimated visually but is typically prone to error in patients with abnormal ventricular 
geometry or extremes of ventricular size (Marwick 2015). To assess LVEF quantitatively, 
accurate volume measurements are required of the left ventricle in end systole and end 
diastole. Typically, these are measured using two separate planes, apical four chamber and 
apical two chamber views, from which volumes can be derived using different calculations, 
the most common of which is the biplane method of disks, frequently referred to as 
Simpson’s rule (Otto 2013). 
End diastolic volume (EDV) – end systolic volume (ESV) is equal to SV, which when 
divided by EDV is equal to the proportion of intracavity blood pumped out per cycle, termed 
the ejection fraction (EF). This can be mathematically represented thus: 𝐸𝐹 =  
𝐸𝐷𝑉−𝐸𝑆𝑉
𝐸𝐷𝑉
 
Diagnosis of HFmrEF or HFpEF requires evidence of relevant structural disease or diastolic 
dysfunction. This can be readily seen on echocardiography, for example using measurement 
of myocardial wall thickness using echocardiographic M-mode, demonstration of valvular 
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pathology on Doppler tracing or pericardial abnormalities again detectable both on 2-
dimensional imaging and changes to movements of the right ventricular wall. Evidence of 
increased atrial area can be demonstrated through increased atrial size on M-mode or via 
border tracing performed in apical 4 chamber view. 
Diagnosis of diastolic dysfunction in the setting of normal LVEF can be difficult and is often 
complicated by the alteration to normal physiology which occurs with aging; slowing of LV 
relaxation is particularly common with age which must be considered when interpreting the 
data.  
Multiple quantitative parameters can be used in assessing diastolic function, including, but 
not limited to, mitral inflow Doppler traces in early diastole (E) and in atrial contraction (A), 
pulmonary venous flow, mitral annular tissue Doppler velocities (e’), tricuspid regurgitation 
velocity and left atrial volume. 
The detailed measurements of diastolic function are beyond the scope of this project but 
Figure 1.4 outlines the components of a standard quantitative assessment of diastolic function 
as required by the joint American Society of Echocardiography (ASE) and European 
Association of Cardiovascular Imaging (EASCVI) guidelines for diagnosis and quantification 
of severity of diastolic dysfunction. 
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Figure 1.4 – Flow diagram for diagnosis and grading of diastolic dysfunction - taken 
from ASE/EASCVI recommendation for grading of severity of diastolic 
dysfunction(Nagueh, Smiseth et al. 2016). (A) Algorithm for diagnosis of LV diastolic 
dysfunction in subjects with normal LVEF. (B) Algorithm for estimation of LV filling 
pressures and grading LV diastolic function.  in patients with depressed LVEFs and 
patients with myocardial disease and normal LVEF after consideration of clinical and 
other 2D data. 
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As outlined below in Table 1.7, typical signs and symptoms plus evidence of a reduced 
LVEF allow the physician to diagnose HFrEF, while the combination of clinical signs and 
symptoms, biochemical evidence and diastolic or structural abnormalities allows a physician 
to make the diagnosis of HFmrEF or HFpEF.  
Type of 
HF 
HFrEF HFmrEF/borderline HFpEF 
C
r
it
e
r
ia
 
1 Symptoms ± Signs 
(as per Table 1.1) 
Symptoms ± Signs (as per 
Table 1.1) 
Symptoms ± Signs (as per 
Table 1.1) 
2 Left Ventricular 
Ejection Fraction 
<40% 
Left Ventricular Ejection 
Fraction 40-49% 
Left Ventricular Ejection 
Fraction ≥50% 
3  1. Elevated levels of 
natriuretic peptide 
2. At least one of either 
relevant structural heart 
disease (left ventricular 
hypertrophy and/or left 
atrial enlargement) or 
diastolic dysfunction 
1. Elevated levels of 
natriuretic peptide 
2. At least one of either 
relevant structural 
heart disease (left 
ventricular 
hypertrophy and/or 
left atrial 
enlargement) or 
diastolic dysfunction 
Table 1.7 – ESC guideline diagnostic criteria for heart failure – adapted from 2016 ESC 
guidelines for the diagnosis and treatment of acute and chronic heart failure (Ponikowski, P., 
Voors et al. 2016). 
 
When considering how intrinsically variable the measurement of LVEF is, categorising HF as 
described above becomes an immediate problem. 2-dimensional TTE is the most widely 
available diagnostic tool for calculating LVEF, but quantitative analysis is hugely dependent 
upon the acquisition of adequate acoustic windows and operator technique. Variations in 
these can lead to significant inter- and intra-observer variability of >10% (Jacobs, Salgo et al. 
2005, Malm, Frigstad et al. 2004, Bellenger, Burgess et al. 2000, Pellikka, She et al. 2018). 
Given that 10% encompasses the entire range of the HFmrEF category, accurate 
categorisation becomes inherently difficult. In addition, due to acquisition technique and 
geometric assumptions there are significant discrepancies in measurement of ventricular 
volumes when compared to volumetric techniques employed in either MRI or 3-dimensional 
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echocardiography (Mistry, Halvorsen et al. 2010, Gouda, AbdelWahab et al. 2015, Foley, 
Mankad et al. 2012, Pellikka, She et al. 2018).   
Even if imaging modalities were perfect and were affected by only minimal inter- or intra-
observer variability, LVEF is a dynamic measurement; LVEF varies considerably according 
to contemporaneous haemodynamic conditions, be it due to alterations in preload or afterload 
(Silke, Verma et al. 1985, Berko, Gaasch et al. 1987, Gaasch, Meyer 2008) or alterations to 
inotropy (Horn, Teichholz et al. 1974, Lim, S. L., Lam et al. 2015). Small variations in the 
time from admission to echocardiography, experience of the sonographer or quality of the 
sonography equipment can lead to significant differences in LVEF measurements and thus 
patient subcategorisation. As a result, there has been much interest in markers of ventricular 
contractile function which are more in (Silke, Verma et al. 1985)dependent of haemodynamic 
state such as strain rate imaging. Indeed, studies using myocardial deformation imaging have 
suggested the existence of contractile abnormalities not previously detected when using 
LVEF as the sole quantitative marker (Kraigher-Krainer, Shah et al. 2014). Interestingly, 
there are little to no data that describe the differences between HF subcategories in terms of 
myocardial deformation imaging parameters.  
1.2.3.4.1 Myocardial deformation imaging 
Myocardial deformation imaging refers to strain and strain rate of the myocardium – the 
former describes 3-dimensional deformation of a cube of myocardium in relation to its 
original shape, while the latter describes the velocity at which this occurs.  
Strain (Ɛ) can be described thus: 
Ԑ =  
𝐿 − 𝐿𝑥
𝐿𝑥
 
where L is the length of the object after deformation and Lx is the original length. This is a 
dimensionless quantity as it is defined relative to its original length and is often denoted in 
percent. By convention, negative strain standardly refers to shortening while positive strain 
denotes lengthening relative to original length (Weidemann, Kowalski et al. 2001). 
Strain rate refers to the speed at which this deformation occurs and is denoted by the symbol 
έ and units are described as s-1. 
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Both strain and strain rate have been demonstrated to correlate significantly with contractile 
function.  Initially there was concern that myocardial deformation values were markedly 
influenced LV size, hypertrophy and haemodynamic loading conditions, however, 
experimental models have demonstrated that, while strain remains relatively load-dependent 
(Yingchoncharoen, Agarwal et al. 2013), strain rate is not (Ferferieva, Van den Bergh et al. 
2011), and experimental studies have demonstrated a correlation between strain rate and 
intrinsic cardiac contractile function (Schlangen, Petko et al. 2014, Dahle, Stangeland et al. 
2016, Abraham, Laskowski et al. 2003, Greenberg, Firstenberg et al. 2002). As such, 
assessing myocardial deformation parameters may allow us to potentially make more precise 
conclusions regarding overall systolic function as well as intrinsic cardiac contractility.   
Myocardial deformation assessment was initially developed using colour-doppler 
echocardiography and validated as a tool using in-vitro cardiac phantoms and 
sonomicrometry; measuring the distance between surgically-implanted intracardiac 
piezoelectric crystals and the displacement and rate of displacement of these crystals allowed 
conclusions to be drawn regarding deformation of the myocardial tissues. Whilst a useful 
initial step, tissue doppler imaging was time-consuming to analyse, modestly robust and 
reproducible and has significant accuracy concerns regarding frame rate and angle 
dependency (Blessberger, Binder 2010). 
Myocardial deformation assessment has potential benefits of assessing regional rather than 
global function in addition to the theoretical reduction in the load-dependence of the 
assessment when compared to volume-oriented assessment of ventricular function. It was 
subsequently developed using other modalities including MRI tissue tagging (MR-T) and has 
now developed to include feature tracking MRI (MR-FT) and speckle-tracking 2-d 
echocardiographic deformation assessments, each of which have their own strengths and 
weaknesses.  
Specifically, echocardiography is widely available, relatively inexpensive and can deliver 
high temporal and spatial resolution, while MR-FT is easily reproducible and offers a better 
analysis of circumferential and radial strains. Regarding disadvantages, echocardiography is 
prone to foreshortening, can be difficult to reproduce in terms of image and plane acquisition, 
while there is inevitably some through-plane motion of the myocardium. MR-FT is based 
upon contour markers only, while MR-T is notably time consuming, and both offer lower 
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spatial and temporal resolution and are more resource intensive than echocardiography 
(Amzulescu, De Craene et al. 2019). 
Both 2-dimensional echocardiography and MRI measurements of myocardial deformation 
have been shown to correlate well with in-vivo sonomicrometry models of myocardial 
deformtation, and similarly well when compared against each other  (Yeon, Reichek et al. 
2001, Amundsen, Helle-Valle et al. 2006, Amzulescu, Langet et al. 2017, Bansal, Cho et al. 
2008, Korinek, Wang et al. 2005). Both appear to represent imaging modalities of substantial 
use for myocardial deformation assessment, with the selection of one modality over the other 
dependent upon the strengths and weaknesses as outlined above alongside considerations of 
patient and disease-specific factors. 
 In contemporary echocardiographic speckle-tracking deformation imaging, specialised 
software allows for tracking of individual interference patterns (speckles) within the 
myocardial tissue and this allows for production of a 2-dimensional displacement curve for 
each point in the myocardium. Speckles are typically defined as visual spots generated by the 
interaction between the ultrasound beam and myocardial fibres. For the purpose of tracking 
and analysis, speckles can be grouped into functional units known as kernels which have a 
unique ultrasonic appearance, an ultrasound fingerprint, and thus their movement can be 
traced throughout the cardiac cycle. This ultimately allows for the calculation of total 
displacement, rate of displacement, deformation and rate of deformation of the myocardial 
region (Mondillo, Galderisi et al. 2011, Perk, Tunick et al. 2007). This technique has been 
validated against sonomicrometry and tagged MRI demonstrating the feasibility and 
reproducibility of the technique (Amundsen, Helle-Valle et al. 2006).  
In dividing the myocardium into a series of small cubes, localised deformation can be 
assessed along three orthogonal axes (typically longitudinal, circumferential and radial) 
across multiple areas of the myocardium (Weidemann, Kowalski et al. 2001). Strain and 
strain rate can thus be calculated for each distinct cube in each axis. 
As described in paragraph 1.2.1, myofibril orientation varies throughout the myocardium 
allowing for the generation of force in different planes and ensuring efficiency of contraction. 
The gradual change in fibre orientation between myocardial layers means that these distinct 
layers have a greater and lesser role to play in developing myocardial deformation in each of 
the above axes. The subepicardium and subendocardium both have fibres that run 
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longitudinally, albeit at diametrically opposed oblique angles to aid development of rotational 
force, whilst the mid-wall fibres run circumferentially to aid the development of 
circumferential force, both combining to produce ‘passive’ radial thickening.  
When considering myocardial deformation in each plane, the sub-layers of the myocardium 
will have a greater or lesser role to play; the subepicardium and particularly the 
subendocardium will contribute more substantially to longitudinal strain, while the mid-wall 
layer will contribute more to circumferential strain, and the combination of all fibre layers 
will be significant in the development of ‘passive’ radial deformation (Bijnens, Cikes et al. 
2012, Kalam, Otahal et al. 2014). 
In the methodology and results chapters of this thesis longitudinal deformation is the only 
plane assessed. Longitudinal strain has emerged as the most commonly measured strain 
tensor in part due to a number of studies validating its use as a marker of function and 
prognosis in a wide range of conditions including hypertrophic cardiomyopathy, HFpEF, 
amyloidosis and diabetes(Caselli, Montesanti et al. 2015, Imbalzano, Zito et al. 2011, Zhang, 
X., Wei et al. 2013, Lo, Haluska et al. 2016). Longitudinal strain and strain rate values can be 
determined for each myocardial segment as described above or averaged to produce a value 
known as global longitudinal strain (GLS).  Reductions in peak systolic GLS have been seen 
in myocardial ischaemia, alongside characteristic patterns of systolic lengthening and post-
systolic shortening (Kukulski, Jamal et al. 2003, Edvardsen, Aakhus et al. 2000). Similarly, 
GLS has been demonstrated to be an independent predictor of clinically-relevant coronary 
heart disease in patients with suspected stable angina (Biering-Sorensen, Hoffmann et al. 
2014). GLS has also been demonstrated to be of use in subclinical cardiomyopathies, 
particularly in hypertrophic cardiomyopathies where LVEF values remain normal or 
supranormal. GLS is diminished in early cardiomyopathic disease but not in physiological 
hypertrophy (Afonso, Kondur et al. 2012), and thus may aid assessment and prognostication 
in this patient group, particularly with a view to demarcating physiological versus 
pathological hypertrophy. 
GLS values are also able to delineate patients with HFpEF from both hypertensives without 
diastolic dysfunction and normal controls, demonstrating reduced strain in comparison 
(Kraigher-Krainer, Shah et al. 2014). This may be important as it is currently difficult to 
correctly identify many patients with HFpEF and HFmrEF given the complexity of the 
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current diagnostic criteria as described above. Strain and strain rate values have also been 
shown to fall as LVEF reduces, and it has been suggested that they could be used as a more 
accurate measure of declining systolic function than LVEF, particularly in patients with 
regional wall-motion abnormalities (Brown, Jenkins et al. 2009). 
GLS has also been shown to predict outcome in those with HFrEF. In patients whose LVEF 
recovers due to therapeutic intervention, GLS is a predictive marker of further stability or 
deterioration (Adamo, Perry et al. 2017). In fact, several studies have shown superiority of 
GLS values to LVEF in predicting outcomes in patients with known HF (Stanton, Leano et 
al. 2009, Ersbøll, Valeur et al. 2013), as well as predicting the development of HF in patients 
with subclinical disease (Russo, Jin et al. 2014). 
GLS is also the variable most widely assessed and reported due to the fact that it has, 
historically, technically been substantially easier to measure and thus there is more software 
developed for the assessment of these values. Studies have demonstrated significantly less 
inter-vendor concordance when assessing circumferential and particularly radial strain as 
opposed to longitudinal strain and thus, due to these practical implications, GLS has been 
more commonly adopted and assessed (Manovel, Dawson et al. 2010, Risum, Ali et al. 2012). 
As a result, there is an intrinsic selection bias in the number of studies demonstrating its 
worth for a range of cardiac pathologies. That being said, there are also data suggesting that 
depending upon in the underlying aetiology, longitudinal strain is a more sensitive marker of 
early pathology in comparison to circumferential and radial strains (Ilardi, Santoro et al. 
2016). This is particularly seen in the myocardial ischaemia due to the greater effect of 
ischaemia on subendocardial fibres compared to subepicardial or midwall (Kalam, Otahal et 
al. 2014), and has also been shown to be an early marker of chemotherapeutic cardiotoxicity 
(Florescu, Magda et al. 2014) as well as being superior to circumferential and radial strains 
for prediction of outcome in aortic valve replacement surgery (Zhang, K., Sheu et al. 2019).  
Despite the above, there are clearly roles for circumferential strain assessment; 
circumferential strain is useful in the assessment of ischaemic scar depth (Dohi, Sugiura et al. 
2016) and has been demonstrated to predict adequate lead placement and subsequent reverse 
remodelling in cardiac resynchronisation therapy (Becker, Kramann et al. 2007). As noted 
above, much of the initial paucity in data regarding circumferential strain is due to difficulties 
and discrepancies between vendors in defining and assessing circumferential strain. As this is 
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resolved by newer imaging techniques a larger role for circumferential strain measurements is 
likely to emerge, particularly regarding conditions largely affecting the myocardial midwall 
such as non-ischaemic cardiomyopathies(Taylor, Umar et al. 2015), systemic vasculitides 
(Edwards, N., Ferro et al. 2007) and lipid-storage disorders such as Fabry’s disease 
(Vijapurapu, Nordin et al. 2018).  
‘Normal’ GLS values have been reported as being between -18 and -25% in healthy 
individuals, but there is substantial variation seen in diseased populations.  
Limited information exists regarding GLS and global longitudinal strain rate (GLSR) in the 
AHF population, partially due to the typical requirements for echocardiographic frame rates 
of nearly 200 frames per second. These are typically only achievable in research conditions, 
and not in the typical clinical setting. 
Further experimental information regarding strain and strain rate values may allow us to more 
clearly define the AHF population in the future, particularly in the context of HFpEF which 
remains a complex and difficult diagnosis to make in many patients. 
As discussed above, a diagnosis of HF requires a combination of clinical signs and 
symptoms, bedside tests such as ECG and chest x-ray, biochemistry and echocardiographic 
data. This process continues to evolve and enhance the sensitivity and specificity of our 
diagnoses, with particular improvements and additions now seen in biochemical and 
echocardiographic parameters. 
1.2.4 Epidemiology 
Chronic HF is seen in approximately 1.2% of the UK population (Bhatnagar, 
Wickramasinghe et al. 2015), consistent with US data which put prevalence at approximately 
1.7 % in 2005 (American Heart Association 2005)and 2.4% in 2012 (Roger, V. L., Go et al. 
2012).  
 
In the United Kingdom (UK) HF is rare in younger patients, particularly in those under 50, 
but rises with age to nearly 8% of those 75 years or older (Bhatnagar, Wickramasinghe et al. 
2015). This approximates data from the United States of America (US) in which prevalence 
has been reported at 12% in those aged 80 years or older (Roger, V. L., Go et al. 2012).  
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When looking exclusively at the elderly population, HF is typically reported in approximately 
6-13% of patients >65 years old across the western world (Mureddu, Agabiti et al. 2012, 
Sánchez, Leiro et al. 2008, Abhayaratna, Smith et al. 2006, Azevedo, Bettencourt et al. 2006, 
Ceia, F., Fonseca et al. 2005, Ceia, Fátima, Fonseca et al. 2002, Raymond, Pedersen et al. 
2003, Di Bari, Pozzi et al. 2004, Davies, MK, Hobbs et al. 2001). Unfortunately, there is a 
relative paucity of data from non-western populations, though data from China do suggest 
similar population prevalence and age distribution (Jiang, Ge 2009). 
 
Incidence of HF in the UK has been declining in the recent decade; currently it is reported as 
approximately 3.2 per 1000 patient years, falling from 3.6 per 1000 patient years in 2002 
(Conrad, Judge et al. 2017). Data from Europe and the USA report similar incidence of 1-5 
per 1000 patient years for the adult populations, with the trend remaining either stable or 
demonstrating declining incidence (Savarese, Lund 2017). As with prevalence, incidence is 
known to rise with age, with global estimates of >100/1000 patient years in those aged ≥65 
years (McMurray, J. J., Stewart 2000). 
 
Large prospective cohort studies such as the Framingham Heart Study (Levy, D., Kenchaiah 
et al. 2002) and Olmsted County group (Roger, Veronique L., Weston et al. 2004) have been 
invaluable in tracking trends within HF. As described above, both groups describe a steady or 
declining incidence of HF but interestingly show improved patient survival. 
 
The trend of incidence and survival seen in both prospective and retrospective cohorts is 
leading to a significant increase in the healthcare burden of HF. Therapeutic options are 
improving and growing in number, but they are largely able to ameliorate rather than cure the 
underlying syndrome. This leads to improvements in long term survival but carries high costs 
for both the individual in terms of symptoms, therapeutic side-effects and hospitalisations, 
but also for the healthcare providers tasked with caring for the individual both in the 
community and in the hospital setting. As a result, the financial burden of HF is predicted to 
grow dramatically in line with increased HF survival (Savarese, Lund 2017). 
  
Gender discrepancies are also seen in HF; prevalence of heart failure is higher in males than 
females at all age groups, with prevalence in males at least double that of females under the 
age of 75, after which the gap narrows (Bhatnagar, Wickramasinghe et al. 2015). Females 
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differentially express genes related to cardiac function (Mendelsohn, Karas 2005) and it is 
well understood that the clinical phenotype of HF in each gender is markedly different (see 
Table 1.8 below).  
 
Clinical Phenotype 
                  Female                           Male 
Hypertensive/Valvular 
disease 
Aetiology Ischaemic 
Preserved LV Function Reduced 
Following decompensation Diagnosis Using BNP biochemistry 
Better compliance Therapy Worse compliance 
More easily affected Quality of life Fewer psychological 
problems 
Better Outcome Worse 
Table 1.8 – Phenotypic differences in the natural history of heart failure compared 
between the genders, each group in reference to the other. Adapted from Gender 
differences in heart failure: paving the way towards personalized medicine? (Schirmer, 
Hohl et al. 2010).  
 
Ethnicity may also play a role in the predisposition to, and clinical course of, HF. Much of 
the data on racial differences within HF patients comes from US populations due to the 
diverse racial mix within the country. Aetiological and pathological differences have been 
described in these studies, with pathological increases in LV mass described in white and 
Hispanic populations when compared to African-American populations (Bahrami, Kronmal 
et al. 2008). Incidence has been shown to be highest in African-American populations, 
followed by Hispanic then age and sex-matched Caucasian groups (Bibbins-Domingo, 
Pletcher et al. 2009). This latter point is likely due to increased levels of reversible risk 
factors in terms of hypertension, diabetes and obesity in both the African-American and 
Hispanic populations. This may not represent a true genetic predisposition but may in fact 
reflect lower socio-economic status and higher atherosclerotic risk as was suggested by the 
authors of the MESA trial (Roger, V. L. 2013).  
 
A similar trend is seen regarding hospital admissions; African-American groups have been 
demonstrated to have the most frequent hospitalisations for HF, followed by Hispanic, then 
32 
 
white then Asian populations, all at statistically different rates. Interestingly, in-hospital 
outcomes have been observed to be better in the African-American group compared to others 
(Sahni, Horwich et al. 2015). One interpretation of these data is that increased readmissions 
arise as a result of poor access to outpatient interventions but these disadvantaged patients 
may have a lower level of disease progression upon admission. 
1.2.5 Aetiology 
As outlined earlier, HF is a syndrome rather than a single disease process. As such, many 
conditions can give rise to the systolic and diastolic abnormalities which lead directly to the 
clinical symptoms described in Table 1.1.  
These can be broadly grouped into diseases of the myocardium, abnormal loading conditions 
and arrhythmias, of which further examples can be seen in Table 1.9. 
Pathophysiological abnormality Example condition 
Diseased myocardium Ischaemic heart disease, toxic damage, 
metabolic derangements 
Abnormal loading conditions Hypertension, valvular defects, high output 
states (sepsis, hyperthyroidism) 
Arrhythmias Tachy/bradyarrhythmias 
Table 1.9 – Common aetiologies of heart failure – adapted from 2016 ESC guidelines 
for the diagnosis and treatment of acute and chronic heart failure (Ponikowski, P., Voors et 
al. 2016). 
 
The Heart Failure the Global Burden of Disease Study estimated 17 primary aetiologies 
within HF but the majority of cases can be attributed to a handful of conditions, namely 
ischaemic heart disease, hypertension and rheumatic heart disease (Hawkins, Petrie et al. 
2009).  
Aetiology of HF also varies geographically. Coronary artery disease (CAD) and hypertension 
(HTN) are the commonest underlying cause seen in the western world but there is a 
substantial proportion of HF secondary to valvulopathies and nutritionally related cardiac 
disease seen in developing countries (Lip, G. Y., Gibbs et al. 2000).  
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The diseases above have been listed as separate entities but they are not mutually exclusive 
and some even have causal links or associations. Many patients suffer from multiple 
concomitant pathologies, all of which may lead to HF, therefore clearly delineating primary 
aetiology often remains a challenge. 
The Framingham study offers useful information concerning aetiological trends. In the initial 
cohort HTN was reported as the most common cause but was superseded by CAD in the 
1970s while HTN and valvular disease declined dramatically (Kannel 1990). This reflects 
trends in therapeutic interventions for HTN but may also represent an increased ability to 
detect CAD with the advent and increased availability of coronary angiography. Similarly, 
the overall burden of HF secondary to CAD has risen alongside the ability to intervene in the 
underlying disease and improve the mortality of acute coronary events. Reductions in short 
term mortality secondary to CAD has led to the advent of a large proportion of patients with 
underlying contractile dysfunction secondary to myocardial ischaemia and consequent HF. 
Recently this has shown signs of decreasing with rates of myocardial infarction declining in 
many western countries (Moran, Forouzanfar et al. 2014). This is likely due to increased 
uptake of primordial and primary prevention measures, particularly with regards to smoking 
cessation. 
Rates of untreated HTN have also been diminishing, which may partly explain the gradual 
reduction in disease incidence described above (Unal, Critchley et al. 2004). In the USA 
treatment of hypertension is estimated to have led to a reduction in incidence of 50% (Levy, 
D., Kenchaiah et al. 2002). Nevertheless, for those who remain untreated, the lifetime risk of 
HF for those with blood pressure (BP) >160/90 is double that of those with BP <140/90 
(Levy, D., Kenchaiah et al. 2002). 
As mentioned, valvular heart disease remains a relatively common cause of HF in developing 
countries. While the incidence of rheumatic fever has declined in western populations to 
<0.01/1000 patient years, in Sudan the incidence has been reported to be 100 times greater 
(Essop, Nkomo 2005). Valvular disease does still play a role in the development of HF in 
Western countries, but typically in the context of degenerative valve diseases such as mitral 
regurgitation and aortic stenosis. 
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1.2.6 Morbidity 
Morbidity in HF is substantial; over 80% of patients with chronic HF have been shown to 
suffer from physical symptoms including dyspnoea, fatigue, oedema and sleeping difficulties 
due to paroxysmal nocturnal dyspnoea, impacting upon all aspects of daily life (Schiff, Fung 
et al. 2003). 
 
HF is also associated with poor subjective quality of life. The prevalence of clinically 
significant depression in this patient group is approximately 21% (Rutledge, Reis et al. 2006) 
which compares extremely poorly with a general population burden of 3.3% (Edwards, J. 
2016). This can have disastrous consequences, as the presence of depression is known to lead 
to significantly poorer prognosis irrespective of comorbidity burden (Bush, Ziegelstein et al. 
2001, Williams, Ghose et al. 2004), particularly with regards to its impact on cardiovascular 
mortality (Penninx, Beekman et al. 2001).  
Furthermore, treatment comes with its own burdens. Typical pharmacological therapies have 
a range of known and relatively common side-effects, with adverse reactions reported in up 
to 10% of those taking bisoprolol (TRIAL 1999), 7-8% of those taking ramipril (Heart 
Outcomes Prevention Evaluation (HOPE) Study Investigators 2000) and up to 30% of those 
taking spironolactone (Aronson 2009).   
HF is one of the most common causes of hospitalisation throughout the western world, with 
approximately 1-2% of all admissions secondary to HF as the primary diagnosis (Blecker, 
Paul et al. 2013). Readmissions rates are incredibly high for those hospitalised with AHF; 
typical all-cause readmission rates in HF have remained stable in the last 10-15 years at 
around 20% readmitted at 30 days (Ross, Chen et al. 2010), 25% at 3 months (Alla, Zannad 
et al. 2007) and rising to 40% by 6 months (Krumholz, Parent et al. 1997). HF is the most 
common single cause for readmission in this group (Vader, LaRue et al. 2016, Desai, 
Stevenson 2012). 
As shown, HF has a profound symptomatic and psychological impact on patients’ lives, but 
also leads to increased morbidity in terms of medication side effects, hospital admissions, 
incredibly high readmission rates and, as is discussed below, mortality. 
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1.2.7 Mortality 
HF has long been understood to have a poor prognosis, both in the short and long term. In 
2001 Stewart et al. described how 5-year mortality in HF was comparable or worse than that 
of many common types of cancer such as bowel, prostate, bladder, breast and ovarian 
(Stewart, MacIntyre et al. 2001). 
Globally, inpatient mortality after admission due to AHF is approximately 5%, which rises to 
between 5 and 15% at 1-month post discharge, and 17-30% at 1 year (Ambrosy, Fonarow et 
al. 2014).  Few of the global registries collect outcome data for longer than 1 year, but 
smaller prospective studies have suggested 5-year mortality between 45%.and 65% 
(Bleumink, Knetsch et al. 2004, Tribouilloy, Rusinaru et al. 2007). 
As discussed earlier in reference to rising prevalence of HF, mortality has been falling in 
recent decades, but still remains worryingly high. A Danish HF registry describes a fall in 
mortality from 45% to 33% at 1 year and 59% to 43% at 5 years when comparing 1987 to 
2012 (Schmidt, Ulrichsen et al. 2016). 
Similar trends have also been described from the Olmsted county cohort, where a statistically 
significant improvement in 5-year mortality was noted from patients admitted in 1991 to 
those admitted in 2001; in multivariate analysis, year of admission conferred a hazard ratio of 
0.99 (0.97-1.00) demonstrating improving mortality over time. This effect was only seen in 
the HFrEF and not the HFpEF subgroup (Owan, Hodge et al. 2006), and is likely related to 
the introduction of prognosis-modifying medications and interventional therapies with proven 
efficacy in HFrEF. This global trend appears to be driven by decreasing sudden cardiac death 
(SCD) leading a consequent proportional increase in the quantity of patients dying secondary 
to pump failure (Pereira-Barretto, Bacal et al. 2015).  
Reviews of global mortality trends have reported that death from a cardiac cause typically 
accounts for around 50% of overall mortality in HF. They also describe quite substantial 
global variation with Indian, Chinese and middle eastern populations demonstrating a 
particularly large burden of cardiac death (Bleumink, Knetsch et al. 2004).  
Regional studies report similar findings, with cardiovascular disease (CVD) mortality 
approximating at least 50% of all-cause mortality in HF patients (Ni, Xu 2015, Pons, Lupón 
et al. 2010), with some groups reporting up to 90% (Ørn, Dickstein 2002). 
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CVD mortality appears to be falling within the HFrEF group, likely due to the increased 
uptake of disease and outcome modifying drugs (Rush, Campbell et al. 2015). Data from the 
TOPCAT study suggest that CVD accounts for a similar proportion of mortality in HFrEF in 
comparison with HFmrEF and HFpEF (60-70%), but with a higher annualised incidence of 
death (Bajaj, Claggett et al. 2018).  
HF has also been reported as the leading cause of CVD mortality amongst the general 
population, followed by sudden cardiac death (SCD) and acute myocardial infarction (MI) 
(Pons, Lupón et al. 2010). 
As has been demonstrated above, the mortality of HF, irrespective of subcategorisation, 
remains high. Additional understanding of the underlying disease processes and ability to 
focus our therapeutic efforts on those whom they will best serve is imperative to reduce the 
mortality burden of HF worldwide. 
1.2.8 Prognosis-altering pharmacological interventions 
Despite the high rates of mortality, for the majority of the 20th century pharmacotherapy in 
HF consisted of digoxin, diuretics and little else despite these therapies being supported by no 
studies demonstrating prognostic benefit (Hurst 1974). Both digoxin and diuretics are still 
used in HF, though digoxin has fewer recommended applications and is typically used for 
patients with tachycardia related HF. It offers no prognostic benefit, though it may aid with 
symptom amelioration and readmission rates (Digitalis Investigation Group 1997). In 
contrast, diuretics are used in all forms of HF to reduce afterload and thus improve stroke 
volume (Wilson, Reichek et al. 1981) but again are used for symptomatic benefit only. 
Observational studies have demonstrated that increased diuretic use is an independent marker 
of increased mortality (Eshaghian, Horwich et al. 2006). There have been no large 
randomised controlled trials (RCTs) that demonstrate prognostic benefits of diuretics in any 
HF subset, though meta-analyses have suggested that loop and thiazide diuretics may reduce 
the risk of HF admission and death compared to placebo (Faris, Rajaa F., Flather et al. 2012, 
Faris, R., Flather et al. 2002). 
Thankfully, due to progression in RCTs pharmaceutical companies have developed 
medications with demonstrable efficacy in improving cardiac geometry and function, as well 
as morbidity and mortality. The main foci of current prognosis-altering therapies are the 
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sympathetic nervous system (SNS), RAAS, vasopressin pathway and NPs which will be 
discussed in turn.  
1.2.8.1 Sympathetic nervous system blockade 
As discussed above, short term SNS activation is beneficial in increasing SV via heightened 
chronotropy and inotropy. Chronic SNS activation in response to decreased stroke volume 
leads to down-regulation and desensitisation of cardiac and baroreceptor catecholamine 
receptors. Excessive exposure to SNS stimulation eventually leads to maladaptive 
hypertrophy, apoptosis and necrosis of cardiac myocytes (Mann, D. L., Kent et al. 1992) 
while it is known that genetic polymorphisms which upregulate the response to 
catecholamines increase the likelihood of developing HF (Small, Wagoner et al. 2002). 
Small trials conducted by two groups in the mid to late 1970s were the first to demonstrate 
that beta-adrenergic blockade improved cardiac geometry and survival in HFrEF patients 
(Swedberg, Hjalmarson et al. 1979, Waagstein, Hjalmarson et al. 1975). Further trials using 
carvedilol, bisoprolol and metoprolol indicated a similar effect for the class in general 
(Packer, M., Fowler et al. 2002, Merit-HF Study Group 1999, Poole-Wilson 1999). 
There have been no convincing studies demonstrating a benefit in mortality conferred by BBs 
in HFpEF. Nebivolol has been shown to reduce admissions for patients with HFpEF in sinus 
rhythm (van Veldhuisen, Cohen-Solal et al. 2009), but meta-analysis of available 
observational data and RCTs does not support their general use to improve mortality or 
morbidity in HFpEF (Bavishi, Chatterjee et al. 2015). 
1.2.8.2 Renin-angiotensin-aldosterone system blockade 
Maladaptive SNS activation also contributes to excess RAAS activation, which can be 
separately stimulated by a fall either in pressure at the carotid baroreceptors or flow rate at 
the macula densa. The main downstream substrate of pathology is excess Angiotensin II 
(AT2) production, which contributes to the adverse cardiac remodelling and endothelial 
dysfunction seen in HF. Inhibition of AT2 production by ACEi or receptor blockade by 
ARBs leads to a combination of vasodilation, antagonism of the sympathetic nervous system 
and natriuresis, reducing intracardiac pressure and volume overload (Tham, Bernardo et al. 
2015, Davies, M. K., Gibbs et al. 2000). 
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ACEis have been a mainstay of pharmacotherapy in HFrEF since the late 1980s; the 
CONSENSUS and SOLVD trials first demonstrated that patients with HFrEF given enalapril 
showed improvements in cardiac geometry, symptoms and significant mortality benefits 
when compared to placebo cohort (SOLVD Investigators* 1991, Consensus Trial Study 
Group* 1987). This has subsequently been confirmed by other trials using different ACEis 
suggesting a general class effect (Julian, Moss et al. 1993, Køber, Torp-Pedersen et al. 1995, 
Pfeffer, Braunwald et al. 1992).   
Despite their action on a common physiological pathway, evidence of the prognostic benefit 
of angiotensin receptor blockers (ARBs) has been more equivocal. Meta-analysis of their 
effect has demonstrated that they do not appear to reduce mortality or admissions in HFrEF 
in comparison to ACEis (Heran, Musini et al. 2012), though they may be superior to placebo 
when ACEis cannot be tolerated (Jong, Demers et al. 2002). 
Theoretically, inhibition of AT2-induced ventricular hypertrophy and fibrosis could attenuate 
pathological diastolic changes seen in HFpEF, however large RCTs have demonstrated no 
significant differences in hospitalisation or mortality in this cohort (Massie, Carson et al. 
2008, Cleland, Tendera et al. 2006, Yusuf, Pfeffer et al. 2003).  
Working on the terminal portion of the RAAS pathway, mineralocorticoid receptor 
antagonists (MRAs) are also widely used in HFrEF. The RALES, EPHESUS and 
EMPHASIS studies have variously delineated the clear benefits of MRAs on hospitalisation 
and survival when given in addition to guideline medical therapy (Pitt, Zannad et al. 1999a, 
Zannad, McMurray et al. 2011, Pitt, Remme et al. 2003). In the EMPHASIS trial, at median 
follow up of 21 months, the primary outcome of hospitalisation or mortality in was reduced 
from 25.9% in the placebo group to 18.3% of the Eplerenone group (p<0.001).   
Considering the utility of MRAs in HFpEF, the recent TOPCAT study spironolactone did not 
demonstrate a beneficial effect on the composite outcome of CV death, aborted cardiac arrest 
or HF hospitalisation, though there was a reduction in HF hospitalisations (Solomon, Scott 
D., Claggett et al. 2015). Similar findings have been reported in other studies, though there is 
no clear evidence that MRAs improve mortality in the HFpEF group (Kurrelmeyer, Ashton et 
al. 2014, Edelmann, Wachter et al. 2013, Deswal, Richardson et al. 2011). 
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1.2.8.3 Natriuretic peptide pathway 
Recently a new class of medications has been developed focused on neprilysin-mediated 
degradation of circulating NPs. NPs are released in response to excess pressure and volume 
overload of the ventricles and atria and cause natriuresis and vasodilation while counteracting 
maladaptive cardiac remodelling (Tamura, Ogawa et al. 2000, Yoshimura, Yasue et al. 2001, 
Kalra, Anker et al. 2001). Blocking the action of neprilysin leads to an increase in circulating 
NPs and thus increases their cardioprotective effects. The PARADIGM-HF trial 
demonstrated that angiotensin receptor-neprolysin inhibitors (ARNI) caused a reductions in 
symptoms, hospitalisations and mortality when compared to patients taking ACEi only 
(McMurray, John JV, Packer et al. 2014), and as such their use is now recommended in the 
HFrEF group (Ponikowski, P., Voors et al. 2016). 
The PARAGON-HF study is currently assessing the impact of the ARNI sacubitril/valsartan 
on the HFpEF group. This may provide clinically relevant information about the response of 
the HFmrEF subgroup to these therapies, and thus new therapeutic options in these groups, so 
the data are eagerly anticipated. 
Figure 1.5 summarises the pathological mechanisms and interactions of the above 
pharmacological agents. 
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Having reviewed the current research on HF and touched upon the discrepancies between 
HFrEF and the novel categorisations, the next section will look more in depth at the focus of 
this thesis: echocardiographic discriminators in novel subcategorisations of AHF and the 
ability to effectively prognosticate in AHF. 
1.3 Thesis Foci – current literature and gaps in the evidence 
This section will outline the main foci of the thesis, namely differences in myocardial 
deformation imaging between novel subclassifications of AHF, and the ability to 
prognosticate in HF. Each section will cover the current literature on the subject with critical 
review of the weaknesses of the available data, and the ways in which this study aims to add 
to the current understanding. 
Figure 1.5 - Pathological mechanisms and the interactions of current 
pharmacological agents – Taken from Pharmacologic Therapy for Heart Failure With 
Reduced Ejection Fraction: Closing the Gap Between Clinical Guidelines and 
Practice(Biglane, Becnel et al. 2017). 
ACEI – Angiotensin converting enzyme inhibitor, ARB – Angiotensin receptor blocker, 
ARNI – Angiotensin receptor neprolysin inhibitor, BB – Beta blocker, BNP – B 
natriuretic peptide, BP – Blood pressure, LV – Left ventricle, NP – Natriuretic peptide, 
NT-Pro BNP – N-terminal Pro BNP, RAAS – Renin angiotensin aldosterone system, SNS 
– Sympathetic nervous system. 
 
41 
 
1.3.1 Novel categorisations of HF – current literature and gaps in the 
evidence 
As discussed earlier, HF has typically been categorised according to LVEF. Until the 2013 
AHA/ACC guidelines (and subsequent ESC guidelines) this led to two distinct categories: 
HFrEF which responded to pharmacotherapy, and HFpEF which did not.  
HF with mid-range ejection fraction (HFmrEF) was introduced as a novel categorisation due 
to concerns regarding potential pathological and phenotypical differences that may exist in 
this subgroup (Yancy, Jessup et al. 2013) and was designed to stimulate research into the 
possible pathophysiological and therapeutic differences between the groups (Ponikowski, P., 
Voors et al. 2016). If differences do exist between HFmrEF and the traditional HFpEF group 
then the data heterogeneity induced by the inclusion of this group in previous clinical trials 
may have affected the results derived from these studies. As a result, much of what has just 
been discussed in terms of demographics, pathology and treatment may be inaccurate and it 
may have an impact on the ability to treat another subset of patients. 
First the evidence from studies looking specifically at this novel subgroup will be discussed 
followed by a description of the gaps within the current understanding. 
Retrospective evaluation of large CHF registries suggests that HFmrEF represents between 
12% and 18% of patients (Coles, Tisminetzky et al. 2015, Tsuji, Sakata et al. 2017, Cheng, 
Cox et al. 2014, Kapoor, Kapoor et al. 2016). Demographically these registry studies show 
statistically intermediate characteristics of the HFmrEF group in terms of age and gender 
profiles (Kapoor, Kapoor et al. 2016, Tsuji, Sakata et al. 2017), as well as intermediate 
prevalence of comorbidities such as coronary artery disease (Kapoor, Kapoor et al. 2016), 
obesity (Cheng, Cox et al. 2014, Tsuji, Sakata et al. 2017), hypertension and atrial fibrillation 
(Tsuji, Sakata et al. 2017). 
Estimated total prevalence of HFmrEF can be calculated as a function of the total HF 
population as described above. Registry studies have suggested that the typical HFmrEF 
patients are older and more commonly female than in than HFrEF, thus prevalence of 
HFmrEF is skewed towards these demographic groups (Kapoor, Kapoor et al. 2016). 
Incidence is harder to demonstrate as there is little to no data specifically regarding de novo 
HFmrEF. When looking at previous echocardiography in the HFmrEF subgroup, Rastogi et 
al. reported that 73% of their patients were improved HFrEF, 10% were static HFmrEF 17% 
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were deteriorated HFpEF. This may give an indication that while the HFmrEF subgroup 
represents a substantial proportion of HF patients, only a small share of these present initially 
as HFmrEF, rather than deteriorating or improving from their initial state. If so, incidence of 
HFmrEF is likely to be relatively low. 
When looking at clinical status, HFmrEF patients appear to act as an intermediate 
haemodynamic phenotype in terms of systolic blood pressure (SBP), diastolic blood pressure 
(DBP), heart rate and cardiac geometry (Tsuji, Sakata et al. 2017).  
Biochemically haemoglobin, creatinine, BNP and NT-pro-BNP levels in HFmrEF all appear 
intermediate between HFrEF and HFpEF (Tsuji, Sakata et al. 2017), while ST2 is 
significantly reduced in HFmrEF when compared to HFpEF (Moliner, Lupón et al. 2018). 
When looking at their ability to aid prognostication in the HFmrEF group, levels of 
commonly used markers of treatment response such as NT-pro-BNP, high sensitivity 
troponin T and ST2 appear to be of greater predictive value in this group than in either 
HFrEF or HFpEF (Moliner, Lupón et al. 2018). 
When considering morbidity, the HFmrEF group has been described separately as 
experiencing intermediate length of stay and rates of all cause readmission (Cheng, Cox et al. 
2014, Kapoor, Kapoor et al. 2016) but with higher cardiovascular (CV) readmission rates 
when compared to HFpEF, acting similarly to HFrEF (Cheng, Cox et al. 2014). In the chronic 
setting, HFmrEF patients appear to demonstrate an intermediate severity of clinical 
symptoms when categorised according to the NYHA scale with an intermediate prevalence of 
NYHA class III and IV symptoms (Tsuji, Sakata et al. 2017).  
In terms of all-cause mortality and CV mortality HFmrEF patients have been shown to 
demonstrate either similar or statistically intermediate outcomes compared to HFrEF and 
HFpEF at up to 4 years post discharge (Tsuji, Sakata et al. 2017, Cheng, Cox et al. 2014). In 
an early study in this group, Bhatia et al. described unadjusted mortality rates in HFmrEF of 
5.1% at 30 days and 21.3% at 1 year, compared to HFpEF (5.3% and 22.2% respectively) and 
HFrEF (7.1% and 25.5% respectively) (Hsu, Ziaeian et al. 2017, Bhatia, Tu et al. 2006).  
There have been only limited studies directly assessing the response of the HFmrEF to 
therapeutic intervention. Meta-analysis of 11 trials using beta blockade has suggested that 
HFmrEF patients with sinus rhythm may also benefit, with a statistically similar response 
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seen in both the HFrEF and HFmrEF groups. In contrast, the data from the HFpEF cohort 
demonstrated no mortality benefit, as has been seen in previous trials, while patients with 
HFmrEF and atrial fibrillation also displayed no benefit (Cleland, Bunting et al. 2017).  The 
CHARM study assessed the effect of ARBs against placebo on primary outcome of CVD or 
hospitalisation across a range of ejection fractions. They demonstrated a similar effect of 
RAAS inhibition on the primary outcome in the HFmrEF group to that seen in the HFrEF 
group, with hazard ratios of 0.82 and 0.76 respectively in the treatment arms. This effect was 
not replicated in the HFpEF group. The TOPCAT study also reassessed the effect of MRAs 
in this cohort. They demonstrated a reduction in HF hospitalisation for the whole cohort with 
LVEF >45%. This effect was most pronounced in the group with LVEF 45-50% and 
guidelines have been updated to suggest the use of MRAs in the >45% group to reduce 
hospitalisation. As discussed earlier, the addition of neprilysin inhibitors to the arsenal of 
pharmacotherapy in HFrEF offers new treatment options and the PARAGON-HF study will 
be able to delineate any clinical benefit in this HF subcategory (Solomon, Scott D., Rizkala et 
al. 2017). As yet, however, there is little to no evidence of their efficacy in HFmrEF. 
Echocardiographic parameters appear to have been understudied in HFmrEF, particularly 
concerning novel parameters of ventricular systolic function. Studies in Chinese patients first 
demonstrated significant differences in ventricular geometry between groups when stratified 
according to LVEF groups which approximate the new categories. They showed significant 
differences between groups in both Doppler and geometrical parameters but were limited by 
the size of their study, recruiting only 284 patients of whom 38 were within the group LVEF 
40-55% (He, Burkhoff et al. 2009). Cardiac geometry was studied in greater depth in CHF 
patients using data from the TIME-CHF study. These data demonstrated a progressive 
increase in LV dimensions with a falling LVEF, decreased wall thickness in HFrEF and 
suggested that concentric remodelling is seen preferentially in HFpEF compared to eccentric 
remodelling in HFrEF (Rickenbacher, Kaufmann, Maeder, Bernheim, Goetschalckx, Pfister, 
Pfisterer, and Rocca 2017). 
In a study looking at exercise tolerance in stable CHF, myocardial deformation parameters 
have been shown to be statistically correlated with performance, but due to limited numbers 
the group were unable to demonstrate differences between LVEF subgroups (Tsougos, 
Angelidis et al. 2017).  
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The only notable study of AHF myocardial deformation parameters was undertaken by Park 
et al. Their study of 4,172 consecutive AHF patients suggested that strain imaging is more 
accurate than LVEF in prognostication for HF (Park, Park et al. 2018). This research is 
limited by their exclusion of HF patients with an ischaemic origin, an important omission 
given that this is a large proportion of the total HF burden cited as nearly a third of patients in 
the EuroHeart Survey II (Nieminen, Brutsaert et al. 2006). They also only collected all-cause 
mortality data, and thus did not assess the utility of GLS to predict cardiovascular mortality. 
As described, there has been little assessment and characterisation of parameters of 
myocardial deformation in AHF and specifically between the new HF subcategories. This is, 
no doubt, in part due to the novelty of the recategorisation, also due to the lack of viable 
images from older registry studies. This is an important gap in contemporary knowledge; 
LVEF may not remain the definitive marker of HF categorisation due to its well-understood 
imprecision and the arbitrary nature of the values used to subcategorise patients, thus 
parameters of systolic function less dependent upon haemodynamic variation are likely to add 
to the ability to effectively define these groups. Specifically, given the large inter-observer 
variability of LVEF measurements and imprecision when assessing patients with regional 
wall motion abnormalities, the addition of an adjunctive parameter which is not similarly 
susceptible may offer an improved ability to clearly delineate and categorise these subgroups. 
Many of the studies looking at this patient subgroup have been, understandably, retrospective 
registry-based cohort studies. As a result, they can be prone to selection biases due to a 
heavily reliance on accurate recordkeeping of the involved parties. Unfortunately studies of 
hospital episode statistic (HES) data have demonstrated that accurate documentation of 
primary diagnosis has been as low as 76% (Burns, Rigby et al. 2011)while appropriate 
documentation of HF diagnosis has been shown to be worryingly inaccurate (Goff, Pandey et 
al. 2000) and assessment of large registers has demonstrated significant underreporting of HF 
diagnoses(Kümler, Gislason et al. 2008). These factors, when combined, make it more difficult 
for large scale retrospective registries to include the relevant population in their datasets. 
Despite this, registry studies still represent very large datasets from which useful, statistically 
powerful conclusions can be derived, however large single-centre trials offer benefits in 
terms of homogeneity as discussed above and can be used to validate registry data. 
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The majority of previous studies into this subgroup are derived from large multi-centre 
registries. While this is immensely beneficial in the accrual of greater patient numbers, this 
markedly reduces the homogeneity of the data collected due to intrinsic variations in local 
practice.  
Aside from the variation inherent in multi-centre trials, these trials also introduce variation in 
terms of sonographical practice. As discussed above, echocardiography suffers from 
significant inter-observer variation, dependent upon the skill, experience and equipment of 
the sonographer. Local echocardiography protocols also vary leading to variations in data 
collection and reporting practices.  
Given the growing numerical and financial inpatient burden of AHF it is important to focus 
on underlying pathological differences in HF subcategories in an effort to improve the 
therapeutic options.  
1.3.2 Prognostication in AHF – current literature and gaps in the evidence  
The ability to effectively estimate prognosis in terms of readmission rates and mortality in 
any disease group is essential. Good prognostic information helps patients to develop realistic 
expectations of their disease course, aids in self-management and future planning as well as 
helping them to understand why medical professionals intervene with therapeutic options. For 
the physician it is similarly vital, allowing for evidence-based planning with regards to 
therapeutic interventions, intensity of treatment, as well as allowing for the appropriate 
organisation of health and social resources at a local or state level. 
Tools to aid with prognostication in CHF have been developed over the last 20 years with 
multiple validated tools in existence for use in ambulatory patients. 
Initially, small studies such as that conducted by Aaronson et al. demonstrated the possibility 
of risk stratifying and prognosticating in the ambulatory HF group using invasive parameters 
such as peak oxygen consumption and mean pulmonary capillary wedge pressure and non-
invasive parameters such as aetiology, clinical observations, LVEF and biochemistry 
(Aaronson, Schwartz et al. 1997). These data were derived from a small cohort of only 268 
patients, solely selected from a group of patients with advanced HF being considered for 
heart transplant, but it demonstrated the possibility and value of prognostication. 
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Lucas et al. demonstrated the utility of clinical findings in prediction of outcome, showing 
that freedom from clinical congestion conferred a beneficial prognosis upon patients, but did 
not use this in any formal prediction model. Theirs was again a small patient cohort of 146 
taken exclusively from an outpatient setting (Lucas, Johnson et al. 2000). 
Pocock et al. advanced the concept, constructing a prognostic model in chronic heart failure 
in both HFrEF and HFpEF. This was created using data from the CHARM programme with 
7599 patients, a sizeable CHF cohort, and produced a multivariable model for prediction of 2-
year mortality or HF readmission. This model used a large variety of clinical and comorbid 
criteria, including over 20 variables, while also using a complex algorithm to approximate 
mortality and readmission risks (Pocock, Wang et al. 2005). 
This model was improved upon by Levy et al. who created the Seattle model of risk 
prediction. They developed an online tool based on a prognostic model derived from 1125 
CHF patients followed up to 3 years post clinical evaluation. They produced an online model 
which allowed for the automatic calculation of risk profile by the clinician, markedly 
simplifying the process of risk stratification. They used a similar mix of clinical variables to 
produce their model, using a multi-variate Cox regression method as had been used in 
previous studies (Levy, W. C., Mozaffarian et al. 2006).  
Lupón et al. created a similar model with a large population but using additional novel 
biomarkers which had come to prominence in the mid-2000s (Lupón, de Antonio et al. 2013). 
This, amongst a range of other clinical and biochemical parameters allowed them to produce 
a comprehensive mortality and readmission scoring scale for use in outpatient heart failure. It 
does require a large quantity of data to use and can be time consuming for the physician, but 
again this group produced an online calculator for ease of use, and their data advanced the 
ability to prognosticate in the CHF population. 
These studies and their models have provided useful long-term mortality risk prediction 
models for patients with CHF. Practical models for use in AHF have remained elusive, with 
different gaps existing in both knowledge and application. 
In a similar fashion to those described above, Lee et al. used a cohort of 2624 from the 
EFFECT study to produce a novel model for prognostication of AHF patients at 30 days and 
1-year post admission, using variables easily acquired by the hospital physician. They 
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selected 11 variables which are added to produce an overall score corresponding to overall 
risk. Similar to models described above, their scoring scale requires relatively complex 
mathematical calculation and reference to risk score tables to assess risk for the individual 
patient but it is a useful initial tool in the AHF population (Lee, Austin et al. 2003). 
Similar efforts have been produced by Fonarow et al. using a large AHF inpatient cohort of 
33,046 patients (Fonarow, Adams et al. 2005). This group used their data to instead perform a 
classification and regression tree (CART) analysis to describe inpatient mortality only. CART 
is perhaps slightly better suited to clinical decision making but requires direct access to the 
tool for use as it again would otherwise require large amounts of complex data to be 
remembered by the acute physician at the patient’s bedside. 
Komajda et al. created a risk stratifying tool using readily available bedside parameters but 
have described risk stratification up to 3-year mortality in HFpEF only (Komajda, Carson et 
al. 2011). While this is a useful tool, it is, by definition, restricted to its target population, a 
population which is now obsolete in view of new guideline definitions regarding HFmrEF.  
Okazaki et al assessed a more broadly applicable risk scoring tool, using bedside parameters 
only in the APACHE-HF, APACHE II and Modified APACHE II scoring systems (Okazaki, 
Shirakabe et al. 2014). In their single-centre study they collected data from 824 patients 
admitted to the intensive care unit in their centre and derived a scoring system for risk 
stratification of in-hospital mortality. The most substantial disadvantage of the APACHE II 
and Modified APACHE II risk-prediction tools are their complexity, both in memorising and 
in application of the scoring systems. The APACHE II score uses 17 variables rendering it 
complex to use in the clinical setting, Modified APACHE II uses only 7 variables but each 
variable can confer up to 6 points to the cumulative risk score rendering it complex to 
calculate in the acute clinical setting and the much simpler APACHE score uses non-standard 
variables values which are thus much more difficult to retain and transfer into use (Brod, 
Werkle-Bergner et al. 2013). In addition, the C-statistic of both the APACHE II and Modified 
APACHE II scores are <0.600 which would lead to both being standardly classified as Poor 
or Worthless tests (Obuchowski 2003). 
Data from the OPTIMIZE-HF trial were used to produce a more simplified model predicting 
mortality at 60-90 days post discharge. The model produced uses only 8 variables, all easily 
acquired in the acute setting, though allocation of points to each variable is complex as each 
48 
 
variable is associated with a range of possible scores dependent on the value of the variable. 
As with previous scoring systems this renders it difficult to calculate manually in the acute 
setting without recourse to the scoring tool itself, and interpretation of the sum of these scores 
requires access to a nomogram to determine risk. The nomogram is actually very useful, 
allowing the clinician to give more accurate predictions about risk to each individual patient 
rather than allocate them a broad risk of low, medium or high as is done in many other 
studies. It does, however, preclude the use of this tool in a setting in which you do not have 
access to a visual or tabulated version of the nomogram (O'connor, Abraham et al. 2008). 
Similarly, the ELAN-HF score provides a relatively simple risk score with only 8 variables, 
utilisation of NT-pro BNP levels and a C-statistic of 0.78, but they use certain variables only 
available at discharge. This does not preclude the use of the tool but restricts its application to 
the post-clinical stabilisation phase (Salah, Kok et al. 2014). 
The ESCAPE discharge score has the same disadvantage of using variables only available at 
discharge (though predicting risk at discharge is acknowledged as the explicit intent of the 
study), while it also includes less-commonly performed tests such as the 6-minute walk test 
and requires a discharge BNP level which is not always performed (O'Connor, Hasselblad et 
al. 2010). 
As can be seen from the review of current risk-prediction tools, there are notable problems or 
disadvantages in each. Firstly, the majority of these tools are derived from large retrospective 
registry studies. As described above in relation to the HFmrEF recategorisation, there are 
difficulties intrinsic to this study design. Specifically, they often do not characterise the 
whole burden of HF due to an inability to detect all HF patients. This can particularly stem 
from failures of misdiagnosis or detection. When predicting outcome of HF patients, if 
models are created from an incomplete patient cohort it is unlikely to be fully representative 
of true HF patients. 
Secondly, the majority of current tools are simply too cumbersome to use for the acute 
physician at the bedside. Tools such as CURB65 and CHA2DS2-VaSc are routinely used in 
part due to their ease of use (Blatchford, Murray et al. 2000, Lim, W. S., van der Eerden et al. 
2003). In his seminal work on educational theory Miller posited that information is best learnt 
and retained in units of 7 +/- 2 individual ‘chunks’ (Miller 1956) and is a theory which has 
subsequently been validated by experimental models (Shiffrin, Nosofsky 1994). This 
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correlates with contemporaneous predictive risk stratifying tools in pneumonia, atrial 
fibrillation and gastrointestinal bleeds. The tools produced and described above for both CHF 
and AHF all require retention of large volumes of information, substantially in excess of 9 
variables, and, as such, are understandably difficult to use at the bedside without access to 
visual reminders of the tool, or access to computer-based calculation tools. The authors of the 
Seattle study comment that ‘The calculation of estimated survival included 14 continuous 
variables and 10 categorical values, making it impractical for computation by hand’ (Levy, 
W. C., Mozaffarian et al. 2006), and this remains a common problem for the majority of risk 
scoring models in AHF.  
Those that do require fewer variables use a composite endpoint of mortality or 
rehospitalisation. While this is useful information for the clinician, they are very different 
endpoints from the point of view of the patient. The use of this composite endpoint in the 
study by Xanthopoulos et al appears driven by the relatively limited number of patients 
within their model derivation cohort, and thus the requirement to increase the number of 
potential ‘events’ to be able to satisfactorily derive and validate their model (Xanthopoulos, 
Giamouzis et al. 2017).  
Some of the models which are simpler in their application, such as those derived from the 
ELAN and ESCAPE trials, use data only available at discharge which preclude the use of the 
tool at admission, where it could otherwise be used to make useful predictions regarding need 
for admission and intensity of inpatient therapy due to post-discharge mortality risk. 
Lastly, none of the current models in AHF use echocardiographic information to improve 
their models. Considering that both European and American guidelines recommend prompt 
echocardiography in all patients admitted with AHF it is likely that this information would be 
available for a large proportion of patients early within the course of their admission. It may 
be that echocardiographic parameters offer significant additional predictive power and this is 
something that should at least be assessed. 
In short, the production of a novel predictive tool - one derived from a real life AHF patient 
cohort, which predicts mortality and readmission rates, and which is easily memorisable and 
usable by the acute physician - would be of considerable benefit both to those at the hospital 
front door and those further along the path of the patient journey.  
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1.4 Study synopsis & Hypotheses 
This study uses data from a large, consecutively recruited real-life patient cohort capturing 
the entire range of acute inpatient HF patients, both those with and without a formal diagnosis 
of AHF. In particular, efforts have been made to ensure homogeneity of recruitment and 
echocardiographic practice and interpretation. 
This study will look specifically at whether strain and strain rate values derived from the LV 
align with LVEF categories.  
This study hypothesises that left ventricular strain and strain rate values will vary according 
to subcategory, as defined by LVEF.  
This study will also assess whether a predictive risk-scoring tool can be produced to improve 
the ability to prognosticate in a truly representative AHF cohort in terms of short to mid-term 
mortality.  
This study hypothesises that a simple, valid, tool to stratify 6-month mortality risk in AHF 
can be produced using only data available to the clinician in the acute phase of admission for 
AHF. 
1.5 Chapter summary & Thesis structure 
This chapter has discussed the current understanding of HF as a clinical syndrome and 
outlined the current approach to assessment, diagnosis and management. It has also described 
the current morbidity and mortality profile associated with a diagnosis of HF. It has then 
discussed current gaps in contemporary understanding of two subsections of the above, 
namely current HF categorisations and prognostication in AHF. 
To summarise, further information regarding echocardiographic parameters of novel HF 
subcategories is likely to offer further information to help clarify underlying pathologies.  
Furthermore, there are gaps in ability to prognosticate in the AHF population that can be 
clarified, specifically for the ability to produce a genuinely usable prognostic tool during the 
acute phase of the hospital admission.  
The first results chapter of the thesis will outline the baseline characteristics of the MRAHF 
study cohort and compare this to an existing large AHF registry cohort, the second will assess 
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the differences in myocardial deformation imaging values between heart failure subcategories 
and the third will assess prediction of mortality in AHF using variables easily acquired in the 
acute phase of a hospital admission. 
To do so, data have been collected from consecutive AHF patients admitted to a single-centre 
hospital site. Data collected includes a variety of demographic, clinical, biochemical, 
interventional and echocardiographic information. Echocardiographic data will be compared 
against current HF categorisation subgroups. Post-hoc data collection has been performed to 
assess outcomes at 6-months post recruitment. This will allow for assessment of outcome and 
for production of predictive models. 
The following chapter will describe the materials and methods used in the design and 
implementation of the study, as well as the statistical analyses performed to demonstrate 
statistical significance of the acquired data. 
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Chapter Two: Study Design, Methods and Materials 
2.1 Chapter introduction 
This chapter describes the study design and methodology. The chapter is divided into five 
sections: The first describes the parent study from which this thesis is derived, the second 
clarifies the overriding aims of the study as outlined in the introductory chapter, the third 
describes the methods used to achieve the study aims, the fourth describes the materials 
required to achieve the study aims and the fifth summarises what has been described within 
the chapter. 
2.2 The MRAHF Cohort 
The participants included in this study were recruited as part of a trial entitled ‘Mitral 
Regurgitation in Acute Heart Failure’ (MRAHF), identifier NCT02728739. This is a single-
centre prospective cohort study of consecutive acute heart failure (AHF) patients with a 
specific focus on the effect of mitral regurgitation in AHF in terms of economic burden and 
prognostic impact.  
This thesis is derived from the data acquired as part of the MRAHF trial and the methods and 
materials described in this chapter focus on the recruitment, data collection and analysis 
required to meet the aims of this thesis. Outcome data are still being collected as part of the 
MRAHF trial, but 6-month follow-up data are available for all patients recruited within the 
trial and are included in this thesis. 
2.3 Thesis Aim and Hypothesis 
This thesis aims to study the AHF population of a typical district general hospital in the 
United Kingdom. In doing so, the main foci are twofold:  
Firstly, with reference to the recent European Society of Cardiology guidelines call for data, 
the study aims to characterise and elucidate the differences present within and between the 
new categories of heart failure (HF), namely heart failure with preserved ejection fraction 
(HFpEF), heart failure with mid-range ejection fraction (HFmrEF) and heart failure with 
reduced ejection fraction (HFrEF). Specifically, it aims to look at distinguishing 
echocardiographic features between these groups in terms of myocardial deformation 
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imaging. This study hypothesises that left ventricular strain and strain rate values will vary 
according to subcategory, as defined by LVEF.  
Secondly, the study aims to elucidate clinical parameters, available to the typical medical 
practitioner within the first day of patient admission, that can be used to estimate risk of 
mortality at 6 months post discharge. In doing so it aims to provide information regarding 
factors which can better inform the practitioner and patient about medium term prognosis. 
This can help to guide intensification or relaxation of medical or interventional management.  
This study hypothesises that a simple, valid, tool to stratify 6-month mortality risk in AHF 
can be produced using only data available to the clinician in the acute phase of admission for 
AHF. 
2.4 Methods 
The following section describes the methods used to achieve the study aims. It will cover the 
process of study design, and then the practical logistics of the screening and recruitment 
processes as well as data capture and data management. 
2.4.1 Study design 
This study was completed using data from the MRAHF study. The MRAHF study was 
designed as a prospective cohort study of consecutive patients admitted to a single hospital 
centre with AHF as the presenting complaint over a period of one year. As outlined in chapter 
one, prospective consecutive studies reduce study selection bias and are recognised as the 
optimum study design for assessing and producing clinical risk scores, specifically as it 
allows the trial team to ensure complete data collection at the time of enrolment (Han, Song 
et al. 2016). It also helps to produce a study cohort that is as true to real-life AHF populations 
as possible. This enables us to more confidently use the data to describe differences within 
that cohort as applicable to real-world scenarios, or to make predictions about future 
scenarios with AHF patients.  
While multi-centre studies are able to provide greater numbers of patients, and therefore often 
statistically more powerful results, a single centre offers the ability to reduce study 
variability. By reducing variables such as echocardiography technique, recruitment intensity 
and data collection, inherent variability in the study can be substantially reduced. 
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In the four calendar years preceding the study, the number of HF patients admitted to the 
single hospital site selected numbered 357, 370, 412 and 460 respectively. These data were 
sourced from HES coding data, which are extracted from discharge summaries. Reflecting 
the gradual growth of HF admissions by approximately 30-40 patients per year, a final 
recruitment target of 500 patients was set.  
Ethical approval was received from the NHS Research Ethics Committee (REC) North of 
Scotland 2 with a letter of Favourable Opinion received on 28/04/2016. REC reference for 
this is 16/NS/0047. IRAS project ID is 194815 and Protocol number is MHL-2016-001. 
Ethical approval from the HRA was not applicable for the study as it was to be performed at a 
single hospital site with an existing research contract in place.  
Future project applications wishing to access the study data will be assessed and will have to 
follow strict Medical Research Council ethical guidelines (MRC working group 2012). 
2.4.2 Study population and sampling 
Patients were screened and recruited at the sole participating clinical site, a large district 
general hospital in the south of England. The study population includes patients from the 
surrounding catchment area which encompasses a population of over 410,000 people.  
Sampling of a specific subset of the population in question is typically performed to ensure a 
representative or reproducible cohort. This can be performed via a multitude of means, 
including, but not limited to, random, systematic, stratified and cluster sampling. These 
methods attempt to sample a statistical population in order to avoid the necessity of recruiting 
the entire population of interest. In order to ensure true population representation this study 
has opted for systematic sampling. While this is time-consuming, it guarantees that the 
population data collected is truly representative as it is exhaustive. Consecutive recruitment 
was ensured by screening daily throughout the recruitment period including weekends, bank 
holidays and holiday seasons. 
2.4.3 Inclusion and exclusion 
Inclusion criteria for the study: 
1) Clinical signs and symptoms consistent with AHF as the primary cause for admission 
2) Inpatient admission of <7 days by time of consent 
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3) The ability to give informed consent 
Exclusion criteria for the study: 
1) Point-of-care test (POCT) B natriuretic peptide (BNP) level <100 pg/ml 
2) Echocardiography inconsistent with a diagnosis of HF 
Clinical criteria for diagnosis are based on guidance from the European Society of 
Cardiology (ESC) (Ponikowski, P., Voors et al. 2016) and signs and symptoms consistent 
with AHF is a clinical judgement as described in the first chapter (see Table 1.1). The study 
aimed to identify all consecutive patients admitted with AHF as their primary complaint. For 
the purposes of the study AHF was defined as rapid onset or worsening of symptoms of HF 
requiring non-elective admission to hospital for investigation or treatment as per the ESC HF 
guidelines (Ponikowski, P., Voors et al. 2016) . 
Any patients admitted with AHF as a concomitant issue but not the primary cause for 
admission were not considered for recruitment. CHF is relatively common in the elderly 
population, a population who account for the majority of hospital inpatients. As such many 
patients will be admitted with a concomitant diagnosis of HF which is unrelated to their 
current admissions and thus does not reflect decompensated AHF.  
To reduce heterogeneity of the echocardiographic dataset, patients were required to be 
recruited within a standardised timeframe, preferably as close to admission as possible and 
excluded if time since admission exceeded 6 days. POCT BNP assay was used rather than 
laboratory based biochemical assay to improve speed of assessment. While formal laboratory 
assays of BNP levels are returned to the requesting physician in approximately one to two 
hours, POCT for BNP can be performed by the recruiting physician in less than a quarter of 
the time. This increases the efficiency of the recruitment process with minimal loss of 
diagnostic accuracy; when tested against laboratory analysers, linear regression analysis 
demonstrated that the i-STAT POCT BNP analyser has a correlation coefficient of 0.997 
compared to the laboratory values (Shah, Terracciano et al. 2010). BNP level of <100 pg/ml 
was selected as the exclusion level as data from the manufacturer of the POCT analyser notes 
that in their disease-free sample population, physiological levels were <100 pg/ml in 90% of 
patients (see Appendix 1.1). This also reflects ESC guidance which recommends a using 
BNP levels of <100 pg/ml as a rule-out screening tool for diagnosis of AHF (Ponikowski, P., 
Voors et al. 2016). In comparison with other POCT devices, the Abbott i-STAT has been 
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found to offer significant improvements in accuracy and speed of data availability, while it 
correlates with laboratory values. It is more costly than other POCT devices and laboratory 
methods, but this was not considered a barrier in the administration of this study (Shah, 
Terracciano et al. 2010). 
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Figure 2.1 – Study Flowchart demonstrating the process of screening and recruitment to the 
MRAHF trial. 
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2.4.4 Ethical considerations 
Informed written consent was obtained from all patients recruited to the study prior to any 
investigations being performed or data collected. If the patient was unable to give consent 
due to lack of capacity or writing difficulties, then next of kin were consulted for written 
consent. If this was not possible then patients were excluded from recruitment. 
Necessarily, patients were often approached for recruitment very shortly after admission. To 
facilitate true informed consent patients were given as much time as they wished with the 
patient information sheet and all questions that arose were answered where possible. 
Relatives were encouraged to be part of the discussion. In doing so the patient was offered as 
much information as possible to make an informed decision on their involvement. Where 
requested, patients were given time overnight to await family members to discuss the 
decision and alleviate any specific concerns. This allowed for greater family engagement and 
patients were thus typically keener to engage with the study. 
Where language barriers were an issue, formal translators were requested, and where not 
possible, other members of hospital clinical staff were asked for their assistance in conveying 
the required information. Use of family members was avoided where possible. This was done 
to aid patient understanding and informed consent, while non-clinical staff were not used in 
order to avoid errors of clinical mistranslation and thus misleading the patient. 
Each patient enrolled in the trial was allocated a study number for use in data analysis. This 
enabled anonymization of all data and ensured confidentiality of patient details. A reference 
file was maintained on two secure hard-drives obtained from Western Digital as described 
below in the materials section. This reference file allows matching of patient identifiable 
details to their study number in case this is required at a later date. As the trial intended to 
look at outcomes in all AHF patients under contemporary conditions, biochemical results and 
information obtained via echocardiography performed as part of the study were not revealed 
to either patient or the clinical team unless either test suggested life-endangering or life-
altering pathology. This was done to ensure that clinical practice remained as close to normal 
as possible and that the study itself did not influence outcomes.  
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If there were concerns regarding pathology identified on research echocardiography that was 
not already known by clinicians, these cases were discussed with the academic and clinical 
supervisors to advise on when and how to reveal this data to the clinical team. 
2.4.5 Screening Process 
Screening began in July 2016 and study recruitment ended in September 2017. During this 
period all patients admitted to the hospital were screened for potential recruitment to the 
study. Screening occurred daily, including weekends and holidays, throughout this period to 
ensure complete capture of the dataset. 
Screening was performed by using a range of computer-based tools. Two key pieces of 
hospital software were accessed each morning to search for patients likely to meet the 
inclusion criteria. The first, Inpatient Lists (IPL), is a bespoke piece of software that allows 
tracking of any patient admitted to the hospital. Within this software is a subsection which 
allows for viewing of all patients admitted to the hospital through the medical team in a 24-
hour period, including their presenting complaint. With this tool patients could be identified 
and tracked within the hospital for further screening (see Figure 2.2). The second, RealTime, 
is a bespoke piece of software which displays current bed occupancy throughout the hospital 
with accompanying clinical details. Any patient whose digitally-recorded clinical information 
on RealTime described signs or symptoms consistent with heart failure were noted and 
considered for further screening (see Figure 2.3).  
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Documented clinical notes for each identified patient were examined. If signs and symptoms 
documented within suggested a primary diagnosis of AHF then patient was approached to 
clarify signs and symptoms via clinical history and examination. 
Figure 2.3 – Screenshot taken from RealTime clinical software. This demonstrates the 
ability to locate patients and screen clinical symptoms and provisional diagnosis. 
Figure 2.2 – Screenshot from Inpatient lists software, medical admissions screen. 
From this screen one can look at the details of patients admitted to hospital and screen for 
signs and symptoms related to AHF. 
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Patients with HF clearly as a concomitant problem rather than primary cause of admission 
were excluded from the study. An example of this from the study would include a patient 
admitted due to fracture of the femur who, post-surgery, developed clinical signs and 
symptoms of HF. As this was not the primary admitting pathology they were not considered 
for recruitment.  
Those patients who had been discharged prior to assessment or recruitment were documented 
in the screening list. This typically occurred if patients were admitted and discharged within a 
24-hour period. The total numbers of patients who were suitable for screening but who 
declined assessment or enrolment were noted for completeness and no further data were 
recorded. 
Patients with signs and symptoms consistent with AHF as the cause of their admission were 
provided with patient information sheet version 1.1 25th April 2016 for their consideration 
(see Appendix 1.2). After reading this and answering any questions that had arisen from the 
information provided, they were then then asked for their consent to recruitment into the 
study. If they agreed then written consent was obtained formally using patient consent form 
1.1 25th April 2016 (see Appendix 1.3). Recruited patients then underwent phlebotomy for a 
POCT BNP level. All patients underwent POCT BNP only, with no formal lab BNP used 
throughout the study in order to maintain homogeneity.  
POCT BNP tests were used to increase the speed of screening and efficiency of 
echocardiography; formal laboratory values for BNP are typically returned between 1 and 2 
hours after sampling at the clinical site. If this had been used then the maximum number of 
patients screened per day would have been approximately 5, limiting the number of patients 
possibly recruited each day and negatively impacting upon the feasibility of truly recruiting 
all consecutive patients.    
POCT BNP and formal laboratory BNP assay values correlate well (Shah, Terracciano et al. 
2010). As such, formal inpatient biochemistry values were not reviewed prior to assessment 
of the patient and all documented BNP values were taken from POCT BNP assays.  
Bedside BNP was measured using the i-STAT BNP monitor (Abbott POCT ltd). Regular 
calibration of this device was performed as advised by the user guide (see Appendix 1.4). To 
perform a POCT BNP assay, a sample of peripheral venous blood is taken via phlebotomy, 
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transferred directly onto the i-STAT BNP cartridge and inserted into the i-STAT BNP 
analyser. The test runs for 10 minutes and provides the user with a point-of-care BNP level. 
The BNP range possible using the device is 15-5000 ng/L. Outside of this range it either 
provides the result ‘<15 pg/mL’ or ‘>5000 pg/mL’.   
Patients with a POCT BNP level <100 pg/ml underwent no further investigations and were 
informed of their exclusion from the study.  
2.4.6 Admission data collection 
Patients enrolled in the study with a BNP level ≥100 pg/ml, underwent clinical assessment. 
Clinical characteristics data were collected using a standard data collection form. This was 
subsequently entered to a password-protected online database. Data variables collected are 
outlined in Table 2.1 below: 
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Demographic data Biochemistry data Previous admissions 
data 
Initial investigations 
Date of Birth 
(dd/mm/yyyy) 
Sex  
Ethnicity 
Date of admission 
(dd/mm/yyyy) 
Haemoglobin level (g/L) 
Estimated glomerular filtration rate 
(ml/min) 
Creatinine level (µmol/L) 
Sodium level (mmol/L) 
Potassium level (mmol/L) 
White cell count level (109/L) 
Urea level (mmol/L) 
C-reactive Protein level (mg/L) 
Admissions of any cause at 1,2 
and 3 years 
Admissions due to heart failure 
at 1,2 and 3 years prior to 
index admission 
Length of previous hospital 
stay 
Length of stay by consent for 
study 
ECG – rate (bpm), rhythm, 
QRS duration (ms) 
CXR – Orientation, cardiac 
width (cm), thoracic width 
(cm), radiologist report 
Clinical data Comorbidity data Community 
pharmacotherapeutic use 
on admission (true/false) 
Symptoms leading to admission 
Aetiology of HF 
Height (m) and Weight (kg) on admission 
Non-invasive systolic and diastolic blood pressure 
on admission (mmHg) 
Heart rate on admission (bpm) 
Non-invasive blood oxygen saturation at 
admission (%) 
Presence or absence of cardiac murmur on 
admission assessed by the research team 
Presence or absence of cardiac murmur as 
documented by the admitting team 
AMTS on admission 
Oxygen device requirements on admission 
Venous blood gas pH and lactate on admission 
Heart Failure 
Mitral Regurgitation 
Hypertension 
Diabetes Mellitus 
Chronic Kidney Disease 
Current smoking status 
Chronic obstructive pulmonary 
disease 
Cerebrovascular accident 
Dementia 
Compliance with medications 
ACEi 
ARB 
ARNI 
BB 
MRA 
Nitrate-based vasodilators 
CCB 
Digoxin 
Diuretic 
Selective sinus node inhibitors 
Table 2.1 – Data parameters collected from patient admission records  
ACEi – Angiotensin Converting Enzyme inhibitor, AMTS – Abbreviated mental test score, ARB – Angiotensin Receptor 
Blocker, ARNI – Angiotensin Receptor Blocker and Neprolysin Inhibitor, BB – Beta Blocker, CCB – Calcium Channel 
Blocker, CXR – Chest x-ray, ECG – Electrocardiogram, MRA – Mineralocorticoid Receptor Antagonist. 
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All demographic data were recorded as they had been documented in hospital patient records 
and clarified with the patient.  
 
All clinical data were recorded as documented by clinical staff. Presence of a cardiac murmur 
was assessed by the research team prior to recording documented auscultation by the clinical 
team. This avoided their interpretation biasing the research assessment.  
 
Aetiology of HF was defined using the CHAMP aetiology headings as outlined by ESC 
guidelines (Ponikowski, P., Voors et al. 2016) - acute coronary syndrome (C), hypertensive 
crises (H), arrhythmia (A), mechanical (M), or pulmonary disease (P). Two additional 
categories were used, namely Medication Withdrawal (MW) and Unknown Aetiology (U). 
Decisions regarding aetiology were taken by the recruiting clinicians’ assessment using 
biochemical, radiological and echocardiographic information. Where there was doubt or 
concern over aetiology this was discussed with the other research fellow and PI, a consultant 
cardiologist, to determine likely aetiology according to clinical, biochemical and radiological 
evidence available both upon and prior to admission to hospital. Where no evidence of a 
specific underlying cause was evident then patients were categorised as Unknown Aetiology.  
 
Biochemical data were taken from the earliest available biochemical results at admission. 
eGFR was calculated using the abbreviated modified diet in renal disease equation.  
 
Comorbidity profile was recorded according to either patient self-reporting, documentation of 
comorbidity in their medical notes or in previous discharge summaries. Documentation of 
chronic kidney disease (CKD) is often unclear so this was recorded as positive as per NICE 
guidelines (National Institute for Health and Care Excellence 2014). 
 
Admissions data and length of stay were sourced from electronic discharge summaries 
recorded on the IPL software.  
 
Pharmacological use on admission and compliance data were both recorded as reported by 
patients and/or medicines reconciliation information routinely collected and documented by 
pharmacy staff.  
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Electrocardiographic (ECG) data were extracted from ECG studies routinely performed by 
qualified hospital staff.  Separate analysis of the ECG was performed, and results 
documented. CXR report from the reporting radiologist was printed and retained, either at the 
time of recruitment or retrospectively if not available. Orientation of X-ray image was 
documented. Cardiac shadow width, thoracic width and cardiothoracic ratio were measured 
and calculated as described by Chana et al (Chana, Martin et al. 2015). 
 
Bedside transthoracic echocardiography (TTE) was then performed within 2 hours of 
recruitment by one of 3 ultrasonographers accredited by the British Society of 
Echocardiography (BSE). This was performed according to a standardised image acquisition 
protocol (see Appendix 1.5). The primary sonographer underwent re-accreditation during the 
study period to demonstrate ongoing proficiency at a standard recognised by the BSE. 
2.4.7 Offline and post-discharge data collection 
Further data were collected after recruitment was completed and all enrolled patients had 
been discharged from the hospital. Data variables collected are outlined in Table 2.2 below: 
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Outcome data Admission data Echocardiographic data 
Date of discharge 
(dd/mm/yyyy) 
Length of stay (days) 
Number of readmissions at 
1, 3 and 6 months: Total, 
Cardiovascular disease and 
HF 
Mortality at index 
admission, 1, 3 and 6 
months 
Cause of mortality 
Time from discharge to 
death (days) 
Medication prescription on 
discharge – ACEi, ARB, 
ARNI, BB, MRA, nitrate-
based vasodilators, CCB, 
Digoxin or diuretic 
Diagnosis of a 
cardiovascular 
disease 
Diagnosis of acute 
heart failure on 
admission 
Cardiology review 
on index admission 
Echocardiography 
performed on index 
admission 
LV geometry – LV end diastolic diameter (cm), LV 
end systolic diameter (cm), LV end diastolic 
volume (ml), LV end systolic volume (ml), LVEF 
(%) 
Transmitral flow – LV dp/dt, E (cm/s), A (cm/s), 
E/A ratio 
Tissue Doppler – E’ peak velocity (cm/s), S’ peak 
velocity (cm/s) 
RV geometry – RV diastolic area (cm2), RV 
systolic area (cm2), RVFAC 
Mitral and tricuspid valve geometry – RV basal 
diameter (cm), tricuspid annular diameter (cm), 
mitral valve annular diameter (cm), mitral valve 
commissural annular diameter (cm) 
Severity of mitral regurgitation 
Severity of tricuspid regurgitation 
Systolic pulmonary artery pressure (mmHg) 
Left ventricular strain (%) and strain rate (s-1) 
Table 2.2 – List of variables collected post-discharge and via offline analysis of echocardiography. 
ACEi – Angiotensin Converting Enzyme inhibitor, ARB – Angiotensin Receptor Blocker, ARNI – 
Angiotensin Receptor Blocker and Neprolysin Inhibitor, BB – Beta Blocker, CCB – Calcium Channel 
Blocker, LV – Left ventricle, LVEF – Left ventricular ejection fraction, MRA – Mineralocorticoid 
Receptor Antagonist, RV – Right ventricle, RVFAC – Right ventricular fractional area change. 
 
Length of stay data were obtained from the IPL software and calculated including both the 
day of admission and discharge.  
 
Readmission data were taken from the IPL lists. For the purposes of this study, CVD is 
defined as diseases including coronary heart disease (CHD), cerebrovascular accident (CVA), 
peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep vein 
thrombosis, valvular heart disease, inflammatory heart disease and cardiac arrhythmias.  
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Mortality data were acquired via summary care records online system. Cause of death 1a, 1b 
and 2 were taken from death certificates. These were accessed either through the hospital 
bereavement service for inpatient deaths, general practice records where available or local 
council records. 
 
Diagnosis data were taken from admission clerking notes as documented by either registrar or 
consultant, whichever most senior doctor saw the patient on admission. Cardiology review is 
defined as documented evidence of review by cardiology registrar or a more senior 
cardiologist. Evidence of echocardiography during admission was taken from records of 
echocardiography documented on the IntelliSpace® picture archiving and communication 
software (PACS) enterprise software. Discharge medication lists were taken from digital 
discharge summary accessed via IPL. 
 
All echocardiographic parameters were measured according to BSE recommendations. 
 
Myocardial deformation measurements (strain and strain rate) were made using 
echocardiography derived tissue speckle tracking analysis. As noted earlier a typical echo 
protocol was used with a specific focus on the mitral valve (see appendix 1.4). 
 
2.4.8 Myocardial deformation analysis 
Myocardial deformation analysis of the left ventricle was performed using EchoPac software. 
Each patient had deformation imaging assessed in the 4, 2 and 3 chamber views. 
Mechanical systole was timed according to aortic valve opening and closure, assessed using 
pulse wave Doppler.   
Analysis was considered feasible if the patient had more than 2 segments available for 
analysis. Endocardial border tracing was performed, and the software automatically tracks 
speckles within the echo image to derive strain and strain rate values for 6 segments in each 
view.  
Deformation analysis was performed in each view and global longitudinal strain and strain 
rate was derived by the software.  
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2.4.9 Data management 
The data recorded from both the data record sheet and the echocardiography were uploaded 
to a secure online database maintained by an independent outsourced company, Metanoic 
Health Limited, UK. Copies of the ECG from admission as well as the report of chest 
radiography on admission were digitally scanned and uploaded to the online database.  
 
Data were exported each month to Microsoft Excel spreadsheet software to screen for 
accidental omissions in data. Any omissions in the data were completed by recourse to the 
original data collection proforma, or to the appropriate source material where data had not 
been clearly collected in the data proforma. When all omissions had been replaced the data 
were transferred to the software package Statistical Package for the Social Sciences (SPSS) 
version 24, produced by IBM. Histograms were performed on all continuous data to screen 
for statistical outliers, defined according to visual assessment of the histogram (see Figure 
2.4). Any outlying data were then rechecked via recourse to the original data collection 
proforma or alternate source material to screen for input errors or errors of measurement.  
Errors were corrected and updated on the initial data proforma as well as the online database 
where necessary. 
 
Figure 2.4 – Screenshots of histograms produced to assess for data anomalies. In the 
left histogram (SBP) the data fit the normal distribution whereas in the right (K) there is a 
statistical outlier. These data were checked for accuracy and for data entry errors. 
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The echocardiography data were retained on two separate hard-drives in two separate 
locations to allow for off-site analysis and to reduce the risk of data loss in accordance with 
Good Clinical Practice (GCP) research standards. 
 
2.5 Materials 
The following section describes the materials required to conduct the study using the above 
methods. These materials are required to ensure accuracy and quality of the data collected, 
and thus the validity of the study itself. 
 
2.5.1 Data proforma 
The data collection proforma was developed by the cardiology research team for the MRAHF 
study, forming part of the research protocol and received favourable opinion. Blank 
proformas were stored digitally in a secure research drive, with password protected access 
and were accessed and printed when required for use in recruitment. No specific training was 
required for their use. Once completed these were input onto the online database and the hard 
copies with copies of the ECGs and reports from the chest x-ray radiographs were maintained 
in a folder in a secure research office which has a combination lock for entry.  
2.5.2 Abbott BNP analyser 
The Abbott i-SITE1 BNP machine was obtained from Abbott Laboratories (Abbott) who 
funded the study. Training was provided on use of the device upon initial receipt of the 
device from Abbott, as well as written documentation regarding its use.  
2.5.3 Abbott cartridges  
i-STAT BNP cartridges were obtained from Abbott. They were refrigerated as per instruction 
from Abbott at between 2 and 8ᵒC, using a Labcold Pharmacy Refrigerator.  
 
Quality control was routinely performed on the i-STAT cartridges as per Abbott’s instruction 
(see Appendix 1.6). For each new batch of received cartridges or control materials the 
temperature of transfer was verified using four-window temperature indicator strips included 
in the shipping container. This was followed by testing of a sample cartridge using i-STAT 
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Control levels. These control vials were samples of human serum with pretested levels of 
BNP against which the i-STAT BNP analyser could be tested. Three control levels were 
provided for testing. To test the cartridges a control sample vial was mixed then opened, a 
drop of fluid was transferred to the i-STAT cartridge using the dropper tip then the control 
level was returned to storage. The cartridge was sealed and inserted into the i-STAT BNP 
machine. After 10 minutes this produced a sample value which was compared against 
expected values as per Value Assignment Sheets available from 
www.abbottppointofcare.com. There were no discrepancies noted throughout the study 
period. 
 
When used for patient screening individual cartridges were left to stand for 5 minutes at room 
temperature prior to use as per manufacturer’s instructions. Whole blood samples were 
collected via peripheral venous phlebotomy. Phlebotomy was performed using a butterfly-
needle method attached to an Ethylenediaminetetraacetic acid (EDTA) collecting tube, which 
was filled to capacity as per instructions from Abbott.  
 
The i-STAT BNP analyser was then turned on, the operator identification number was 
entered, the patient identification number was entered, and the barcode of the i-STAT BNP 
cartridge packet was scanned to the device. The cartridge packet was opened, and the 
cartridge removed for use. 
 
The blood sample in the EDTA tube was then transferred to a syringe, from which the first 
1ml of blood were discarded. Remaining blood was then added to the i-STAT BNP cartridge 
which was subsequently closed and inserted into the handheld i-STAT device for analysis. 
After 10 minutes the device provided a result. If <15 pg/ml the device would read ‘<15 
pg/mL’, if between 15 and 5000 pg/ml then the number would be produced, and >5000 pg/ml 
the device would read ‘>5000 pg/mL’. This data was noted in the specialised data proforma.  
 
Training was provided on use of the device upon initial receipt of the device from Abbott, as 
well as written documentation and regarding its use.  
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2.5.4 Refrigeration 
As noted above, cartridge storage required refrigeration. Once cartridges had been delivered 
and checked as above regarding temperature window assessment, they were transferred to the 
Research Refrigerator. The refrigerator used was sourced from Labcold and was maintained 
at approximately 6-7ᵒC. If temperatures deviated outside of 2-8 ᵒC an attached alarm logs the 
aberration. It was monitored daily to ensure that no alarm had occurred, and no alarms were 
encountered throughout the study period. The refrigerator was stored in the research clinic 
room which requires a combination lock for entry. No specific training was required for its 
use.  
2.5.5 Materials used for phlebotomy 
Tourniquets used were standard single-use disposable V-Grip tourniquets manufactured by 
Richardson Healthcare. Blood collection safety needles (23-gauge, Reference number 
450086) were used for phlebotomy and were supplied by Vacuette. These were stored on all 
medical wards and the accident & emergency department within the hospital with no special 
requirements for storage. Training in phlebotomy was received during training at medical 
school with subsequent revalidation during training years as a Foundation Year 1 and 
Foundation Year 2 doctor.  
 
EDTA collection tubes (4ml, reference number 454032) were sourced from the hospital 
supply and were manufactured by Vacutainer. These were stored on all medical wards and 
the accident & emergency department within the hospital with no special requirements for 
storage.  
2.5.6 Auscultation 
Auscultation within the research team was performed using a 3M Littmann Master 
Cardiology Stethoscope. This was supplied personally. Required training was provided 
during medical school with yearly assessment of clinical skills assessment and no further 
training was required nor performed. This was stored within the research office which 
requires a combination lock code for entry. 
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2.5.7 Chest radiography 
Chest x-ray radiography was performed by trained radiographers employed by the on-site 
radiography department. The Philips Digital Diagnost HP was used for patients admitted to 
the hospital wards and the Carestream DRX-1 Evolution was used in the Accident & 
Emergency department.  
2.5.8 Echocardiography 
Echocardiography was performed by three individuals. The primary sonographer was a 
research fellow in cardiology. When he was absent due to sickness or annual leave this was 
performed by two other BSE accredited echocardiographers employed by the NHS Trust. To 
reduce inter-observer variability of interpretation, all images were analysed and underwent 
routine data extraction by the primary sonographer. All echocardiograms were performed 
using the G.E Vivid S70 Cardiovascular Ultrasound system. This was sourced from GE 
Healthcare Ltd. All staff practising echocardiography had up-to-date accreditation from the 
British Society of Echocardiography (BSE) to perform Transthoracic Echocardiography to a 
standard expected by the society.  
 
Images obtained via echocardiography were stored dually on IntelliSpace PACS Enterprise 
software and on EchoPac Software Version 201 (see Figure 2.5) with analysis performed 
using the latter software.  
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2.5.9 Chest radiography storage and Echocardiography image storage 
Chest radiograph images with attached interpretation were stored electronically using the 
Philips IntelliSpace® PACS Enterprise Version 4.4.516.21 (PACS) as used within the NHS 
Trust. This was maintained by the Information Technology (IT) department at the NHS Trust 
and required no specific training to use. Access to this software was granted using an 
individual username and password. 
 
2.5.10 Electrocardiography 
All ECGs were performed on admission by nursing and healthcare assistant staff, trained to 
perform electrocardiography. The machine used was the GE Healthcare MAC 5500 HD with 
standard calibration. Values such as rate and QRS duration are calculated automatically by 
the machine. Where not calculated, these calculations were performed manually. Assessment 
of rhythm was also performed manually. Where unclear, ECG data was reviewed with the 
primary investigator, a consultant cardiologist. 
 
Figure 2.5 – Screenshot demonstrating the review function of Echopac software. 
Echopac is used to store, view and analyse echocardiographic images. 
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2.5.11 Data manipulation and statistical analysis software 
Data were exported initially to Microsoft Excel 2010, used by the local NHS Trust as part of 
the Microsoft Office 2010 software bundle.  
 
Data were then transferred to SPSS software package. All data analysis was performed using 
this software. Training in the use of SPSS was provided by Royal Holloway University of 
London as part of the postgraduate research course.  
 
2.5.12 Data storage 
After echocardiography had been performed, the image data were transferred to two separate 
hard drives, stored separately so as to avoid the possibility of data loss. The hard drives used 
were 1 Terabyte Western Digital My Passport Ultra External Hard drives. They required no 
specific training prior to use. 
 
2.5.13 Online database 
Data were input to a bespoke online database created and maintained by an independent 
outsourced company; Metanoic Health limited. This database contained data input sections 
for each of the above data streams. It is password protected, with access granted only to the 
administrator and the two research fellows working with the data. Data from the database 
could be downloaded as a Microsoft Excel file during the study to allow for data screening 
and correction. Upon completion of the study and subsequent to error correction this database 
was locked, with the option to download a read-only excel file to ensure accuracy and 
consistency of the data used within the research group. 
2.5.14 Data analysis 
All data were analysed using SPSS software version 24 as described above.  
 
Continuous variables were tested for normality using the Shapiro-Wilk tests, and evidence of 
skew was inspected visually using histograms, Q-Q plots and box plots.  
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Parametric continuous data are displayed as mean +/- standard deviation (SD). Non-
parametric continuous data are presented as median with interquartile range (IQR). 
Categorical variables are presented as a percentage proportion of the population.  
 
Continuous parametric variables were analysed using Student’s T test when categorised as 
two groups or using one-way analysis of variance (ANOVA) when more than 2 groups 
existed, as for AHF subcategories. 
 
Categorical data were compared statistically using Pearson’s Chi-squared test. 
 
Statistical differences in non-parametric continuous variables were assessed using the Mann-
Whitney U test or Kruskal-Wallis test when more than 2 groups were present. 
 
Binomial logistic regression analysis was performed to assess contribution of variables within 
models assessing mortality and binary presence of readmission at 6 months post discharge. 
Receiver operator characteristic curve area under the curve (ROCAUC) analysis was 
performed on the models created and Net reclassification index analysis was performed on 
the two models to assess for evidence of statistical improvement.  
An alpha value of 0.05 was set as the threshold for statistical significance and familywise 
multiple testing correction was performed where appropriate. 
 
2.6 Chapter Summary 
This chapter has described the various methods used in the design of this study and has 
subsequently described the materials required to execute it. The following chapters will 
describe results obtained from analysis of the dataset obtained.  
 
Firstly, the dataset will be examined according to HF subcategory as defined by LVEF and 
compared to a large prospective registry study, the EuroHeart Survey II. Secondly, the 
difference between myocardial deformation parameters within novel heart failure 
subcategories with be assessed, and finally this study will assess the ability of using data 
collected from this patient cohort to produce risk scoring models to predict all-cause 
mortality at 6 months post discharge. This first will use only clinical, demographic and 
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biochemical data, while the second will include echocardiographic data. The two will be 
compared to assess the statistical and predictive benefit of the additional data. Both will look 
at variables which are feasibly acquired during the acute admission period to allow for early 
prognostication and assessment of the likely patient journey. 
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Chapter Three: Baseline characteristics of the MRAHF 
cohort and comparison against the EuroHeart Failure II 
survey 
3.1 Chapter introduction 
This chapter describes the baseline characteristics of the acute heart failure (AHF) cohort 
included in this thesis and compares the patients according to the novel HF subcategories 
outlined in the 2016 European society of cardiology (ESC) guidelines (Ponikowski, P., Voors 
et al. 2016). This comparison demonstrates the extent to which the mitral regurgitation in 
acute heart failure (MRAHF) cohort is consistent with previous literature on inter-category 
differences. It then compares the MRAHF cohort to that of an international registry study, the 
EuroHeart Failure Survey II (EHS II) (Nieminen, Brutsaert et al. 2006) to demonstrate the 
advantages and disadvantages of each study, as well as the inter-cohort differences which 
may affect generalisability of the results. 
This chapter first summarises the current literature regarding the novel HF subclassifications. 
It then describes the recruitment criteria for the MRAHF study and outlines the baseline 
characteristics of the MRAHF cohort stratified by left ventricular ejection fraction (LVEF) 
subcategory. Finally, it outlines the recruitment criteria for the EHS II study and contrasts the 
characteristics and advantages and disadvantages inherent to the study design of the two 
cohorts.  
3.1.1 Current literature and aims 
The concept of HF as a consequence of reduced systolic function has existed for as long as 
the concept of the disease and is now formally recognised as HF with reduced ejection 
fraction (HFrEF), while HF with preserved ejection fraction (HFpEF) was recognised in the 
1980s (Dougherty, Naccarelli et al. 1984).  
Since 2016, both European and American guidelines have included three HF subcategories, 
defined according to LVEF (Ponikowski, P., Voors et al. 2016, Yancy, Jessup et al. 2013). 
The subcategory of HF with borderline or mid-range ejection fraction (HFmrEF) was 
introduced due to concerns that patients with this intermediate LVEF value may represent an 
alternate HF phenotype with different pathology when compared to either HFrEF or HFpEF. 
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By better identifying HFmrEF patients and delineating the characteristics of this group, the 
underlying pathological mechanisms provoking their disease may be identified. Ultimately, 
this may aid the development and provision of prognosis-altering medications. This is 
important as currently only patients in the HFrEF group have evidence-based 
pharmacotherapeutics, despite HFrEF only accounting for approximately 50% of the total 
burden of HF (Chioncel, Mebazaa et al. 2017). 
Since the introduction of the novel category, HFmrEF has been well characterised in terms of 
demographic, clinical and biochemical parameters by re-evaluating large registry studies. 
Typically, parameters from the HFmrEF group have been found to act as an intermediate of 
those found in HFrEF and HFpEF (Tsuji, Sakata et al. 2017, Cheng, Cox et al. 2014). Data 
derived from registry studies are often hindered by the study design, and frequently fail to 
recruit all eligible patients as they are largely non-consecutive studies. 
The MRAHF study recruited a consecutive cohort of AHF patients, representative of typical 
AHF patients within a district general hospital in the United Kingdom. In addition, the aim 
was to focus on recruiting every admitted AHF patients, specifically attempting to recruit 
those who may have been initially misdiagnosed as having a non-cardiological admission, to 
ensure representation of the entire possible AHF cohort. This therefore includes the full range 
of patients in the HFrEF, HFmrEF and HFpEF subcategories. 
The EHS II study was a multi-centre prospective study, designed to assess characteristics of 
patients with AHF throughout Europe, with a specific focus on aetiology, treatment and 
outcome. It was designed to represent typical AHF patients and ran from 2004 to 2005 
(Nieminen, Brutsaert et al. 2006). 
It is the most recent large AHF registry with adequate data for quantitative comparison; other 
more recent studies such as the European Society of Cardiology Heart Failure Long-Term 
study (ESC-HF-LT) do not provide data in terms of standard deviations to allow comparative 
quantitative analysis (Chioncel, Mebazaa et al. 2017). 
In the following chapter the baseline characteristics of the MRAHF cohort used in this study 
will be outlined, with data stratified according to HF subcategories, and then the data from 
the MRAHF cohort will be compared to existing registry data from the EHS II study to 
demonstrate similarities and difference from an existing cohort of AHF patients. In addition, 
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the advantages and disadvantages inherent to both studies will be discussed. This will help to 
assess the generalisability of the results and the conclusions drawn from them.  
3.2 Methods 
Chapter two describes the materials and methods required for recruitment of the MRAHF 
cohort in detail. A summary of this is outlined below. 
3.2.1 The MRAHF study cohort 
The patient population used in this thesis is derived from the MRAHF study of AHF patients. 
Patients were recruited into the study cohort as described in detail in the previous chapter, but 
major inclusion and exclusion criteria are included below in Table 3.1. Patients within this 
study were recruited from throughout the hospital, in all medical, surgical, high dependency 
and intensive care wards, and included patients seen in the Accident and Emergency 
department. 
Inclusion criteria Exclusion criteria 
Clinical Signs or symptoms consistent with 
AHF as the primary cause for admission 
Point-of-care BNP level <100 pg/ml 
Inpatient for <7 days by time of consent Echocardiography inconsistent with a 
diagnosis of AHF 
Ability to give informed consent  
Table 3.1 – Inclusion and exclusion criteria for recruitment to the MRAHF study. 
 
The entire patient cohort recruited in the MRAHF study was used for analysis in this study. 
616 patients were screened in a period of 13 months from July 2016 to September 2017. 500 
patients gave informed consent to take part in the study and were recruited. 447 patients 
remained after subsequent exclusions based upon Point-of-care test B natriuretic peptide 
(POCT BNP) level and Echocardiography. A flow chart demonstrating patient recruitment 
numbers is included below in Figure 3.1. 
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 Figure 3.1 – Study flowchart demonstrating the screening and exclusions process. Included to the 
right are final numbers of patients recruited and excluded at each stage. 
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3.2.2 Categorisation of the MRAHF cohort 
Patients were subdivided into categories according to LVEF as per Table 3.2 and compared 
to assess for statistical differences between demographic, observational, biochemical and 
radiographical parameters. 
HFrEF HFmrEF HFpEF 
LVEF <40% LVEF 40-49% LVEF ≥50% 
Table 3.2 – AHF cohort subcategories according to LVEF values. 
 
3.2.3 Statistical analysis 
All statistical tests were performed using the Statistical Package for the Social Sciences 
(SPSS) version 24 developed by International Business Machines (IBM).  
Continuous variables were tested for normality using the Shapiro-Wilk tests, and evidence of 
skew was inspected visually using histograms, Q-Q plots and box plots. 
Continuous parametric variables were analysed using two-tailed Student’s T test when 
categorised as two groups or using one-way analysis of variance (ANOVA) when more than 
2 groups existed, as for AHF subcategories. Tukey’s post-hoc test was used to determine 
statistical significance of specific inter-group variations.  
Statistical differences in non-parametric continuous variables were assessed using the Mann-
Whitney U test, or Kruskal-Wallis test when more than 2 groups were present. Dunn’s post-
hoc test was used to delineate the statistical significance of specific inter-group variations.  
 
Pearson’s Chi-squared test was used to assess for statistical differences between categorical 
variables. 
 
Baseline characteristics of the MRAHF cohort are reported stratified by HF subcategory as 
described in Table 3.2. 
When comparing data from the MRAHF and EHS II cohorts, outlying data from the MRAHF 
cohort were excluded from analysis to allow for parametric testing. Student’s T-test was then 
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performed comparing the remaining data to the available means and standard deviations from 
the EHS II study. 
 
Parametric continuous data are presented as a mean ± standard deviation. Non-parametric 
continuous data are presented as a median with interquartile range. Categorical variables are 
presented as a proportion within the population. 
An alpha value of 0.05 was set as the threshold for statistical significance. 
 
3.3 Results 
447 patients were recruited into the study. LVEF was measurable in 444 patients with 3 
patients having images in which assessment of LVEF was not feasible due to the image 
quality. Of the remaining 444 patients, 180 were categorised as HFrEF, 103 as HFmrEF and 
161 as HFpEF.  
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N 
Whole cohort 
 444 (100%) 
HFrEF 
180 (40.5%) 
HFmrEF 
103 (23.2%) 
HFpEF 
161 (36.3%) 
Significance (p) 
- 
Demographics 
Median age, years (IQR) 
 
82 (76-88) 
 
82 (75–89) 
 
85 (80–85) 
 
81 (76–86) 
 
0.06 
Gender, % female 47.7 39.4 45.6 57.8 <0.01 a,c 
European Caucasian, %  91.7 92.8 87.7 93.2 0.20 
Median BMI, kg/m2 (IQR) 26.5 (22.5-31.0) 24.7 (21.5-27.9) 27.0 (21.0–33.0) 28.8 (23.7–33.9) <0.01 * 
Hospitalisation in last year, % 
Median length of stay by recruitment, days (IQR) 
41.2 
1 (0-2) 
43.3 
1 (0-2) 
35.0 
1 (0-2) 
42.9 
1 (1-1) 
0.34 
0.06 
Median length of stay on index admission, days (IQR) 7 (3-11) 7 (4-10) 7 (3-11) 6 (1-11) 0.59 
Alternate primary diagnosis on admission, % 3.7 4.0 2.0 4.4 0.58 
HF Aetiology, n (%) 
Ischaemic 
Arrhythmogenic 
Hypertensive 
Pulmonary Disease 
Mechanical 
Medication withdrawal 
Unclear 
 
 
69 (15.4) 
117 (26.2) 
6 (1.3) 
9 (2.0) 
63 (14.1) 
26 (5.8) 
157 (35.1) 
 
 
37 (20.6) 
48 (26.7) 
3 (1.7) 
0 (0.0) 
15 (8.3) 
12 (6.7) 
65 (36.1) 
 
 
11 (10.7) 
23 (22.3) 
2 (1.9) 
2 (1.9) 
23 (22.3) 
4 (3.9) 
38 (36.9) 
 
 
21 (13.0) 
45 (28.0) 
1 (0.6) 
7 (4.3) 
25 (15.5) 
10 (6.2) 
52 (32.3) 
 
<0.05 
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Comorbidities, % 
HF 
 
58.2 
 
57.2 
 
64.1 
 
55.3 
 
0.35 
IHD 37.8 47.2 31.1 31.7 <0.001 a 
HTN 55.0 56.1 47.6 58.4 0.21 
DM 31.5 30.6 28.2 33.5 0.64 
CKD 46.5 48.3 48.5 42.9 0.52 
COPD 14.3 11.1 13.6 18.0 0.18 
CVA 15.4 16.7 10.7 16.8 0.33 
Admission medication, % 
ACEi 
Whole Cohort 
28.4 
HFrEF 
33.7 
HFmrEF 
20.4 
HFpEF 
28.1 
Significance (p) 
0.06 
ARB 15.1 12.9 17.5 15.0 0.58 
BB 57.9 56.2 51.5 64.4 0.09 
MRA 12.6 12.4 7.8 15.6 0.17 
Diuretic 52.5 52.2 48.5 54.4 0.65 
CCB 18.2 15.2 14.6 23.8 0.07 
Digoxin 12.4 14.6 8.7 12.5 0.36 
ARNI 
 
 
0.0 0.0 0.0 0.0 - 
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Biochemistry, Median (IQR) 
Haemoglobin, g/L 
 
118 (104 – 132) 
 
118 (105-131) 
 
112 (100-124) 
 
119 (104-134) 
 
<0.05 ¥ 
White cell count, 10*9/L (IQR) 8.2 (6.4 – 10.0) 8.5 (7.2-9.8) 6.6 (4.9-7.5) 7.9 (6.0-9.8) 0.23 
Sodium, mmol/L  140 (137 – 143) 139 (136-142) 140 (138-142) 140 (137-143) 0.52 
Potassium, mmol/L  4.4 (4.0 – 4.8) 4.4 (4.0-4.8) 4.3 (4.0-4.6) 4.4 (4.0-4.8) 0.65 
Urea, mmol/L  9.0 (5.6 – 12.4) 9.0 (5.4-12.6) 9.5 (6.0-13.0) 8.7 (5.6-11.8) 0.08 
Creatinine, µmol/L  96 (65-127) 97 (71-123) 101 (67-135) 91 (59-123) 0.108 
POCT BNP tertile, %: 
  100-999 pg/ml 
  1000-2999 pg/ml 
  ≥3000 pg/ml 
 
52.8 
35.3 
11.9 
 
35.6 
43.3 
21.1 
 
50.5 
42.7 
6.8 
 
72.6 
22.4 
5.0 
 
<0.005 a,c 
<0.00001 a,c 
<0.001 a,c 
Clinical Observations, Median (IQR) 
SBP, mmHg (IQR)  
Whole cohort 
135 (118 – 152) 
HFrEF 
128 (113-143) 
HFmrEF 
141 (124-158) 
HFpEF 
140 (124-156) 
Significance (p) 
<0.05 *¥ 
DBP, mmHg (IQR) 73 (61 – 85) 73 (61-85) 80 (70-90) 71 (59-83) 0.09 
AMTS, n/10 (IQR) 10 (10-10)  10 (10-10) 10(10-10) 10 (10-10) 0.31 
NYHA class, %: 
  II 
  III 
  IV 
 
8.7 
38.5 
52.8 
 
10.0 
36.1 
53.9 
 
6.8 
42.7 
50.5 
 
8.1 
39.1 
52.8 
0.78 
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ECG 
Mean heart rate, bpm (SD) 
 
93 (± 29) 
 
97 (± 27) 
 
92 (± 29) 
 
88 (± 31) 
 
<0.005 * 
Rhythm, %: 
  Sinus 
  Atrial Fibrillation 
  Paced 
  Other 
 
40.5 
45.9 
9.3 
4.3 
 
41.9 
41.9 
11.7 
4.5 
 
40.6 
48.5 
8.9 
2.0 
 
39.0 
49.1 
6.2 
5.7 
0.17 
Median QRS duration, ms (IQR) 98 (73 – 123) 114 (91-137) 90 (63-117) 90 (70-110) <0.005 *¥ 
Echocardiography, Median (IQR) 
LVEDV, ml  
Whole Cohort 
110 (76-144) 
HFrEF 
127 (92-165)  
HFmrEF 
109 (81-137) 
HFpEF 
75 (53-97) 
Significance (p) 
<0.005 *¥ Ω 
LVESV, ml  64 (35-93) 91 (64-118) 60 (44-76) 31 (22-40) <0.00001 *¥ Ω 
LVEF, %  44 (33-55) 30 (24-36) 44 (42-46) 58 (54-62) <0.00001 *¥ Ω 
E/A, ratio  1.35 (0.57-2.13) 1.60 (0.90-2.30)  1.00 (0.50-1.50) 1.30 (0.65-1.95) 0.05 
RVFAC, %  40 (30-50) 35 (25-45) 35 (28-42) 40 (32-48) <0.00001 * 
SPAP, mmHg  51 (38-64) 50 (37-63)  52 (39-65) 53 (40-66) <0.05 * 
LAs, cm2  
 
 
 
26 (21-31) 29 (25-34) 30 (26-34) 27 (22-32) 0.74 
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6-month outcomes, % Whole Cohort HFrEF HFmrEF HFpEF Significance (p) 
All-cause readmission 59.1 62.8 57.8 55.0 0.34 
HF readmission 23.7 24.0 23.5 23.2 0.99 
All-cause mortality 28.1 31.7 18.6 30.0 0.05 
CVD mortality 13.8 16.8 9.1 13.1 0.20 
Table 3.3 – Baseline characteristics of the MRAHF study stratified by LVEF subcategory 
* = HFrEF versus HFpEF, ¥ = HFrEF versus HFmrEF, Ω= HFmrEF versus HFpEF                    a – HFrEF, b – HFmrEF, c – HFpEF 
ACEi – Angiotensin Converting Enzyme Inhibitor, ARB – Angiotensin Receptor Blocker, ARNI – Angiotensin Receptor Blocker and Neprolysin Inhibitor, AMTS – Abbreviated Mental Test 
Score, BB – Beta Blocker, CKD – Chronic Kidney Disease, COPD – Chronic Obstructive Pulmonary Disease, CVA – Cerebrovascular Accident, CVD – Cardiovascular disease,  DBP – 
Diastolic Blood Pressure, DM – Diabetes Mellitus, E/A – E:A Ratio,  ECG – Electrocardiogram, HF – Heart failure, HTN – Hypertension, IHD – Ischaemic Heart Disease, IQR – Interquartile 
range LAs – Left Atrial Area in systole, LVEDV – Left Ventricular End Diastolic Volume, LVEF – Left Ventricular Ejection Fraction, LVESV – Left Ventricular End Systolic Volume, MRA – 
Mineralocorticoid Receptor Antagonist, NYHA – New York Heart Association, POCT BNP – Point of care test B Natriuretic Peptide, RVFAC – Right Ventricular Fractional Area Change, 
SaO2 – Oxygen Saturations,  SBP – Systolic Blood pressure, SPAP – Systolic Pulmonary Artery Pressure. 
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3.3.1.1 Demographics 
The median age of the cohort is 82 years (IQR 76-88) and 91.2% are of Caucasian European 
descent. These were statistically comparable between subcategories. 39.4% of patients with 
HFrEF were female, compared to 47.7% in HFmrEF and 57.8% in HFpEF (p<0.01).  Median 
BMI increased from HFrEF to HFmrEF then HFpEF, BMI was significantly lower in HFrEF 
than HFpEF (24.7 kg/m2 (IQR 21.5-27.9) versus 28.8 kg/m2 (IQR 23.7–33.9), p<0.01). A 
diagnosis of a cause other than cardiovascular disease was made by the admitting physician 
in 3.7% of cases, a proportion that was seen statistically comparably throughout all HF 
subcategories. 
3.3.1.2 Aetiology 
Aetiology varies between HF subgroup – Ischaemic aetiology is more common in HFrEF at 
20.6% compared to 10.7% and 13.0% for HFmrEF and HFpEF respectively, while 
Mechanical abnormalities are more common in the HFmrEF and HFpEF subgroups 
compared to HFrEF (22.3% and 15.5% compared to 8.3% respectively). Due to the nature of 
the testing performed none of these are significant when the Bonferroni correction is applied 
but these demonstrate similar signal regarding underlying aetiology seen in each subgroup as 
has been previously described in literature. 
3.3.1.3 Comorbidities 
Comorbidity burden was similar across all groups except in IHD which was significantly 
more prevalent in HFrEF versus the whole cohort (47.2% versus 37.8%, p<0.001). 
3.3.1.4 Admission medications 
Pre-admission medication use was similar across all subcategories with no statistically 
significant differences evident. 
3.3.1.5 Biochemistry 
Median haemoglobin levels were increased in HFrEF compared to HFmrEF (118 g/L (IQR 
105-131) versus 112 g/L (IQR 100-124), p<0.05). POCT BNP levels were relatively higher 
in the HFrEF group and lower in HFpEF; 35.6% of HFrEF patients had BNP levels of 100-
999 pg/ml compared to 52.8% of the total cohort, in contrast to 72.7% of HFpEF patients 
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compared to 52.8% of the total cohort (both p<0.005). 21.1% of HFrEF patients had BNP 
levels in the ≥3000 pg/ml group compared to 11.9% of the total cohort, in contrast 5.0% of 
HFpEF patients compared to 11.9% of the total cohort (both p<0.005). This is demonstrated 
in graphical form below in Figure 3.2: 
 
3.3.1.6 Observations 
Median systolic blood pressure was lower in the HFrEF subcategory upon admission when 
compared to both HFmrEF and HFpEF (128 mmHg (IQR 113-143) versus 141 mmHg (IQR 
Figure 3.2 – Comparison of BNP tertile distribution by HF subcategory. The proportion of patients with 
BNP levels in the first tertile (100-999 pg/ml) increases from 35.56% in HFrEF to 72.67% in HFpEF. A 
corollary diminution in the proportion of patients with BNP levels in the third tertile (≥3000 pg/ml) is seen, from 
21.11% in HFrEF to 4.97% in HFpEF. In both cases HFmrEF has intermediate characteristics. 
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124-158) versus 140 mmHg (IQR 124-156), p<0.05). Other observations and NYHA 
functional class were similar across all groups. 
3.3.1.7 ECG 
Mean ECG rate was higher in HFrEF compared to HFpEF (93 bpm ± 29 versus 88 bpm ± 31, 
p<0.005) and median QRS duration was increased in HFrEF compared to both HFmrEF and 
HFpEF (114 ms (IQR 91-137) versus 90 ms (IQR 63-117) versus 90 ms (IQR 70-110), 
p<0.005). Underlying cardiac rhythms were similarly distributed in all groups. 
3.3.1.8 Echocardiography 
Left ventricular size was statistically distinct across all three groups, with ventricular size 
inversely correlated with ejection fraction. Median LVESV was 91 ml (IQR 64-118) in 
HFrEF, 60 ml (IQR 44-76) in HFmrEF and 31 ml (IQR 22-40) in HFpEF (p <.00001). 
3.3.1.9 Outcomes 
Outcomes were similarly poor across all groups. Whole cohort readmission rate at 6 months 
was 59.1% of which 23.7% was accounted for by readmission due to HF. 
Whole cohort 6-month all-cause mortality rate was 28.1% of which 13.8% was accounted for 
by mortality due to cardiovascular disease. 
3.3.2 The EuroHeart Survey II cohort 
The EHS II is a large prospective registry cohort derived from 133 centres across 30 
European countries, all of which were specifically invited to participate by the ESC 
EuroHeart network. Each site was expected to contribute at least 20 patients to the study. 
Patients were considered appropriate for inclusion to the EHS II according to symptoms, 
signs and radiological findings as described below in Table 3.4. Patients in the EHS II cohort 
were recruited only from the emergency department, internal medicine and cardiology wards 
or intensive care units. 
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Inclusion criteria Exclusion criteria 
Symptomatic dyspnoea No specific exclusion criteria  
Signs of heart failure including rales, 
hypotension, hypoperfusion or right 
ventricular heart failure 
 
Lung congestion evident on chest X-ray  
Table 3.4 – Inclusion and exclusion criteria from the EHS II study. 
 
The EHS II cohort comprises 3580 patients recruited throughout Europe, of whom 3.5% were 
from Northern Europe, 20.4% from Western Europe, 34.4% Central Europe and 42.4% from 
Mediterranean Europe.  
3.3.3 Comparison of the MRAHF and EHS II cohorts 
The baseline characteristics of the two cohorts will now be described and compared. These 
will be described sequentially in terms of patient demographics, comorbidity profile, 
haemodynamic profile, echocardiographic parameters and patient outcomes. 
Statistical outliers in the continuous variables from the MRAHF dataset have been omitted 
where necessary to compare the two datasets using parametric statistical tests. Parametric 
continuous data are presented below as mean ± standard deviations and non-parametric data 
are presented as median value with interquartile range. 
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 MRAHF EHS II Significance (p) 
Number 447 3580 - 
Demographics 
Mean age, years (SD) 
 
79.0 (±11.5) 
 
69.9 (±12.5) 
 
<0.00001 
Female, % 47.7 38.7 <0.0005 
Mean BMI, kg/m2 (SD) 26.7 (±8.1) 26.8 (SD not reported) - 
De Novo AHF, % 41.8 37.1 0.051 
Hospitalisation for HF within last 12 months, % 28.0 44.5 <0.00001 
Comorbidities, % 
HTN 
 
55.0 
 
62.5 
 
<0.005 
IHD 37.8 53.6 <0.00001 
DM 31.5 32.8 0.59 
AF 45.2 38.7 <0.01 
CVA 15.4 13.3 0.21 
CKD 46.5 16.8 <0.00001 
COPD 
 
 
14.3 19.3 <0.05 
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Haemodynamics, median (IQR) 
SBP, mmHg (IQR) 
MRAHF 
135 (100-170) 
EHS II 
135 (110-160) 
Significance (p) 
- 
HR, bpm (IQR) 89 (65-123) 95 (77-114) - 
Admission Medications, % 
ACEi 
 
28.4 
 
55.0 
 
<0.00001 
ARB 15.1 9.3 <0.0005 
BB 57.9 43.2 <0.00001 
MRA 12.6 28.1 <0.00001 
Echocardiography 
Echo availability 
 
447 (100%) 
 
3062 (85%) 
 
- 
Median LVEDD, mm (IQR) 50 (46-56)  58 (51-65) - 
Mean LVEF, % (SD) 43 (±15) 38 (±15) <0.00001 
Outcome 
Median length of stay, days (IQR) 
 
8 (2-14) 
 
9 (6-14) 
 
- 
In-hospital mortality, n (%) 22/447 (4.9%) 239/3580 (6.7%) 0.15 
Table 3.5 – Comparison of the MRAHF and EHS II cohorts. ACEi – Angiotensin converting enzyme inhibitors, AF – Atrial fibrillation, ARB – Angiotensin receptor blockers, BB – 
Beta blockers, BMI – Body mass index, CKD – Chronic kidney disease, COPD – Chronic obstructive pulmonary disease, CVA – Cerebrovascular accident, DM – Diabetes mellitus, HR – 
Heart rate, HTN – Hypertension, IHD – Ischaemic heart disease, IQR – Interquartile range, LVEDD – Left ventricular end diastolic diameter, LVEF – Left ventricular ejection fraction, 
MRA – Mineralocorticoid receptor antagonist, SBP – Systolic blood pressure.  
 94 
 
The data included in the table below will now be discussed in greater depth. 
3.3.3.1 Demographics 
Mean age of patients in the MRAHF cohort was higher (79.0 years ± 11.5 versus 69.9 years ± 
12.5, p<0.00001), the cohort was proportionally more female (47.7% versus 38.7%, 
p<0.0005) and had substantially lower rates of hospitalisation in the 12 months prior to index 
admission than patients from the EHS II cohort (28.0% versus 44.5%, p<0.00001). 
3.3.3.2 Comorbidities 
Comorbidity burden was significantly higher in the EHS II cohort except in the cases of atrial 
fibrillation (38.7% versus 45.2%, p<0.01) and chronic kidney disease (16.8% versus 46.5% 
p<0.00001) which were more prevalent in the MRAHF cohort. 
3.3.3.3 Haemodynamics 
Haemodynamic parameters appear similar between cohorts, but inadequate data are available 
from the EHS II to compare statistically. 
3.3.3.4 Admission medications 
The use of both ACE inhibitors and mineralocorticoid receptor antagonist was lower in 
MRAHF compared to the EHS II cohort (28.4% versus 55.0%, p<0.00001 and 12.6% versus 
28.1%, p<0.00001 respectively), while beta blockade and ARB use were higher (57.9% 
versus 43.2%, p<0.00001 and 15.1% versus 9.3%, p<0.0005 respectively). 
3.3.3.5 Echocardiography 
Echocardiography was performed in 85% of subjects in the EHS II survey compared to 100% 
in the MRAHF study. Mean LVEF was higher in the MRAHF cohort compared to EHS II 
(43% ± 15 versus 38% ± 15, p<0.00001). 
3.3.3.6 Outcomes 
Length of stay was comparable between cohorts though data were unavailable to make a full 
comparison. In hospital mortality was comparable at 4.9% in the MRAHF cohort and 6.7% in 
the EHS II cohort. 
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3.4 Discussion 
This section will, in turn, discuss the differences within the MRAHF cohort according to 
LVEF subcategorisation, and then the differences between the MRAHF and EHS II cohorts. 
3.4.1 MRAHF cohort – HFrEF, HFmrEF and HFpEF subcategories 
Demographically, the subcategories are relatively homogeneous in terms of age and ethnicity 
but the prevalence of females within each subcategory increases in each category from 
HFrEF to HFpEF. A similar trend is seen for BMI. There is also a trend to increasing age in 
HFmrEF and HFpEF when compared to HFrEF which is typically seen in other studies, but 
this is not statistically significant in the MRAHF cohort. The data from the MRAHF cohort 
appear consistent with existing literature in terms of demographic breakdown. A small but 
important proportion of patients across all subcategories were diagnosed with an alternative 
condition upon admission. When not actively searching for these patients they are likely to be 
missed in larger registry studies which can negatively impact on the completeness of the data 
collected. 
Comorbidity profile is relatively uniform across the groups except in the case of IHD. IHD is 
routinely reported as higher in the HFrEF subcategory (Kapoor, Kapoor et al. 2016)and that 
is again something that has been demonstrated here. History of ischaemic heart disease 
typically causes insufficient metabolic supply to myocardial regions and has long been 
understood to depress systolic function, hence an overrepresentation of IHD in the HFrEF 
subcategory is seen (Braunwald, Kloner 1982). The burden of IHD is often reported as 
statistically similar in the HFrEF and HFmrEF groups but this is not seen in the MRAHF 
cohort (Chioncel, Mebazaa et al. 2017). These data are borne out in this study by the 
aetiology of HF. Whilst not achieving significance due to the Bonferroni correction, there is 
signal that IHD is the substantially and significantly more common in HFrEF when compared 
to the other groups, whilst mechanical disease is more prevalent in HFmrEF and HFpEF, 
again without achieving statistical significance. 
Preadmission medication prescription is similar across groups which is somewhat surprising. 
Intuitively, prognosis-altering medications should be more prevalent in the HFrEF group in 
which their use is proven, however this is not the case. The relative dearth of ACE inhibitor 
and MRA use could be explained by the high prevalence of chronic kidney disease 
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throughout the cohort and especially in the HFrEF subgroup. This is often considered a 
relative contraindication to ACEi and MRA use in primary care settings and may preclude 
their use. Beta blockade may be high in the HFpEF group due to the high prevalence of 
comorbid atrial fibrillation seen in this group as is commonly described in the literature 
(Chioncel, Mebazaa et al. 2017). 
Biochemically the subgroups appear largely similar however POCT BNP levels vary across 
subgroups. A markedly increased proportion of the HFrEF subgroup has BNP levels in the 
highest tertile compared to the other groups, while HFmrEF appear intermediate between 
HFrEF and HFpEF. This may be explained by the significant differences in ventricular 
dimensions also demonstrated. Increased intraventricular pressure and wall stress is the 
stimulus for both BNP release and ventricular remodelling, thus increases in ventricular 
volumes are consistent with elevated BNP levels (Karakilic, Kepez et al. 2010). 
Clinical observations are largely consistent across the subgroups except for a reduction of 
SBP seen in HFrEF. Arterial pressure is a function of cardiac output and systemic vascular 
resistance. A reduction in cardiac output due to falling contractile function seen in HFrEF 
will reduce SBP and is likely to account for this difference. This is perhaps supported by the 
fact that heart rate is elevated in the HFrEF group which, as described in chapter one, is a 
physiological response to attempt to maintain cardiac output, a function of heart rate and 
stroke volume. 
Also, within ECG parameters, the HFrEF subgroup has a comparatively increased QRS 
duration. This is likely secondary to the increase in ventricular volumes previously described 
and concomitant increase in myocardial fibrosis that occurs with ventricular remodelling. 
This leads to a prolongation of electrical passage through the myocardium and elongation of 
the QRS complex. 
Outcomes are similar across the groups with similar prevalence of readmission and mortality 
at 6 months. This is important as it demonstrates the poor outcomes still seen in over 50% of 
the MRAHF patient cohort for whom there are no prognosis-improving medication. This is 
consistent with other groups who report similar mortality across subcategories (Hsu, Ziaeian 
et al. 2017, Bhatia, Tu et al. 2006). 
 97 
 
3.4.2 MRAHF cohort versus EHS II cohort 
This section compares the MRAHF and EHS II cohorts. Firstly, it must be noted that the EHS 
II cohort is larger and more heterogeneous, recruited from the entirety of Europe, but with 
only a small proportion from northern Europe (3.5%). Secondly, the recruitment criteria for 
EHS II are dependent exclusively upon clinical and chest x-ray parameters which may lead to 
inclusion of non-HF patients. Specifically, echocardiography is available in only 85% of the 
EHS II cohort which leaves the study open to type 1 error in terms of patient selection. This 
is a recognised deficiency of the EHS II cohort. 
This deficiency aside, there remain many differences between patients recruited in each 
study. The MRAHF cohort is typically older, with a larger proportion of female patients and 
reduced requirement for hospital admissions in the preceding 12 months. 
The reduced comorbidity burden seen in the MRAHF cohort and indeed in Britain compared 
to particularly southern eastern Europe likely accounts for the increased age of patients in the 
MRAHF cohort, as these patients remain healthy for longer (Carlson, P. 2004) and is perhaps 
a reflection of the difference in life-expectancies. The variance in comorbidities and mortality 
has been variously linked to diet, exercise and smoking (Meslé 2004), the latter of which is 
likely higher in the EHS II cohort as suggested by comparatively raised rates of chronic 
obstructive pulmonary disease (COPD).  
The notable exceptions are AF and CKD. The prevalence of AF is known to increase with 
age which may explain the higher prevalence in the MRAHF cohort which is significantly 
older than the population described in EHS II (Heeringa, van der Kuip, Deirdre AM et al. 
2006). The increased prevalence of CKD appears to represent a classification artefact. The 
MRAHF study defined and recorded CKD status according to NICE guidelines on Chronic 
Kidney Disease (National Institute for Health and Care Excellence 2014), while in the EHS II 
survey it is defined as present in patients with creatinine >177umol/L or awaiting/undergoing 
dialysis. This is equivalent to NICE guideline CKD stage 4/5, hence the significantly lower 
prevalence of CKD in EHS II due to the omission of patients with CKD stages 1, 2 or 3 in 
their comorbidity statistics. 
Haemodynamic variables upon admission appear qualitatively similar, but inadequate data 
are provided to quantitatively compare the two cohorts. 
 98 
 
Community prognostic medication prescription is reduced in the MRAHF cohort in terms of 
ACEi and MRA, almost half that of the EHS cohort. This is disappointingly low given the 
known benefits of these medications but may be somewhat explained by the higher mean 
LVEF in the MRAHF cohort, thus fewer patients are likely to be eligible for prognosis-
altering medications. This is, however, unlikely to account for the entire difference between 
cohorts. Beta blockade use is higher in the MRAHF cohort, likely secondary to the increased 
prevalence of AF within this cohort, given the relative dearth of other prognosis-altering 
medications. 
Some of the variation noted between the two cohorts is likely to exist due to the methodology 
of patient capture. As noted, no echocardiographic criteria were included in the EHS II study, 
relying solely on clinical selection, while the MRAHF study had strict biochemical and 
echocardiographic criteria. It also represented consecutive patients, recruited from all areas 
within the hospital. Large registry studies can suffer from under-representation of cases of HF 
misdiagnosed as respiratory or dermatological complaints such as community acquired 
pneumonia or bilateral peripheral cellulitis. If, and how, this is likely to skew the data is 
unclear, however it must be acknowledged that this is likely to play a role in inter-cohort 
variation.  
Despite the variations described above, inpatient mortality is consistent across both groups. 
While patients in the MRAHF cohort may live healthier for longer with fewer comorbidities, 
once they become inpatients due to AHF, prognosis appears similar to other AHF patients. 
3.4.3 Limitations 
The MRAHF and ESH cohorts differ in important ways. There are differences in patient 
demographics, comorbidity profiles, pre-hospital treatments and cardiac geometry which 
prevent results derived from the MRAHF cohort from being generalisable to a pan-European 
cohort.  
Despite this the MRAHF cohort is a robustly collected consecutively acquired AHF dataset, 
representative of the local patient group. While results may not be immediately generalisable, 
conclusions drawn from the dataset may be used to suggest further tests in larger more 
heterogeneous populations to better establish the hypotheses tested. 
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In fact, it could be argued that the MRAHF cohort is more representative of an AHF cohort 
than EHS II given that it had stringent exclusion criteria to avoid recruiting non-AHF patients 
and had echocardiographic data for all patients retained within the study. 
The EHS II study is recognised to have limitations intrinsic to its study design. As a multi-
centre registry study, ensuring homogeneity of practice is always difficult, but this is 
rendered particularly relevant by the flexibility of the inclusion criteria; inclusion into the 
EHS II study is essentially a clinical diagnosis only, with no confirmatory biochemistry or 
echocardiographic testing. As such the reliability of the data is highly reliant upon uniformity 
of clinical acumen across clinical sites and the authors indeed note that neither diagnosis nor 
echocardiography was assessed or confirmed centrally, limiting confidence in the accuracy of 
the original diagnosis (Nieminen, Brutsaert et al. 2006). As demonstrated above, incorrect 
alternate diagnoses are a small but relevant occurrence in hospital admissions and can lead to 
type II errors when considering recruitment or inclusion in a trial. 
Certain data points are not provided by the EHS II study in enough detail to perform 
comparative statistical analysis between the MRAHF and EHS II cohorts, particularly in the 
cases of BMI, haemodynamic variables and left ventricular dimensions. This is unfortunate as 
it detracts from the ability to fully compare the two datasets. A qualitative analysis of these 
data is still feasible, but conclusions cannot be drawn about the statistical significance of any 
similarity or difference noted. In addition, certain data points had to be excluded from the 
MRAHF dataset to render it parametric and permit inter-cohort analysis. This potentially 
reduces the validity of conclusions drawn regarding differences and similarities between the 
two cohorts. 
The EHS II cohort is not the largest, nor the most recent AHF registry, with others such as the 
ALARM-HF (Follath, Yilmaz et al. 2011) and ESC HF LT studies (Chioncel, Mebazaa et al. 
2017) enrolling a greater number of patients in a more recent timeframe. Unfortunately, the 
requisite data are not available from these studies to make a statistical comparison (standard 
deviations are not provided) and thus only a qualitative analysis is feasible. This may be 
qualitatively useful, but it is difficult to draw definite numerical conclusions from such data. 
As such, I have compared the MRAHF cohort to the most recent large European registry 
study of AHF patents that reports adequate data for quantitative comparisons of the two 
datasets. 
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3.5 Chapter summary 
This chapter has described the baseline characteristics of the MRAHF cohort used in this 
study, with specific comparison of the three HF subgroups demonstrating consistency with 
what is already known in the literature regarding these subclassifications.  
In addition, it has compared the MRAHF cohort to the EHS II cohort and described the 
underlying differences between the two cohorts so as to appreciate the context in which this 
data has been collected. In general, the MRAHF cohort was older, with fewer comorbidities 
and was less heavily medicated upon admission, but similar inpatient outcomes were seen in 
both cohorts. 
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Chapter Four: Myocardial deformation imaging 
parameters in novel heart failure subcategories 
4.1 Chapter Introduction 
This chapter describes myocardial deformation imaging values in the Mitral Regurgitation in 
Acute Heart Failure (MRAHF) cohort and contrasts them according to left ventricular 
ejection fraction (LVEF) based subcategories. 
The chapter briefly reviews the current literature regarding heart failure (HF) 
subcategorisation, the gaps in understanding and what this study can add to the literature. It 
then outlines the materials and methods used to obtain the dataset. Myocardial deformation 
parameters are then shown to vary significantly and substantially between HF subcategories, 
with deformation values of patients with HF with mid-range ejection fraction (HFmrEF) 
intermediate between HF with reduced ejection fraction (HFrEF) and HF with preserved 
ejection fraction (HFpEF). Further results demonstrate the likely stability of myocardial 
deformation values compared to LVEF in the acute phase, and finally an interpretation of 
these results is offered with discussion of the limitations of the study and suggestions for 
further work. 
4.2 Current literature – evidence and omissions 
HF has typically been subclassified according to LVEF, with both European and American 
guidelines recognising separate clinical syndromes of HFrEF and HFpEF.  
The 2013 ACC/AHA and 2016 ESC guidelines recognised the novel concept of HF with 
borderline ejection fraction and mid-range ejection fraction respectively, defined as HF in 
patients with LVEF of 40-49%. This was introduced due to concerns that patients with LVEF 
in this range may represent an alternate HF phenotype (Ponikowski, P., Voors et al. 2016, 
Yancy, Jessup et al. 2013).  
While many studies have examined the relationships between HFrEF, HFmrEF and HFpEF 
concerning demographic, biochemical, and outcome discrepancies, minimal data exists 
regarding the differences in myocardial deformation parameters of the AHF cohort (Cheng, 
Cox et al. 2014, Kapoor, Kapoor et al. 2016, Tsuji, Sakata et al. 2017).  
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Myocardial strain and strain rate parameters are of interest due to their ability to more 
accurately demonstrate regional and global deformation and contractile function than other 
commonly used markers of systolic function such as LVEF. Particularly in the case of strain 
rate values, the speed of deformation has been shown to be much more closely correlated to 
intrinsic systolic function, independent of contemporaneous loading conditions which are 
known to significantly affect the representative accuracy of LVEF (Ferferieva, Van den 
Bergh et al. 2011). In addition, deformation imaging parameters more accurately represent 
contractile function in patients with regional wall abnormalities than measurement of LVEF 
(Brown, Jenkins et al. 2009). 
When investigated in other cardiological conditions strain and strain rate parameters have 
been shown to identify clinically relevant coronary disease and systolic dysfunction in both 
hypertrophic cardiomyopathies and chronic HF (Kraigher-Krainer, Shah et al. 2014, 
Kukulski, Jamal et al. 2003, Afonso, Kondur et al. 2012). 
Limited data have been reported regarding strain and strain rate in AHF. Park et al did 
suggest that strain and strain rate parameters could be of value to aid prognostication in AHF, 
above and beyond LVEF but their study excluded patients with AHF of an ischaemic 
aetiology. Ischaemic AHF accounts for approximately 20-30% of AHF admissions and thus it 
could be argued that their study is not representative of the typical AHF population (Park, 
Park et al. 2018). 
In this study differences have been assessed between regional and global strain and strain rate 
parameters in HF subcategories, using consecutively acquired AHF patients in a large district 
general hospital.  
4.3 Study hypotheses 
This chapter will assess the following hypotheses: 
a) Left ventricular strain values differ between patients labelled as HFrEF, HFmrEF and 
HFpEF in the MRAHF cohort and this difference is statistically significant. 
b) Left ventricular strain rate values differ between patients labelled as HFrEF, HFmrEF 
and HFpEF in the MRAHF cohort and this difference is statistically significant. 
 103 
 
4.4 Methods 
Chapter two of this thesis described the main methods and materials used for study design 
and patient recruitment. Below is a summary of these with emphasis on echocardiographic 
data capture and offline strain and strain rate analysis. 
4.4.1 Study design and population 
The MRAHF study was designed as a prospective cohort study of all consecutive patients 
admitted to a single hospital site with signs and symptoms consistent with AHF as the 
primary driver of admission.  
The hospital receives patients from a catchment area containing approximately 410,000 
people and has typically seen between 300-400 patients admitted secondary to AHF in each 
of the previous four years. This study uses the entire dataset captured from the MRAHF study 
cohort. 
4.4.2 Inclusion and exclusion criteria 
Inclusion criteria for the study: 
1) Clinical signs and symptoms consistent with AHF as the primary cause for admission 
2) Inpatient admission of <7 days by time of consent 
3) The ability to give informed consent 
Exclusion criteria for the study: 
1) Point-of-care test (POCT) B natriuretic peptide (BNP) level <100 pg/ml 
2) Echocardiography inconsistent with a diagnosis of HF 
4.4.3 Patient recruitment and data capture 
Patient recruitment began in July 2016 and concluded in September 2017.  616 patients were 
approached for recruitment, 500 gave informed consent to join the study of whom 447 
remained post exclusions. Data capture was carried out at the time of recruitment and 
included baseline demographic, biochemical, observational and radiological data as outlined 
in chapter two.  
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4.4.4 Echocardiography 
Echocardiography was performed on all patients within 48 hours of recruitment. Offline 
analysis was subsequently performed to assess cardiac geometric, haemodynamic and 
myocardial deformation parameters. Cardiac geometry and haemodynamic status were 
assessed according to a standardised echocardiography protocol (see Appendix 1.4) and 
quantified as per standard British Society of Echocardiography (BSE) guidelines (Wharton, 
Steeds et al. 2015). Patients were excluded from the study if echocardiography did not 
support a diagnosis of HF. For those patients retained within the study, they were categorised 
as either HFrEF, HFmrEF or HFpEF according to their measured LVEF - <40%, 40-49% and 
≥50% respectively.  
Reproducibility is a key factor in the utility of any investigative modality. Typically, this can 
be discussed in terms of intra-observer and inter-observer variability, whilst in the case of 
strain and strain rate, there is also the factor of inter-software variability to consider.  
Many developers produced software to resolve myocardial deformation values from 2-
dimensional, and more latterly 3-dimensional, echocardiography. Due to different in-house 
decisions regarding reference points and definitions of cardiac borders there was initially 
quite considerable variation in terms of strain and strain rate values from one software vendor 
to another within subjects. As recently as 2012, studies demonstrated the non-
interchangeability of vendors and software due to substantial and significant differences in 
strain measurements in longitudinal, radial and circumferential axes (Takigiku, Takeuchi et 
al. 2012). Concerted international efforts by the EASCVI-ASE-industry task force regarding 
consensus on definitions and measurements have led to a reduction in inter-vendor variability 
(Voigt, Pedrizzetti et al. 2014, Farsalinos, Daraban et al. 2015) though they do still caution 
single segment strains demonstrate significant variability and GLS has the greatest 
reproducibility and (Mirea, Oana, Pagourelias et al. 2018).  
Inter-observer and intra-observer variability in strain measurements has always been 
relatively low, at least comparable if not better than other common echocardiographic 
measurements such as EF (Stanton, Leano et al. 2009). This has been a longstanding concern 
for LVEF which is commonly considered to be +/- 7% of the stated value (Himelman, 
Cassidy et al. 1988), whilst GLS values have been demonstrated to have a variance 
coefficient up to half that of LVEF depending on the vendor(Farsalinos, Daraban et al. 2015).  
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Studies have demonstrated that expert level competency with intra-observer correlation 
coefficients of >0.9 are achievable for GLS within 50 patients assessed and monitored (Chan, 
Shiino et al. 2017). To achieve this and thus enhance intra-observer reproducibility in this 
study, both research fellows attended an off-site training event in Berlin with industry and 
academic experts where >100 cases were examined, discussed and assessed. 
In this study inter-observer variability for strain measurements was eliminated by the use of 
one sole data analyser for all LV strain measurements. In order to reduce inter-observer 
variability of basic cardiac measurements including LVEF, of 447 patients retained within the 
study, 426 (95.3%) were scanned by the principle ultrasonographer, 12 (2.6%) by the second 
sonographer and 9 (2.1%) by the third. All off-line assessment of cardiac geometry and basic 
functional parameters was performed by the principle ultrasonographer, again to ensure 
homogeneity of practice and eliminate inter-observer variability. 
Large AHF studies use multiple echocardiography-trained sonographers, but by using one 
sonographer for >95% of images in this study, inter-observer variability of technique is 
reduced. This is intended to reduce the inter-observer variability found in acquisition of 
acoustic windows. In addition, all studies were assessed and reported by the principal 
ultrasonographer, reducing inter-observer interpretation variability. Echocardiographic 
studies were performed within 48 hours of admission. This limit was intended to reduce the 
variability of haemodynamic status caused by therapeutic interventions provided during 
inpatient admission. The above measures were instigated to ensure that measurement of 
LVEF was consistent with minimal confounders. This aimed to ensure that patients were 
consistently attributed to the same subcategory and are genuinely representative of these 
subcategories.  
Unless echocardiographic findings indicated life or management-altering pathology, the 
results of the scans were not passed to the clinical team. In cases where such pathology was 
detected, these were discussed with the Principal Investigator of the MRAHF study when not 
time-sensitive or with the on-call consultant when immediate action was required. 
Subsequent to image acquisition, offline analysis of myocardial deformation imaging 
parameters was then performed as described below. 
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4.4.5 Myocardial deformation imaging assessment 
All images were exported to EchoPac for statistical analysis. 
The timing of the cardiac cycle was assessed by timing aortic valve opening and closure for 
each patient using Pulse wave Doppler signal through the aortic valve (see Figure 4.1 for 
illustration).  
Myocardial deformation assessment was then performed in each of the apical 4, 2, and 3 
chamber views of the left ventricle (LV) in order to obtain comprehensive strain and strain 
rate measurements for the majority of the LV. The following approach was used: 
Once the appropriate image of the LV had been selected, the Strain function on the GE 
EchoPac software was selected and the frame rate of the selected image was recorded. The 
endocardial border was then traced in the end systolic frame from one end of the mitral 
annulus to the other. The software automatically generates a ‘region of interest’ (ROI) which 
includes the depth of the myocardium. This was adjusted when necessary to reflect 
myocardial wall thickness. When satisfied with accurate border tracing and ROI depth, the 
software was run.  
The software automatically reports the ability to perform speckle tracking in all segments of 
the cardiac wall in this view. If all segments were not trackable using the ROI, attempts were 
Figure 4.1 – Aortic valve opening and closure assessment using pulse wave Doppler 
images. Valve opening and closure are timed with commencement and cessation of flow 
through the aortic valve as demonstrated above. 
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made to retrace the endocardial border until the software was able to track the individual 
segments. If this remained non-feasible for all segments then this image was considered non-
feasible and this was noted in the dataset. If tracking was feasible in at least 2 segments, then 
the data were considered usable and the frame rate of the used image was noted - see Figure 
4.2 below.  
Once an acceptable trace had been performed and image tracking was feasible, the strain 
analysis would be performed automatically by the software. This would provide 6 strain 
values for 6 individual myocardial segments in each view. In addition, strain and strain rate 
values for all segments are recorded and averaged to produce GLS and GLSR. Segments 
acquired in each view can be seen in Table 4.1.  
 
 
 
 
 
 
Figure 4.2 – Left ventricular border tracing in EchoPac software. 
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Acoustic View Segment assessed 
4 Chamber View Basal Inferior septum 
Mid inferior septum 
Apical Inferior septum 
Basal anterior lateral wall 
Mid anterior lateral wall 
Apical anterior lateral wall 
2 Chamber View Basal inferior wall 
Mid inferior wall 
Apical inferior wall 
Basal anterior wall 
Mid anterior wall 
Apical anterior wall 
3 Chamber View Basal inferior lateral wall 
Mid inferior lateral wall 
Apical inferior lateral wall 
Basal anterior septum 
Mid anterior septum 
Apical anterior septum 
Table 4.1 – Myocardial segments assessed for myocardial deformation parameters in 
each acoustic view. 
Timing of the strain calculation was automatically calculated but adjusted to ensure that 
analysis begins at end diastole, as defined by the peak of the R wave, and ends at the same 
point of the next cardiac cycle. End systole was defined according to aortic valve closure as 
measured earlier. 
Visual assessment of the strain curve was made to assess for obvious abnormalities. If these 
were distinctly abnormal the above process was repeated to try and obtain a normal appearing 
strain curve. If it remained abnormal in morphology these values were considered likely 
representative of ventricular strain patterns. 
Peak systolic strain (PSS) was then noted, defined as the peak value achieved between the 
end of diastole and the closure of the aortic valves as ascertained earlier through Doppler 
traces. These values were noted for all segments measurable in each image with an additional 
averaged GLS value.  
To ascertain strain rate (SR) values, the SR function was then selected. The software would 
then provide SR values for each of the available 6 myocardial segments in each image and an 
averaged GLSR value. Peak SR values were noted in the first half of systole as maximal 
 109 
 
physiological systolic SR is generated in the first half of systole (Weidemann, Jamal et al. 
2002). This is defined as half the duration between end diastole and aortic valve closure. 
By measuring only physiological strain and strain rate prior to aortic valve closure the 
measurement of myocardial deformation which does not contribute to systolic force 
generation is avoided. Pathological deformation curves with post-systolic strain peaks are 
commonly seen in myocardial ischaemia but the deformation measured subsequent to closure 
of the aortic valve is not an indication of true contractile function of the myocardium, but 
rather is an artefactual representation of the relaxation of other local segments and subsequent 
rebound contraction of the ischaemic region(Sutherland, Hatle et al. 2006). As such, values 
measured after the aortic valve closure do not represent true underlying myocardial 
contractile function, the variable of interest, hence why it is typical throughout the literature 
to measure peak systolic strain values prior to aortic valve closure.  
Different areas of the myocardium produce peak physiological strain at marginally but 
different times and amplitudes. While this is important in the understanding of the underlying 
mechanism of force generation, physiological maximums still occur prior to aortic valve 
closure thus measurement at this time point will still capture maximal physiological force in 
all regions assessed(Sutherland, Hatle et al. 2006). 
4.4.6 Statistical analysis 
All statistical tests were performed using the Statistical Package for the Social Sciences 
(SPSS) version 24 developed by IBM.  
Continuous variables were tested for normality using the Shapiro-Wilk tests, and evidence of 
skew was inspected visually using histograms, Q-Q plots and box plots. 
All myocardial deformation variables demonstrated statistically significant skew in the 
Shapiro-Wilk test, rejecting the null hypothesis. Visual inspection of histograms, Q-Q and 
box plots confirmed positive skew throughout the dataset. This is likely due to the typical 
lower value of systolic strain and strain rate values of 0, with no upper limit defined. 
Mean strain and strain rate values were compared across AHF subcategories, defined 
according the LVEF as described above. Due to the non-parametric nature of the data, a 
Kruskal-Wallis test was used to compare groups and demonstrate statistically significant 
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differences between the three subcategories. Dunn’s pairwise post-hoc test was used to assess 
for specific inter-group variations. 
An analysis is then made of differences seen in markers of systolic function categorised 
according to time of recruitment into the study. 
One-way analysis of covariance (ANCOVA) was performed to assess the effect of 
confounding variables on mortality differences between groups. 
Parametric continuous data are presented as a mean ± standard deviation. Non-parametric 
continuous data are presented as a median with interquartile range. Categorical variables are 
presented as a proportion within the population. An alpha value of 0.05 was set as the 
threshold for statistical significance. 
4.5 Results 
In this section the baseline characteristics of the study population will be presented and 
compared according to LVEF subcategory, then the differences in strain and strain rate values 
between the subgroups will compared and the effect of time to recruitment on LVEF, strain 
and strain rate values will be demonstrated.  
4.5.1 Baseline characteristics of the AHF subcategories 
Baseline characteristics of the MRAHF cohort have been described according to HF 
subcategories in chapter three. A summary of these is presented below. 
Of 447 patients, LVEF was measurable in 444 patients. Of these, left ventricular strain 
analysis was possible in 442 patients as two patients did not have images adequate for 
deformation analysis. 
40.5% patients were categorised as HFrEF, 23.2% as HFmrEF and 36.3% as HFpEF. 
The median age of the total cohort was 82 (IQR 76-88), 47.7% were female, median BMI 
was 26.5 kg/m2 (IQR 22.5-31.0) and the median LVEF was 44% (IQR 33-55).  
Ischaemic heart disease was more prevalent in the HFrEF subcategory compared to HFmrEF 
and HFpEF (47.2% versus 31.1% and 31.7%, p<0.005). The HFrEF subcategory also 
demonstrated lower median systolic blood pressures (128 mmHg (IQR 113-143) versus 141 
 111 
 
mmHg (IQR 124-158) and 140 mmHg (IQR 124-156), p<0.05) and faster mean heart rates 
(97 bpm ± 27 versus 92 bpm ± 29 and 88 bpm ± 31, p<0.005). 
POCT BNP values were higher in the HFrEF group compared to HFmrEF and HFpEF 
(proportion of patients with BNP ≥3000 pg/ml - 21.1% versus 6.8% and 5.0%, p<0.0001). 
Left ventricular geometry varied significantly between the groups; median left ventricular 
end systolic volume was significantly different in all groups, HFrEF, HFmrEF and HFpEF 
respectively (91 ml (IQR 64-118) versus 60 ml (IQR 44-76) versus 31 ml (IQR 22-40), 
p<0.05)  
4.5.2 Left ventricular myocardial deformation imaging – Peak systolic 
strain values 
Frame rate values were comparable between groups. LV PSS values were consistently 
statistically distinct between HF subcategories in almost all myocardial regions studied, with 
intermediate LV PSS values in HFmrEF when compared to HFrEF and HFpEF. GLS values 
were significantly and substantially different in each subcategory; median GLS increased by 
nearly half from HFrEF to HFmrEF and nearly double from HFrEF to HFpEF (-6.62% (IQR -
4.41 – -8.83) versus -9.03% (IQR -6.28 – -11.78) versus -13.12% (IQR -10.02 – -16.22), 
p<0.0001). 
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 HFrEF 
n = 180 (40.5%) 
HFmrEF 
n = 103 (23.2%) 
HFpEF 
n = 161 (36.3%) 
Significance (p) 
Mean frame rate, fps (SD) 
 
Median peak systolic strain, % (IQR) 
 
4 Chamber View 
Basal inferior septum  
Mid inferior septum  
Apical inferior septum 
Basal anterior lateral wall  
Mid anterior lateral wall 
Apical anterior lateral wall 
 
2 Chamber View 
Basal inferior wall 
Mid inferior wall 
Apical inferior wall 
Basal anterior wall 
Mid anterior wall 
Apical anterior wall 
 
3 Chamber View 
Basal inferior lateral wall 
Mid inferior lateral wall 
Apical inferior lateral wall 
Basal anterior septum 
Mid anterior septum 
Apical anterior septum 
 
Global Longitudinal Strain 
48 (±6) 
 
 
 
 
-5.08 (-2.63 – -7.53) 
-7.20 (-4.04 – -10.36) 
-7.11 (-1.11 – -13.11) 
-6.64 (-3.32 – -9.96)   
-6.88 (-3.48 – -10.28) 
-6.64 (-1.84 – -11.44)   
 
 
-7.27 (-3.39 – -11.15)  
-7.42 (-3.53 – -11.31) 
-7.66 (-2.68 – -12.64)  
-4.84 (-1.75 – -7.93)  
-4.80 (-1.64 – -7.96)  
-4.49 (0.00 – -8.98) 
 
 
-5.55 (-0.56 – -10.54)  
-6.17 (-3.00 – -9.34) 
-7.19 (-2.99 – -11.39) 
-5.31 (-2.26 – -8.36) 
-6.25 (-2.46 – -10.04)  
-6.41 (-1.56 – -11.26 
 
-6.62 (-4.41 – -8.83)  
 
49 (±6) 
 
 
 
 
-7.05 (-4.53 – -9.67) 
-10.32 (-7.27 – -13.37)  
-13.20 (-7.50 – -18.90)  
-7.91 (-4.13 – -11.69) 
-8.10 (-4.42 – -11.78)  
-10.00 (-4.67 – 15.33)  
 
 
-8.83 (-4.65 – -13.01) 
-11.46 (-7.83 – -15.09)  
-15.13 (-10.17 – -20.09)  
-6.88 (-3.01 – -10.75)  
-7.19 (-3.21 – -11.17) 
-10.56 (-5.48 – -15.64)  
 
 
-7.83 (-3.94 – 11.72) 
-9.53 (-4.55 – -14.51) 
-12.25 (-6.22 – -18.28) 
 -7.81 (-4.55 – -11.07) 
-9.06 (-4.45 – -13.67) 
-10.47 (-4.57 – -16.37) 
 
-9.03 (-6.28 – -11.78) 
49 (±7) 
 
 
 
 
-10.25 (-6.65 – -13.85)  
-15.00 (-11.22 – -18.78) 
-19.47 (-13.39 – -25.55)  
-9.50 ( -4.36 – -14.64)  
-10.12 (-4.96 – -15.28)  
-15.00 (-8.89 – -21.11) 
 
 
-12.34 (-8.18 – -16.50)  
-14.69 (-10.80 – -18.58)  
-19.38 (-12.92 – -25.84)  
-8.59 (-3.85 – -13.43)  
-9.63 (-4.00 – -15.26) 
-13.59 (-6.62 – -20.56)  
 
 
-9.25 (-4.80 – -13.70) 
-11.72 (-7.72 – -15.72)  
-16.56 (-11.45 – -21.67) 
-10.78 (-6.97 – -14.59) 
-13.13 (-8.30 – -17.96) 
-15.78 (-9.45 – -22.11) 
 
-13.12 (-10.02 – -16.22) 
0.07 
 
 
 
 
<0.0001 *¥Ω 
<0.0001 *¥Ω 
<0.0001 *¥Ω 
<0.01 * 
<0.05 *Ω 
<0.05 *¥Ω 
 
 
<0.01 *Ω 
<0.005 *¥Ω 
<0.001 *¥Ω 
<0.05 * 
<0.05 *¥ 
<0.05 *¥Ω 
 
 
<0.05 * 
<0.05 *¥Ω 
<0.005 *¥Ω 
<0.001 *¥Ω 
<0.005 *¥Ω 
<0.005 *¥Ω 
 
<0.0001 *¥Ω 
 
Table 4.2 – Left ventricular peak systolic strain versus AHF subcategory * = HFrEF versus HFpEF, ¥ = HFrEF versus HFmrEF, Ω= HFmrEF versus HFpEF. 
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4.5.3 Left ventricular myocardial deformation imaging – strain rate values 
Frame rate values were comparable between groups. Median LV SR values were consistently 
statistically distinct between HF subcategories in almost all myocardial regions studied, with 
intermediate LV SR values in HFmrEF when compared to HFrEF and HFpEF. GLSR values 
were statistically and substantially different between groups; Median GLSR increased by 
nearly half from HFrEF to HFmrEF and nearly double from HFrEF to HFpEF (-0.48 (IQR -
0.34 – -0.62) versus -0.66 (IQR -0.49 – -0.83) versus -0.87 (IQR -0.70 – -1.04), p<0.0001). 
Figure 4.3 – Left ventricular peak systolic strain versus heart failure subcategory. Median peak systolic 
strain values increase (become more negative) from HFrEF to HFmrEF and then HFpEF in all myocardial areas 
assessed. Global longitudinal strain shows the same pattern. 
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 HFrEF 
n = 180 (40.5%) 
HFmrEF 
n = 103 (23.2%) 
HFpEF 
n = 161 (36.3%) 
Significance (p) 
Mean frame rate, fps (SD) 
 
Median strain rate, S
-1 
(IQR) 
 
4 Chamber View 
Basal inferior septum  
Mid inferior septum  
Apical inferior septum 
Basal anterior lateral wall  
Mid anterior lateral wall 
Apical anterior lateral wall 
 
2 Chamber View 
Basal inferior wall 
Mid inferior wall 
Apical inferior wall 
Basal anterior wall 
Mid anterior wall 
Apical anterior wall 
 
3 Chamber View 
Basal inferior lateral wall 
Mid inferior lateral wall 
Apical inferior lateral wall 
Basal anterior septum 
Mid anterior septum 
Apical anterior septum 
 
Global longitudinal strain rate 
 
48 (±6) 
 
 
 
 
-0.44 (-0.31 – -0.57) 
-0.52 (-0.67 – -0.67) 
-0.56 (-0.27 – -0.85)  
-0.41 (-0.18 – -0.64) 
-0.41 (-0.26 – -0.58) 
-0.47 (-0.21 – -0.73) 
 
 
-0.52 (-0.30 – -0.74) 
-0.53 (-0.34 – -0.72) 
-0.57 (-0.27 – -0.87) 
-0.38 (-0.21 – -0.55) 
-0.35 (-0.16 – -0.54) 
-0.41 (-0.14 – -0.68) 
 
 
-0.44 (-0.25 – -0.63) 
-0.39 (-0.20 – -0.58) 
-0.53 (-0.27 – -0.79) 
-0.38 (-0.24 – -0.52) 
-0.44 (-0.22 – -0.66) 
-0.48 (-0.21 – -0.75) 
 
-0.48 (-0.34 – -0.62) 
 
49 (±6) 
 
 
 
 
-0.50 (-0.37 – -0.63) 
-0.65 (-0.48 – -0.82) 
-0.86 (-0.56 – -1.16) 
-0.56 (-0.39 – -0.73) 
-0.49 (-0.29 – -0.69) 
-0.64 (-0.40 – -0.88) 
 
 
-0.65 (-0.42 – -0.88) 
-0.70 (-0.49 – -0.91) 
-0.86 (-0.55 – -1.17) 
-0.54 (-0.32 – -0.76) 
-0.51 (-0.27 – -0.75)  
-0.72 (-0.45 – -0.99) 
 
 
-0.61 (-0.39 – -0.83) 
-0.58 (-0.35 – -0.81) 
-0.78 (-0.47 – -1.09) 
-0.48 (-0.19 – -0.67) 
-0.61 (-0.36 – -0.86) 
-0.74 (-0.40 – -1.08) 
 
-0.66 (-0.49 – -0.83) 
49 (±7) 
 
 
 
 
-0.72 (-0.50 – -0.94) 
-0.85 (-0.63 – -1.07)  
-1.22 (-0.83 – -1.61) 
-0.75 (-0.48 – -1.02) 
-0.70 (-0.45 – -0.95) 
-0.93 (-0.56 – 1.30)  
 
 
-0.88 (-0.56 – -1.20) 
-0.98 (-0.73 – -1.21) 
-1.22 (-0.90 – -1.54) 
-0.65 (-0.35 – -0.95) 
-0.62 (-0.33 – -0.91) 
-0.91 (-0.56 – -1.26) 
 
 
-0.74 (-0.45 – -1.03) 
-0.82 (-0.57 – -1.07) 
-1.03 (-0.71 – -1.35) 
-0.66 (-0.39 – -0.83) 
-0.81 (-0.49 – -1.13) 
-1.08 (-0.67 – -1.49) 
 
-0.87 (-0.70 – -1.04) 
0.07 
 
 
 
 
<0.05 *¥Ω 
<0.0001 *¥Ω 
<0.0001 *¥Ω 
<0.01 *Ω 
<0.0001 *Ω 
<0.01 *¥Ω 
 
 
<0.05 *¥Ω 
<0.005 *¥Ω 
<0.005 *¥Ω 
<0.01 *¥ 
<0.01 *¥Ω 
<0.05 *¥Ω 
 
 
<0.01 *¥Ω 
<0.0001 *¥Ω 
<0.01 *¥Ω 
<0.005 *¥Ω 
<0.005 *¥Ω 
<0.005 *¥Ω 
 
<0.00001 *¥Ω 
 
Table 4.3 – Left ventricular systolic strain rate versus heart failure subcategory. * = HFrEF versus HFpEF, ¥ = HFrEF versus HFmrEF, Ω= HFmrEF versus 
HFpEF. 
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Figure 4.4 – Left ventricular strain rate versus heart failure subcategory. Median strain rate 
values increase (become more negative) from HFrEF to HFmrEF and then HFpEF in all myocardial 
areas assessed. Global longitudinal strain rate shows the same pattern. 
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4.5.4 Global Longitudinal Strain vs LVEF 
 
 
When LVEF is plotted against Global Longitudinal Strain there is a curvilinear relationship 
seen, with a gradual flattening of the Loess line of best fit curve at higher levels of LVEF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 – Scatter plot – Left ventricular Ejection Fraction vs Global Longitudinal Strain. Left 
ventricular ejection fraction compared against global longitudinal strain. A Loess line of best fit 
demonstrates a curvilinear relationship at higher ejection fractions. 
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4.5.5 Global Longitudinal Strain Rate vs LVEF 
 
When LVEF is plotted against Global Longitudinal Strain Rate there is a curvilinear 
relationship seen, with a gradual flattening of the Loess line of best fit curve at higher levels 
of LVEF. 
4.5.6 Time to recruitment and markers of left ventricular contractile 
function 
Median LVEF values were significantly lower in patients recruited ≥2 days after admission 
(44% (IQR 33-55) versus 39% (IQR 24-54), p<0.05). This was not seen in terms of median 
GLS or GLSR values (both p >0.05).  
 
Patients recruited to the study ≥2 days post admission were demographically similar with 
statistically comparable age and gender profiles. They were significantly more likely to have 
been admitted to hospital during a weekend (68.2% versus 21.9%, p<0.0001). 
 
Figure 4.6 – Scatter plot – Left ventricular Ejection Fraction vs Global Longitudinal Strain rate. 
Left ventricular ejection fraction compared against global longitudinal strain rate. A Loess line of best 
fit demonstrates a curvilinear relationship at higher ejection fractions. 
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They had a similar burden of comorbidities and biochemical profiles were comparable 
between groups. They had significantly higher rate of mortality at 6 months post discharge 
(36.4% versus 24.6%, p<0.05).  
 
A one-way ANCOVA was conducted to determine a statistically significant difference 
between patients recruited <2 days and ≥2 days post admission in terms of mortality 
controlling for variables including demographic profile, comorbidity burden, biochemical 
parameters and weekend admission. The statistically significant difference in mortality 
between the two groups is eliminated after performing an ANCOVA controlling for weekend 
admission, F (1,441) = 3.279, p = 0.07. This indicates that statistical differences in mortality 
are no longer significant when adjusting for the effect of weekend admission.
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 Time to recruitment <2 days 
n = 315 
Time to recruitment ≥2 days 
n = 132 
Significance (p) 
Demographics 
Median age, years (IQR) 
Gender, % female 
Weekend admission, % 
 
Comorbidities, % 
HF 
IHD 
HTN 
CKD 
 
Biochemistry, median (IQR) 
Haemoglobin, g/L  
Creatinine, µmol/L  
Sodium, mmol/L  
Potassium, mmol/L  
Urea, mmol/L 
POCT BNP Tertile: 
100-999 pg/ml, % 
1000-2999 pg/ml, % 
≥3000 pg/ml, % 
 
Outcomes 
6-month readmission, % 
6-month mortality, % 
 
82 (76-88) 
48.9 
21.9 
 
 
58.4 
38.4 
56.5 
44.1 
 
 
122 (107 – 137) 
99 (70-128) 
139 (136 – 142) 
4.4 (4.0 – 4.8)   
9.0 (6.1 – 11.9) 
 
54.9 
34.3 
10.8 
 
 
61.7 
24.6 
 
81 (73-89) 
44.7 
68.2 
 
 
57.6 
36.4 
51.5 
52.3 
 
 
119 (102 – 136) 
115 (86 – 144)  
140 (136 – 144) 
4.5 (4.1 – 4.9)  
9.9 (6.2 – 13.8) 
 
47.7 
37.9 
14.4 
 
 
53.0 
36.4 
 
0.62 
0.40 
<0.0001 
 
 
0.87 
0.68 
0.33 
0.12 
 
 
0.30 
0.14 
0.21 
0.08 
0.07 
 
0.32 
 
 
 
 
0.09 
<0.05 
Echocardiographic parameter, median (IQR) 
LVEF, % 
GLS, % 
GLSR, S-1  
 
45 (34-56) 
-9.15 (-5.97 – -12.33) 
-0.65 (-0.45 – -0.85) 
 
41 (30-52) 
-9.10 (-5.64 – -12.56) 
-0.66 (-0.46 – -0.86) 
 
<0.05 
0.44 
0.59 
Table 4.4 – A comparison of markers of left ventricular contractile function according to time recruited post admission to hospital. 
CKD – Chronic kidney disease, GLS – Global longitudinal strain, GLSR – Global longitudinal strain rate, HF – Known heart failure, HTN – Hypertension, IHD – 
Ischaemic heart disease, IQR – Interquartile range, LVEF – Left ventricular ejection fraction, POCT BNP – Point of care test B natriuretic peptide. 
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4.6 Discussion  
This chapter has demonstrated differences found in myocardial deformation parameters 
between HF subcategories in the MRAHF cohort. It has also demonstrated the feasibility and 
applicability of myocardial deformation imaging in the AHF setting. 
Myocardial deformation imaging has traditionally been constrained by difficulties achieving 
adequate frame rates. In a research setting it has typically been performed with frame rates 
approximating 200 frames per second due to concerns about the introduction of statistical 
noise in strain rate values when frame rate falls below 100 frames per second. It has been 
demonstrated that strain values can be robustly acquired at lower frame rates of 50-60 Hz 
(Rösner, Barbosa et al. 2015), but concerns have been raised concerning estimating strain rate 
values at this speed (Mirea, O., Duchenne et al. 2016).  
In this study of AHF patients, in the acute setting with a standard echocardiography protocol, 
frame rates of 30-50 frames per second were typical. Even with these frame rates values, 
useful strain and strain rate values can be derived from the dataset; the results from the study 
demonstrate the ability of strain and strain rate values to discriminate between patients with 
varying gross contractile function as assessed by LVEF and this may suggest a further use for 
myocardial deformation values outside of the carefully constrained research settings. 
As has been described for many other clinical, demographic, biochemical and 
echocardiographic factors, in the MRAHF cohort HFmrEF appears to be an intermediate 
group, with both strain and strain rate values located between those of HFrEF and HFpEF and 
statistically distinct from both groups. Both left ventricular strain and strain rate values 
appear to vary significantly according to LVEF-based subcategorization of HF. Throughout 
all measured segments of the LV, there is either a statistically significant difference between 
each group or demonstration of a trend from lowest deformation values in HFrEF to highest 
in HFpEF.  
Both strain and strain values demonstrate a trend, with the least negative values seen in 
HFrEF, most negative in HFpEF, and HFmrEF acting as a statistically distinct intermediate 
class. The differences between median values of each subcategory are large, with both strain 
and strain rate values increased by between 50-100% in HFpEF compared to HFrEF and 
HFmrEF values intermediate between these values.  
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The trends demonstrated in both strain and strain rate values are consistent throughout the 
different segments of the myocardium in each of the assessed views, and this is represented 
by the trend seen in GLS and GLSR values.  
These trends are more frequently statistically significant for strain rate values than strain 
values. This may be an artefact and could resolve with a greater quantity of measurements but 
may reflect the fact that strain rate is less dependent upon contemporaneous haemodynamic 
status. As such, strain rate values may be more likely to demonstrate statistically significant 
intrinsic contractile differences present between each subcategory. This is consistent with the 
known data on the relative load dependence of strain versus strain rate values (Ferferieva, 
Van den Bergh et al. 2011, Greenberg, Firstenberg et al. 2002, Yingchoncharoen, Agarwal et 
al. 2013), but also with data demonstrating that strain and strain rate values correlate well 
with accurately and consistently measured LVEF (Adamo, Perry et al. 2017). 
When plotting GLS vs LVEF and GLSR vs LVEF in Figures 4.5 and 4.6 respectively, in both 
cases we see that the Loess line of best fit demonstrates a curvilinear relationship with 
flattening of the curve at higher ejection fractions. This is consistent with previous data from 
other research groups who demonstrate a curvilinear relationship between GLS/GLSR and 
LVEF (Pedrizzetti, Mangual et al. 2014, Yip, Zhang et al. 2011, Dalen, Thorstensen et al. 
2009). This has particularly been demonstrated to be of use in patients with pathological vs 
physiological hypertrophy and patients with HFpEF compared to those without; in both 
cases, those with pathology demonstrate depressed GLS compared to their control 
counterparts (Wasfy, Weiner 2015, Ersbøll, Valeur et al. 2013). 
Patients recruited ≥2 days post admission were demonstrably similar in terms of their 
demographic, comorbidity and biochemical profiles to those recruited <2 days, but did have a 
higher rate of mortality. Due to the gross similarities it is unlikely that this patient group is 
phenotypically or pathologically distinct, but the discrepancy in mortality may be explained 
by the fact that the majority of them were admitted to hospital on a weekend, a recognised 
risk factor for higher mortality (Kostis, Demissie et al. 2007, Sharp, Choi et al. 2013). Rather 
than representing a group with different anatomical profile and higher mortality, this may be 
a function of the effect of variance in weekend healthcare provision. In the MRAHF cohort, 
when adjusting for the effect of weekend admission, these differences in mortality were no 
longer statistically significant. 
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Despite the fact that patients from both groups shared similar demographic, comorbidity and 
biochemical profiles, there is a statistically significant difference between their LVEF values 
which is not seen in terms of GLS and GLSR values. LVEF values are known to be heavily 
affected by preload (Konstam, Abboud 2017) and acute management of AHF is typically 
centred around diuresis which leads to a fall in cardiac preload. As a result, LVEF typically 
falls in accordance with the Frank-Starling mechanism and this may be the cause of the fall in 
LVEF seen in patients recruited later in their hospital stay.  
If this reduction in median LVEF is purely due to diuresis, this change is not only statistically 
significant but the effect size is clinically relevant, as the median patient is almost 
recategorised from HFmrEF to HFrEF which would entirely change their prospective 
treatment pathway. The ESC guidelines recommend that patients with AHF undergo 
echocardiography within 48 hours (Ponikowski, P., Voors et al. 2016); if LVEF is variable in 
the acute phase and likely to fall after this period, prognostic management guided solely by 
the LVEF measured within 48 hours may lead to the inappropriate omission of prognostic 
medications for patients whose LVEF subsequently falls post diuresis. 
In contrast with LVEF, GLS and GLSR values are not significantly different in patients 
recruited ≥2 days post admission. This is consistent with previous literature in which both 
values, but particularly GLSR, have been demonstrated to be less load dependent (Ferferieva, 
Van den Bergh et al. 2011). As a result, these parameters are more consistent across time and 
may better represent intrinsic contractile function of the patient independent of acute 
haemodynamic profile. One should note that these findings are not proof of a causal 
relationship but serve as an interesting marker and guide to further work and assessment of 
these findings. 
The differences in deformation parameters between the subgroups are interesting for their 
own sake and for the understanding of the underlying pathologies but may also be useful in 
terms of aiding diagnosis, subcategorisation and discriminating between HF categories. Strain 
and strain rate parameters are discriminators between subgroups and are consistent across 
time periods unlike LVEF. This is valuable given that there are currently only evidence-based 
pharmacotherapeutic interventions for the HFrEF subgroup. Inadvertently commencing 
therapies in patients unlikely to benefit from them will likely only increase the frequency of 
well-recognised side effects of prognostic medications such as bradycardia and 
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hyperkalaemia with no morbidity or mortality benefit. The corollary of that is that the failure 
to start therapies in patients who would benefit will inevitably worsen their prognosis. 
Stratifying HF patients using deformation imaging values in addition to standard LVEF 
assessment could add additional diagnostic weight and accuracy given that the supplementary 
information is derived from a preload-independent source. For instance, a patient with an 
LVEF of 42% but poor strain and strain rate values may be better placed in the HFrEF group 
rather than HFmrEF due to the evidence of underlying intrinsic contractile dysfunction. 
Furthermore, the combination of LVEF and deformation imaging may allow us to better 
subcategorise patients with AHF according to loss of intrinsic myocardial contractile 
function, rather than due to the gross change in cavity size, with the inherent flaws as 
described earlier. Averaged GLS and GLSR values demonstrate less statistical variance than 
individual segment data when comparing between the various vendors of strain and strain 
rate software (Mirea, Oana, Pagourelias et al. 2017), and this may prove a more fruitful 
avenue to pursue. 
This has already been suggested in the context of the intensive care setting or to aid novice 
echocardiographers (Benyounes, Lang et al. 2015), whilst the ESC guidelines had previously 
recognised that ‘deformation imaging is more sensitive than ejection fraction in detecting 
minor changes in LV systolic function’ (McMurray, John JV, Adamopoulos et al. 2012). 
Given that small differences in LVEF can have an important impact on management and 
outcome this is not something that should be overlooked. As limitations in its use such as 
inter-vendor or software variability and consensus on normal values improve, opinion is 
shifting to suggest an increased use for deformation imaging (Duncan 2015). Since 2015, 
guidelines have recommended the use of GLS and GLSR values in many cardiovascular 
conditions, including, but not limited to, assessment of patients with mitral valve pathology 
(Ponikowski, P., Voors et al. 2016), hypertension (Marwick, Gillebert et al. 2015), restrictive 
cardiomyopathies (Habib, Bucciarelli-Ducci et al. 2017) and prior to cardiotoxic 
chemotherapy in patients with cancer (Ponikowski, P., Voors et al. 2016), so extension of the 
assessment to patients with AHF is a realistic possibility. 
Due to the variety of software programmes which can now automatically derive strain and 
strain rate measurements, the training required to produce these results at an expert level via 
offline data analysis has been suggested at 50 cases (Chan, Shiino et al. 2017), and would not 
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represent an onerous addition to the routine training cardiac physiologists or clinicians. As 
such, adding myocardial deformation imaging values to the standard assessment would be 
feasible and may add additional discriminatory power for assessment of borderline cases. 
This would help to suggest or refute intrinsic contractile dysfunction, and thus enable us to 
appropriately classify the severity of systolic dysfunction in AHF patients. 
4.6.1 Limitations 
There are limitations intrinsic to the study. The mean frame rates achieved in the study are 
noticeably lower than those typically used in strain and strain rate studies. This is largely due 
to the use of a standard echocardiographic protocol in a standard acute clinical setting. As 
frame rates fall, strain, and particularly strain rate values become complicated by an 
increasing amount of statistical noise, and strain rate curves become less smooth in 
appearance due to loss of data points. While this is certainly true, the results above suggest 
that strain and strain rate values can still be analysed in the acute population to derive 
meaningful values, irrespective of lower frame rate speeds. It cannot be claimed that these 
values are an absolute representation of the underlying contractile function, but certainly as a 
discriminatory tool in AHF patients they appear to be consistent, with significantly different 
and widely variable values seen between subcategories. 
There remains some caution in the interpretation of strain and strain rate values, particularly 
with reference to inter-vendor software variations. This has certainly been a concern 
historically but newer studies suggest this variation may be improving (Yang, Marwick et al. 
2015). Indeed, inter-vendor and inter-operator differences between strain values are now 
significantly less than differences between LVEF measurements and other measurements 
such as E and E/A (Farsalinos, Daraban et al. 2015). There are, however, still difficulties in 
agreeing standardised norms for strain and strain rate values due to the small but statistically 
significant variation encountered when assessing similar patient cohorts using different 
machines and software (Farsalinos, Daraban et al. 2015). Deformation values have even been 
shown to vary between intra-vendor software upgrades (Nagata, Takeuchi et al. 2015). As 
such, the absolute values contained within this study may not be transferrable to other centres 
using different materials, however the trends described are likely still applicable and 
informative. Nevertheless, a consensus on strain and strain rate algorithms and their 
application would be beneficial in order to expand the use of deformation imaging. This was 
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recognised by the ESC and led to the first consensus document on speckle tracking imaging 
to attempt to improve uniformity of reporting (Voigt, Pedrizzetti et al. 2014). 
While the above results refer to specific PSS and SR values, it is understood that specific 
patterns of strain and strain rate curves are of diagnostic and qualitative value in a variety of 
cardiac conditions with post-systolic shortening in ischaemic the best described (Smiseth, 
Torp et al. 2015). The results above focus very specifically on the utility of absolute PSS and 
SR values as this is perhaps easier to standardise and compare, but the qualitative value of 
strain and strain rate curve patterns should not be forgotten in clinical practice. 
The MRAHF patient cohort is significantly older than the typical European patient as 
described in chapter three, and overwhelmingly white and Caucasian. This introduces 
difficulties in generalising the findings outlined here to a generalised European population. 
This must be acknowledged, but the demographic breakdown of the MRAHF study 
population is qualitatively similar to that described in the British National Heart Failure Audit 
in terms of age, gender and comorbidity burden (Donkor, Cleland et al. 2015), and thus is 
likely to be representative of the British AHF population.  
4.6.2 Further Work 
This study has demonstrated both the feasibility and utility of myocardial deformation in an 
AHF but would benefit from being repeated in other AHF populations with different 
demographic characteristics to assess the reproducibility and generalisability of the results 
reported here. 
Verification of these findings with larger datasets, representative of different geographical 
populations, will be beneficial in assessing the extent to which these findings can be 
generalised throughout the AHF population, though there is no clear theoretical reason why 
other populations should act in a different manner.  
Normal values for strain and strain rate are still not clear, particularly given the inter-vendor 
and inter-software variability. Consensus regarding algorithms and values would be of 
immense value if strain and strain rate are to be more widely used in assessment and 
management of the failing heart. 
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LVEF is lower in patients recruited after ≥2 days of admission while GLS and GLSR remain 
statistically similar between patients recruited at <2 days of admission. To clarify this 
finding, one could perform a study assessing LVEF, GLS and GLSR on all AHF patients at 
the time of admission and 2 days subsequent to admission. This would help clarify if LVEF 
does indeed fall in these patients while GLS and GLSR remain static. If this is the case, they 
may represent a more consistent marker of LV function, particularly in the acute phase.   
If this is the case then the utility of using GLS/GLSR with LVEF versus LVEF in isolation 
could be assessed as a guide to prognostic management. If this was of additive benefit this 
could offer a more accurate and useful diagnostic or prognostic test which may improve the 
ability to accurately delineate and subcategorise patients with AHF, and thus focus 
therapeutic efforts upon patients more likely to benefit from their use. It would also help to 
shift the focus from a crude marker of systolic function to incorporate more precise and 
representative correlates of systolic function. 
Ultimately, classifying and treating patients according to a preload-independent marker such 
as strain or strain rate values may be more accurate and more useful than LVEF. In order for 
this to be tested, one could envisage a randomised controlled trial in which patients were 
allocated to current guideline therapies according to strain or strain rate values, while the 
other arm is treated according to LVEF values. Changes in cardiac geometry, function and 
patient outcome could be compared between the two groups to assess the utility of 
categorising patients in this manner. The data may not yet exist to support such a study but 
this could represent a highly interesting avenue of research. 
4.7 Chapter summary 
This chapter has outlined the current literature regarding myocardial deformation parameters 
in HF and the gaps within the evidence. It has then recovered the materials and methods used 
in the MRAHF study to acquire and analyse the dataset.  
There are large, statistically significant differences in myocardial deformation imaging values 
between HF subcategories. These findings add to the understanding of different HF 
phenotypes, particularly with a view to accurately distinguishing between the groups which 
can be challenging using standardly available and used diagnostic tools. In addition, LVEF 
values are significantly lower in patients recruited later in their hospital admission but 
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myocardial deformation values are not. This may suggest a use for either repeated 
measurement of LVEF or an enhanced role for deformation imaging in the acute phase. 
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Chapter Five: Prediction of 6-month mortality in an acute 
heart failure cohort using variables available upon 
admission to hospital 
5.1 Chapter Introduction 
This chapter describes the production of novel risk scoring tools, designed to help stratify 6-
month mortality risk in patients with acute heart failure (AHF), early within their inpatient 
hospital admission. 
This chapter first reviews the current literature and gaps in current understanding then outline 
what this study has aimed to address. It then outlines the materials and methods required to 
produce the risk scoring tools and describes the production of two separate scoring tools, one 
which includes echocardiographic data and one which does not. Both tools are demonstrated 
to have good calibration, predictive power and discriminatory ability. A comparison is then 
made of the improvement to the scoring models with the inclusion of biochemical data from 
Point of Care test B type natriuretic peptide levels. Finally, there is a discussion of the 
conclusions that can be drawn from the data and the limitations intrinsic to the study, and 
lastly suggestions for further work. 
5.2 Current literature – evidence and omissions 
The ability to predict risk of adverse outcomes in a given disease is essential in modern 
medicine. Therapeutic interventions are predicated on the concept that they reduce the risk of 
adverse outcomes, be that symptom burden, admission to hospital, or ultimately death. 
Similarly, clinical management decisions regarding intensification or relaxation of treatment 
are made based upon recognition of factors which confer prognostic risks to the individual 
patient. In order to know this, it is important to first understand the original mortality and 
morbidity risk of the underlying disease and the variables which contribute negatively to 
both. 
The risk or probability of a particular outcome, be that hospital admission, disease 
manifestation or mortality, can be predicted using a number of statistical and arithmetic 
means. These include correlations, linear and logistic regressions to produce hazard and odds 
ratios. The conversion of these into statistical risk prediction models and simple clinical risk 
scores has become commonplace in many medical specialties.  
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Well-known risk stratification models include CURB-65 which predicts mortality in 
community acquired pneumonia (Lim, W. S., van der Eerden et al. 2003), the Blatchford 
score which predicts requirement for invasive intervention, transfusion and mortality in 
gastrointestinal bleeding (Blatchford, Murray et al. 2000) and the CHA2D2S VaSc score (Lip, 
Gregory YH, Nieuwlaat et al. 2010) which is used in patients with atrial fibrillation to predict 
risk of cerebrovascular accident and requirement for anticoagulative therapy. All three 
models use simple, easy-to-remember variables which are applicable by the emergency or 
acute medical physicians to aid risk stratification and subsequent patient management.  In 
each study the authors emphasise the benefits of simplicity of their risk scoring formulae, 
noting how this translates into adoption of the risk scoring model. 
Similar, if more complicated, scores are available for the chronic heart failure (CHF) 
population; online tools such as the Seattle risk score and Barcelona Bio-Heart Risk 
calculator use the input of more than 12 variables, both continuous and categorical, to 
produce readmission and mortality risk probabilities (Lupón, de Antonio et al. 2013, Levy, W. 
C., Mozaffarian et al. 2006).  
As yet, there is no simple tool that can be used in the AHF population for prediction of 
mortality risk using data available upon admission. Many tools exist, but limitations exist in 
their application due to a variety of factors including, but not limited to, the inclusion of 
variables not available at admission (O'connor, Abraham et al. 2008b, Salah, Kok et al. 
2014), the use of a very large number of predictive variables (Okazaki, Shirakabe et al. 
2014), complex scoring algorithms (Lee, Austin et al. 2003), non-routine tests (O'Connor, 
Hasselblad et al. 2010) and the omission of echocardiographic data. 
These factors can render it difficult to make early, evidence-based, management decisions 
regarding patient admission, treatment and follow-up care using the currently available risk-
stratification tools. 
This study describes the creation and application of two novel risk scoring tools for use upon 
acute admission, able to offer useful information about 6-month mortality risk with data 
easily obtainable at an early stage in the patient journey. 
In doing so it aims to demonstrate the feasibility of such a task and suggest avenues for 
expansion of such a model with validation in a larger patient cohort. 
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5.3 Study hypotheses 
This chapter will assess the following hypotheses: 
a) Using data from the Mitral Regurgitation in Acute Heart Failure (MRAHF) cohort it 
is possible to produce a risk-scoring tool, able to give prognostic information to 
healthcare professionals regarding likely 6-month mortality risk in the AHF patient 
cohort.  
b) It is possible to produce the above risk-scoring tool using information readily 
available to the acute physician directly upon admission to allow for early patient 
prognostication without necessitating recourse to specialist or complex data. 
5.4 Methods 
Chapter two describes the methods and materials used for study design and patient 
recruitment. Below is a brief summary of these with a specific emphasis on the statistical 
methods employed to produce a risk-stratifying and scoring tool. 
5.4.1 Study design and population 
This study uses data from the entire cohort of the MRAHF study. This is a prospective, 
cohort study of consecutive patients admitted to a single hospital site with signs and 
symptoms consistent with AHF as the primary driver of admission.  
5.4.2 Inclusion and exclusion criteria 
Inclusion criteria for the study: 
1) Clinical signs and symptoms consistent with AHF as the primary cause for admission 
2) Inpatient admission of <7 days by time of consent 
3) The ability to give informed consent 
Exclusion criteria for the study: 
1) Point-of-care test (POCT) B natriuretic peptide (BNP) level <100 pg/ml 
2) Echocardiography inconsistent with a diagnosis of HF 
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5.4.3 Patient recruitment and data capture 
Patient recruitment began in July 2016 and ceased in September 2017.  616 patients were 
approached for recruitment, 500 patients gave informed consent to be recruited into the trial 
of whom 447 remained subsequent to exclusions. Data capture was carried out at the time of 
recruitment and included baseline demographic, biochemical, observational and radiological 
data including echocardiography as outlined in chapter two.  
Mortality data, including date of death, for patients within the cohort was obtained from the 
online NHS Summary Care Record at 6-months post discharge. Cause of death for each 
patient was obtained from the patient’s death certificate via either general practitioner (GP) 
records or, where unavailable, the local County Registrar’s office.    
5.4.5 Statistical analysis 
5.4.5.1 Baseline characteristics 
All statistical analysis was performed using SPSS version 24 as accessed at Royal Holloway 
University, with all statistical analysis researched, planned and performed by myself with 
subsequent checking of methods and suggestion for further analysis provided by Dr David 
Crook.  
Continuous variables were tested for normality using the Shapiro-Wilk tests, and evidence of 
skew was inspected visually using histograms, Q-Q plots and box plots. 
Continuous parametric variables were analysed using Student’s T test when categorised as 
two groups. One-way analysis of variance (ANOVA) was used to compare data when more 
than 2 groups existed, as for AHF subcategories. Tukey’s post-hoc test was used to ascertain 
specific inter-group variations within the ANOVA.  
Statistical differences in non-parametric continuous variables were assessed using the Mann-
Whitney U test or Kruskal-Wallis test when more than 2 groups were present with Dunn’s 
post-hoc test used to assess for specific inter-group variations. 
 
Pearson’s Chi-squared test was used to assess for statistical differences between categorical 
variables. 
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Parametric continuous data are presented as a mean ± standard deviation. Non-parametric 
continuous data are presented as a median with interquartile range. Categorical variables are 
presented as a proportion within the population. 
An alpha value of 0.05 was set as the threshold for statistical significance. 
5.4.5.2 Risk prediction modelling 
Logistic regression analysis cannot be performed using repeated measurements or matched 
data therefore the data from any repeat admission within the study period was excluded from 
analysis (Dayton 1992).  
Logistic regression requires minimal assumptions regarding linearity, normality or 
homoscedasticity of the included variable. Assessment of multicollinearity is not mandatory 
in prediction models as one is not attempting to demonstrate causality, but rather produce a 
risk probability model.  
 
Variables were selected according to clinical availability within 48 hours of patient admission 
to hospital and remaining variables were selected according to previously reported predictive 
value.  
 
These variables were used in forward conditional binary logistic regression modelling to 
select the model that accounted for the greatest variance of mortality according to Nagelkerke 
R2 values. 
Each continuous independent variable included in the model was assessed for linearity with 
the logit transformation of 6-month mortality. This was performed using the Box-Tidwell 
test. All continuous variables demonstrated linearity and thus results of the Box-Tidwell test 
were not statistically significant. 
Continuous variables which were selected for the model were then converted into categorical 
variables using values which provided maximum statistical discriminatory power. Where 
possible, these values were assessed at commonly used discriminatory or reference values. 
Binary logistic regression analysis was then repeated using only these derived categorical 
variables to assess for significance. Using the derived model, predictive scoring systems were 
produced using the odds ratios (OR) of each categorical variable to allocate points relative to 
 133 
 
the other variables. In the context of a prospective cohort study, B(exp) is synonymous with 
the OR for each variable. Variables for whom the exponentiation of the coefficient (B(exp)) 
values produced were <1.000 were inverted to simplify comparison of B(exp) values.  
Having assessed model association statistically, tests of model performance were then 
performed. 
The total score for each patient was then calculated using the model. The predictive utility of 
the scores were assessed using receiver operator characteristic curve area under the curve 
(ROCAUC) analysis. This compared the patients’ risk score, and thus their predicted 
mortality risk to actual 6-month mortality. The ROCAUC is equal to the concordance statistic 
or concordance index (C-Index) for binary outcomes as assessed in this study. The C-index is 
the standard measure of a predictive model’s goodness of fit in a binary logistic regression 
and can be defined as the estimated probability that the predictive model will predict higher 
risk of event in a ‘case’ (6-month mortality) than in a ‘control’ (alive at 6-months). A C-index 
of 0.500 would indicate that the model is no better than chance at predicting the increased 
probability of case vs control, whereas a C-index of 1.000 would demonstrate that in 100% of 
pairings the predictive model would indicate a higher risk of an event for a ‘case’ than a 
‘control’ (Uno, Cai et al. 2011).   
The accuracy of the predictive score was assessed according to values as described in Table 
5.1, as has been standardly reported in clinical literature (Obuchowski 2003, Metz 1978).  
C-Index Predictive accuracy 
0.900-1.000 Excellent 
0.800-0.899 Good 
0.700-0.799 Fair 
0.600-0.699 Poor 
0.500-0.599 Worthless test 
Table 5.1 C-Index ranges and their associated predictive accuracy. 
 
Actual patient mortality was then assessed for each individual risk score. Risk scores were 
then grouped into three categories in which there were different levels of 6-month mortality 
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risk, namely <10%, 10-29% and ≥30%. These point score ranges were then denoted as low, 
medium and high-risk for 6-month mortality. 
The discriminatory value of these three points’ categories was demonstrated using Kaplan-
Meier survival curves and statistical independence was determined using Pearson’s Chi-
squared test. 
The risk modelling process was performed first using only clinical data, and then 
subsequently repeated including echocardiographic variables to assess the predictive value of 
echocardiographic data. 
Net reclassification index (NRI) analysis was performed to assess the additional 
discriminatory power of the model which included echocardiographic variables.  
5.5 Results 
5.5.1 Baseline characteristics 
52 cases were excluded due to repeat recruitment into the study. Baseline characteristics of 
the study cohort post these exclusions are included below in Table 5.2. 
Excluded cases were typically of a higher median age (83 years (IQR 79-87) versus 81 years 
(IQR 75-87), p<0.05), were more likely to have known HF (96.2% versus 53.2%, p<0.0001) 
and were more likely to have been admitted in the previous year for any cause (80.8% versus 
35.9%, p<0.0001). Otherwise they shared similar demographic, comorbidity and outcome 
profiles.  
After exclusions, the median age of cases remaining for inclusion in risk modelling was 81 
years (IQR 75-87), 47.1% of the cohort were female. 
Median length of stay on index admission was 6 days (IQR 3-9). At 6 months 58.5% of 
patients had been readmitted, 22.6% due to decompensation of HF and 27.7% of patients had 
died, 13.0% due to cardiovascular causes. 
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N 
Whole cohort 
 392 (100%) 
HFrEF 
156 (40.5%) 
HFmrEF 
91 (23.2%) 
HFpEF 
145 (36.3%) 
Significance (p) 
- 
Demographics 
Median age, years (IQR) 
 
81 (75-87) 
 
80 (72-88) 
 
83 (77-89) 
 
81 (74-88) 
 
0.07 
Gender, % female 46.9 38.5 46.2 56.6 <0.01 a,c 
European Caucasian, %  92.1 93.6 89.0 92.4 0.43 
Median BMI, kg/m2 (IQR) 27.3 (22.8-31.8) 26.5 (22.5-30.5) 26.7 (22.7-30.7) 28.6 (24.0-33.2) 0.10 
Hospitalisation in last year, % 36.0 36.5 30.8 38.6 0.47 
Median length of stay on index admission, days (IQR) 6 (3-9) 7 (3-11) 5 (2-8) 6 (3-9) 0.18 
Comorbidities, % 
HF 
 
52.8 
 
51.9 
 
59.3 
 
50.3 
 
0.36 
IHD 36.2 44.9 29.7 31.0 <0.05 a 
HTN 55.6 57.1 49.5 57.9 0.39 
DM 30.4 29.5 26.4 33.8 0.46 
CKD 45.2 48.1 49.5 40.0 0.28 
COPD 14.0 10.3 13.2 17.9 0.21 
CVA 15..1 14.7 12.1 17.9 0.43 
6-month outcomes, %      
All-cause readmission 58.5 62.2 56.7 54.9 0.35 
HF readmission 22.5 22.4 22.2 22.7 0.99 
All-cause mortality 27.7 30.8 20.0 29.2 0.17 
CVD mortality 12.8 15.9 9.2 11.7 0.29 
Table 5.2 – Baseline characteristics of the AHF cohort used for model production post exclusions of data from patients’ repeat admissions.  
a – HFrEF, b – HFmrEF, c – HFpEF 
BMI – Body mass index, CKD – Chronic kidney disease, COPD – Chronic obstructive pulmonary disease, CVA – Cerebrovascular accident, CVD – Cardiovascular disease, 
DM – Diabetes mellitus, HF – Heart failure, HTN – Hypertension, IHD – Ischaemic heart disease, IQR – Interquartile range. 
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5.5.2 Variable selection 
All 316 collected variables in the dataset were initially considered for inclusion. 251 variables 
which would not be available to the clinician within 48 hours of admission were excluded.  
One variable with <50% data available was excluded (Abbreviated Mental Test Score 
(AMTS)). POCT BNP level was excluded from the main models as it is typically replaced by 
laboratory BNP values in clinical practice and laboratory BNP values were not recorded in 
this study. 
A literature search was performed to search for evidence of the predictive value of the 
remaining 63 variables. Variables with no evidence within the literature of increasing 
mortality risk in HF were excluded. 33 variables remained of which 7 were collected from 
echocardiography. The variables included in model assessment and production and can be 
seen in Table 5.3. All variables were collected and are defined according to the methods 
described in chapter two. 
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Two models were then assessed – one which omits echocardiographic variables (Clinical 
model) and one including all variables (Clinical & Echo model).  
Demographic Medications on 
admission 
Clinical 
Observations 
Common 
investigations 
Age, years 1 Mineralocorticoid receptor 
antagonist 5  
NYHA functional 
class, I-IV 2 
ECG Rate, bpm 1 
Sex 2 ACE inhibitor 6 SBP, mmHg 1 ECG Rhythm 1 
BMI, Kg/m2   3 Angiotensin receptor 
blocker 7 
DBP, mmHg 6 ECG QRS duration, ms 
8 
Weekend admission 4 Beta blocker 6   
Clinical History Biochemistry Echocardiogram 
Previous admissions – all 
cause, and HF 9 
Creatinine, µmol/L 6 LVEF, % 6 
Cause of acute decompensation 
2 
Haemoglobin, g/L 1 RVFAC, % 11 
Known HF 6 Sodium, mmol/L 1 TAPSE, cm 12 
Known IHD 1 Potassium, mmol/L 1 SPAP, mmHg 13 
Known CKD 6 Urea, mmol/L 1 Severity of mitral regurgitation, I-IV 14 
 VBG pH 10 Severity of tricuspid regurgitation, I-IV 14 
 VBG lactate, mmol/L 10 Left atrial area in systole, cm2 15 
Table 5.3 – Retained variables used in binary logistic regression to produce a scoring model. Numeric 
suffixes denote the literature evidence supporting their use in HF prognostication. 
ACE – Angiotensin converting enzyme, BMI – Body mass index,  CKD – Chronic kidney disease,  DBP – 
diastolic blood pressure,  ECG – electrocardiogram, HF – Heart failure, IHD – Ischaemic heart disease,  LVEF – 
Left ventricular ejection fraction,  NYHA – New York Heart Association,  RVFAC – Right ventricular fractional 
area change,  SaO2 – Blood oxygen saturation, SBP – Systolic blood pressure, SPAP – systolic pulmonary artery 
pressure, TAPSE – Tricuspid annular plane systolic excursion,  VBG – Venous blood gas.  
1 – (Lee, Austin et al. 2003), 2 - (Levy, W. C., Mozaffarian et al. 2006), 3 - (Oreopoulos, Padwal et al. 2008), 4 - 
(Horwich, Hernandez et al. 2009), 5 - ((Pitt, Zannad et al. 1999), 6 -  (Siirilä-Waris, Lassus et al. 2006), 7 - 
(Pocock, Wang et al. 2005), 8 - (Harjola, Follath et al. 2010), 9 - (Gheorghiade, Vaduganathan et al. 2013), 10 - 
(Park, Choi et al. 2015), 11 - (Melenovsky, Hwang et al. 2014), 12 - (Burke, Katz et al. 2014), 13 - (Komajda, Jais 
et al. 1990), 14 - (Grayburn, Appleton et al. 2005), 15 - (Quiñones, Greenberg et al. 2000). 
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5.5.3 Clinical model 
5.5.3.1 Model production 
Forward conditional binary logistic regression was performed for prediction of 6-month 
mortality using the variables in Table 5.3 omitting echocardiography. The model produced is 
included below in Table 5.4. 
   95% C.I for Exp(B) 
Variable Significance (p) Exp(B) Lower Upper 
Age <0.0001 1.087 1.049 1.127 
BMI <0.0001 0.940 0.910 0.970 
Sodium <0.05 0.939 0.888 0.993 
Urea <0.0001 1.101 1.046 1.159 
SBP <0.005 0.977 0.964 0.990 
Table 5.4 – Predictive model produced using continuous variables. 
Exp(B) – Exponentiation of the coefficient, SBP – Systolic blood pressure. 
 
All potential continuous variables were converted to binary categorical variables and the 
forward conditional regression was repeated to determine a model. This model can be seen in 
Table 5.5. Of the 7 categorised causes of decompensation, only arrhythmogenic/non-
arrhythmogenic decompensation was found to contribute significantly to the prognostic 
model with non-arrhythmogenic HF conferring an OR of 2.537 compared to arrhythmogenic 
HF.  
   95% C.I for Exp(B)   
Variable Significance 
(p) 
Exp(B) Lower Upper Nagelkerke 
R2 
Variance accounted for 
by each variable, % 
Age ≥80 years <0.005 2.717 1.541 4.794 0.094 9.4 
Admission in previous year <0.01 2.026 1.189 3.449 0.157 6.3 
Non-arrhythmogenic 
decompensation 
<0.01 2.537 1.257 5.122 0.199 4.2 
BMI <26 kg/m2 <0.05 1.847 1.078 3.165 0.242 4.3 
Known CKD <0.05 1.749 1.003 3.051 0.261 1.9 
Sodium <135 mmol/L <0.05 2.122 1.166 3.859 0.278 1.7 
Urea ≥12 mmol/L <0.0001 2.642 1.489 4.689 0.295 1.7 
SBP <130 mmHg <0.005 2.364 1.408 3.967 0.308 1.3 
Table 5.5 - Predictive model produced after conversion of continuous variables into categorical variables. 
BMI – Body mass index, CKD – Chronic kidney disease, Exp(B) – Exponentiation of the coefficient, SBP – Systolic blood 
pressure. 
5.5.3.2 Regression Coefficient 
The regression coefficient of the model produced is described below: 
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Regression coefficient = -4.248 + 0.971*Non-Arrhythmogenic + 0.588* Known CKD + 
0.721* Admission in last year +0.779* Na<135 mmol/L + 1.034*Age ≥80 + 0.622* BMI <26 
Kg/M2+ 1.008*Urea ≥12 mmol/L + 0.877* SBP<130 mmHg 
 
Boundary score for group membership, i.e. prediction of alive or dead, is 0.50. 
5.5.3.3 Model Calibration 
Prior to modelling the null model predicts that all patients will remain alive as seen in table 
5.6. 
  Predicted mortality Percentage Correct 
  Alive Dead 
Observed 6-month 
mortality 
Alive 283 0 100.0 
Dead 108 0 0.0 
Accuracy   72.4 
Table 5.6 – Clinical model calibration plot – prior to addition of predictive variables. 
 
Table 5.7 demonstrates the changes to the predicted vs observed outcomes after application 
of the clinical model: 
  Predicted mortality Percentage Correct 
  Alive Dead 
Observed 6-month 
mortality 
Alive 259 24 91.5 
Dead 67 41 38.0 
Accuracy   76.7 
Table 5.7 -Clinical model calibration plot – post addition of predictive variables. 
 
Table 5.8 compares the diagnostic test statistics pre and post application of the clinical 
model: 
Test statistic Pre-model value Post-model value 
Sensitivity 0.0% 38.0% 
Specificity 100.0% 91.5%% 
Positive Predictive Value NA 63.1% 
Negative Predictive Value 72.4% 79.5%% 
Accuracy 72.4% 76.7%% 
Table 5.8 – Comparison of diagnostic test statistics pre and post application of the clinical model 
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Table 5.8 demonstrates substantial improvements in test sensitivity, positive predictive value, 
negative predictive value and test accuracy, while specificity falls from 100% to 91.5%. 
The Hosmer and Lemeshow test was not statistically significant for the model, suggesting 
good statistical calibration (N = 391, X2 = 9.975, p = 0.267). 
The cumulative Nagelkerke R2 of the model produced can be seen in Figure 5.1. 
 
5.5.3.4 Risk score point allocation 
Each variable was allocated a point value according to the ratio of exponentiation of the 
coefficients (Exp (B)) which are equivalent to the OR. One point was allocated per variable 
Figure 5.1 – Cumulative Nagelkerke R2 values of the variables included in the clinical model 
BMI – body mass index, CKD – chronic kidney disease, Na – sodium, SBP – Systolic blood pressure. 
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as all OR were approximately on a 1:1 ratio. The minimum score possible per patient is 0 and 
maximum is 8. 
5.5.3.5 Discriminatory ability - Receiver operator curve assessment  
Risk score was calculated for each patient in the dataset. Predictive power for mortality of the 
risk scores were assessed using a receiver operator curve (ROC). Area under the curve 
statistics are presented in Table 5.9 and the ROC is shown in Figure 5.2. 
   Asymptotic 95% confidence 
interval 
Area under the 
curve 
Standard error Asymptotic 
significance (p) 
Lower bound Upper bound 
0.746 0.026 <0.0001 0.695 0.798 
Table 5.9 – Area under the curve statistics for the Clinical model. 
 
 
Figure 5.2 – Receiver operator curve for the Clinical model. The black diagonal line is the 50% reference. 
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5.5.3.6 Score stratification 
Frequency of mortality was assessed for each point score from 0-8 and can be seen below in 
Table 5.10.  
Clinical risk score N 6-month mortality, % 
0 3 0.0 
1 24 8.3 
2 76 3.9 
3 83 19.3 
4 79 31.6 
5 85 47.1 
6 36 50.0 
7 4 50.0 
8 3 100.0 
Table 5.10 – Percentage 6-month mortality of each Clinical risk score. 
 
Clinical risk score values were then grouped together and stratified into low, medium and 
high risk. Low risk was defined as 6-month mortality <10%, medium risk as 6-month 
mortality of 10-29% and high risk as 6-month mortality ≥30%. This corresponded with 
Clinical risk scores of 0-2, 3-4 and ≥5 respectively. 
 
Chi squared testing demonstrated that these scores allowed for statistically significant 
discrimination of mortality risk between groups; mortality in the low risk group was 0%, 
25.6% in the medium risk group and 65.6% in the high-risk group (p<0.0001).  
 
Risk Group N Mortality Significance (p) 
Low 103 4.9% <0.0001 
Medium 162 25.3% 
High 128 49.2% 
Table 5.11 – Risk stratification table for the Clinical risk score demonstrating mortality risk in each 
group. 
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5.5.3.7 Clinical risk score summary 
The Clinical risk score can be summarised thus: 
Risk Variable Point score 
Age ≥80 years 1 
Hospital admission in previous year 1 
Non-arrhythmogenic aetiology of HF 1 
BMI <26 kg/m2 1 
Known CKD 1 
Sodium <135 mmol/L 1 
Urea ≥12 mmol/L 1 
Systolic blood pressure <130 mmHg 1 
Points scored Risk category 6-month mortality risk, % 
0-2 Low 4.9 
3-4 Medium 25.3 
5-8 High 49.2 
Table 5.12 – Summary table of the Clinical risk score including variables, allocated point score per 
variable and risk category stratification table for the Clinical model.  
BMI – Body mass index, CKD – Chronic kidney disease. 
Figure 5.3 – Kaplan-Meier curve demonstrating survival versus Clinical risk score category. 
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5.5.4 Clinical & Echo Model 
5.5.4.1 Model production 
Echocardiographic parameters were added to the list of variables used in the clinical model 
and forward conditional binary logistic regression for prediction of 6-month mortality was 
repeated with the new variables. 
The model produced is included below in Table 5.13. 
   95% C.I for Exp(B) 
Variable Significance (p) Exp(B) Lower Upper 
Age ≥80 years <0.0001 3.415 1.843 6.328 
Admission in previous year <0.05 2.040 1.171 3.553 
Non-arrhythmogenic aetiology <0.05 2.567 1.241 5.310 
BMI <26 kg/m2 <0.05 1.767 1.011 3.087 
Known CKD <0.05 2.567 1.241 3.318 
Sodium <135 mmol/L <0.01 2.402 1.299 4.441 
Urea ≥12 mmol/L <0.005 2.523 1.396 4.559 
SBP <130 mmHg <0.005  2.235 1.301 3.842 
RVFAC <0.05 0.975 0.953 0.998 
SPAP <0.05 1.015 1.000 1.030 
Table 5.13 – Variables included in logistic regression in the Clinical & Echo model 
BMI – Body mass index, Exp(B) – Exponentiation of the coefficient, RVFAC – Right ventricular fractional area 
change, SBP – Systolic blood pressure, SPAP – Systolic pulmonary artery pressure. 
 
Continuous variables were converted to categorical variables and the regression was repeated 
to assess for validity of the model. Body mass index <26 kg/m2 was eliminated from the 
model by the regression algorithm at this stage. 
   95% C.I for Exp(B)   
Variable Significance (p) Exp(B) Lower Upper Nagelkerke 
R2  
Variance 
accounted for by 
each variable, % 
Age ≥80 <0.0001 3.963 2.164 7.259 0.112 11.2 
Urea ≥12 mmol/L <0.01 2.252 1.263 4.016 0.173 6.1 
SBP<130 mmHg <0.01 2.293 1.334 3.943 0.213 4.0 
SPAP ≥50 mmHg <0.01 2.166 1.240 3.786 0.254 4.1 
Non-arrhythmogenic  <0.01 2.696 1.311 5.545 0.288 3.4 
Na <135 mmol/L <0.01 2.422 1.306 4.491 0.307 1.9 
Known CKD <0.05 1.907 1.070 3.401 0.324 1.7 
Admission in previous year <0.05 1.818 1.059 3.123 0.338 1.4 
RVFAC <32% <0.05 1.815 1.027 3.207 0.350 1.2 
Table 5.14 – Variables included in the model after conversion of continuous variables to categorical variables. 
CKD – Chronic kidney disease, Exp(B) – Exponentiation of the coefficient, Na – Sodium, RVFAC – Right ventricular 
fractional area change, SBP – Systolic blood pressure, SPAP – Systolic pulmonary artery pressure. 
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5.5.4.2 Regression Coefficient 
The regression coefficient of the model produced is described below: 
Regression coefficient = -4.811 + 0.992*Non-arrhythmogenic + 0.646*Known CKD + 
0.598*Admission in last year + 0.885* Na <135 mmol/L + 1.377*Age ≥80 + 0.812*Urea ≥12 
mmol/L + 0.830*SBP <130 mmHg + 0.596* RVFAC<32% + 0.773*SPAP ≥50 mmHg 
Boundary score for group membership, i.e. prediction of alive or dead, is 0.50. 
5.5.4.3 Model Calibration 
Prior to modelling the null model predicts that all patients are alive as seen in table 5.15. 
  Predicted mortality Percentage Correct 
  Alive Dead 
Observed 6-month 
mortality 
Alive 272 0 100.0 
Dead 105 0 0.0 
Accuracy   72.1 
Table 5.15 – Clinical & Echo model calibration plot – prior to addition of variables. 
 
Table 5.16 demonstrates the changes to the predicted vs observed outcomes after application 
of the clinical & echo model: 
  Predicted mortality Percentage Correct 
  Alive Dead 
Observed 6-month 
mortality 
Alive 247 25 90.8% 
Dead 63 42 40.0% 
Accuracy   76.7% 
Table 5.16 – Clinical & Echo model calibration plot – post addition of variables. 
 
Table 5.17 compares the diagnostic test statistics pre and post application of the clinical & 
echo model: 
Test statistic Pre-model value Post-model value 
Sensitivity 0.0% 40.0% 
Specificity 100.0% 90.8% 
Positive Predictive Value NA 62.7% 
Negative Predictive Value 72.1% 80.0% 
Accuracy 72.1% 76.7% 
Table 5.17 - Comparison of diagnostic test statistics pre and post application of the clinical & echo 
model 
 
 146 
 
Table 5.17 demonstrates substantial improvements in test sensitivity, positive predictive 
value, negative predictive value and test accuracy, while specificity falls from 100% to 
90.8%. 
The Hosmer and Lemeshow test was not statistically significant for the model, suggesting 
good statistical calibration (N = 375, X2 = 5.302, p = 0.725). 
The cumulative Nagelkerke R2 of the model produced can be seen in Figure 5.4. 
  
Figure 5.4 - Cumulative Nagelkerke R2 values of the variables included in the Clinical & Echo model 
CKD – chronic kidney disease, Na – Sodium, RVFAC – Right ventricular fractional area change, SPAP – 
Systolic pulmonary artery pressure. 
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5.5.4.4 Risk score point allocation 
Each variable was allocated a point value according to the ratio of exponentiation of the 
coefficients (Exp (B)) which are equivalent to the OR. The median OR was approximately 2. 
The Exp(B) for Age ≥80 was almost double the median so a positive answer in this category 
was allocated a score of two points, all other variables were allocated one point. The 
minimum score possible is 0 and maximum is 10. 
5.5.4.5 Discriminatory ability - Receiver operator curve assessment 
Risk score was calculated for each patient in the dataset. Predictive power for mortality of the 
risk scores were assessed using a receiver operator curve (ROC). Area under the curve 
statistics are presented in Table 5.18 and the ROC is shown in Figure 5.5. 
   Asymptotic 95% confidence 
interval 
Area under the 
curve 
Standard error Asymptotic 
significance (p) 
Lower bound Upper bound 
0.804 0.023 <0.0001 0.758 0.849 
Table 5.18 – Area under the curve statistics for the Clinical & Echo risk score. 
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5.5.4.6 Score stratification 
Frequency of mortality was assessed for each point score from 0-10 and can be seen below in 
Table 5.19.  
Clinical & Echo risk score N 6-month mortality, %  
0 5 0.0 
1 33 0.0 
2 24 0.0 
3 65 9.2 
4 68 19.1 
5 67 28.4 
6 64 43.8 
7 44 56.8 
8 17 70.6 
9 6 100.0 
10 0 - 
Table 5.19 – Percentage 6-month mortality of each Clinical & Echo risk score. 
Figure 5.5 – Receiver operator curve for the Clinical & Echo model. The black diagonal line is the 50% 
reference. 
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Clinical & Echo risk score values were then stratified into low, medium and high risk. Low 
risk was defined as 6-month mortality <10%, medium risk as 6-month mortality of 10-29% 
and high risk as 6-month mortality ≥30%. This corresponded with Clinical & Echo risk 
scores of 0-3, 4-5 and ≥6 respectively. 
 
Chi squared testing demonstrated that these scores allowed for statistically significant 
discrimination of mortality risk between groups; mortality in the low risk group was 4.7%, 
23.7% in the medium risk group and 54.2% in the high-risk group (p<0.0001).  
Risk Group N Mortality Significance (p) 
Low 135 4.7% <0.0001 
Medium 150 23.7% 
High 160 54.2% 
Table 5.20 – Risk stratification table for the Clinical & Echo risk score demonstrating 
mortality risk in each group. 
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5.5.4.7 Clinical & Echo risk score summary 
 
The Clinical & Echo risk score can be summarised thus: 
Risk Variable Point score 
Age ≥80 2 
Urea ≥12 mmol/L 1 
Systolic blood pressure <130 mmHg 1 
SPAP ≥50 mmHg 1 
Non-arrhythmogenic aetiology 1 
Sodium <135 mmol/L 1 
Known CKD 1 
Admission in previous year 1 
RVFAC <32% 1 
Points scored Risk category 6-month mortality risk, % 
0-3 Low 4.7% 
4-5 Medium 23.7% 
6-10 High 54.2% 
Table 5.21 – Summary table of the Clinical & Echo risk score including variables, allocated point score 
per variable and risk category stratification table for the Clinical & Echo model.  
CKD – Chronic kidney disease, RVFAC – Right ventricular fractional area change, SPAP – Systolic 
pulmonary artery pressure. 
Figure 5.6 – Kaplan-Meier curve demonstrating survival versus Clinical & Echo risk score 
category. 
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5.5.5 Model comparison 
The ROC curves of the two models are compared visually in Figure 5.7. 
The two models produced were then compared statistically using NRI analysis.  
28 events moved up category, 9 events moved down category, 7 non-events moved up 
category and 3 non-events moved down category. 
NRI value for the Clinical & Echo model versus Clinical model =0.164 (S.E 0.05, p<0.005). 
This is equivalent to a 16.4% improvement in within-patient performance of the Clinical & 
Echo model compared to the Clinical model. This improvement is statistically significant. 
Figure 5.7 – Visual comparison of the two risk scoring methods using receiver operator characteristic. 
The black diagonal line is the 50% reference. 
 curves 
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5.5.6 Addition of POCT BNP as a variable to both models 
POCT BNP was omitted from both models due to the lack of its availability in many 
hospitals. When the variable ‘BNP ≥ 1000 pg/ml’ was added to both models, statistically 
significant additional discriminatory power was seen. 
Model calibration of the Clinical Model improved from 76.7% to 78.0%, whilst the Clinical 
& Echo model improved from 77.1% to 78.7% and in both cases the regression modelling 
demonstrated that this additional variable added discriminatory value at p<0.05. 
Total Nagelkerke R2 value of the Clinical model rose from 30.8% to 32.1%, while the 
Clinical & Echo model rose from 35.0% to 37.2%.  
In both models the OR of BNP ≥ 1000 pg/ml was approximate to other variables (excepting 
age ≥80) so would be allocated 1 point for a positive result. 
C-statistic of the Clinical model improved from 0.746 (0.695 – 0.798) to 0.769 (0.723 – 
0.815) while the Clinical & Echo model improved from 0.804 (0.758 – 0.849) to 0.817 (0.776 
– 0.859). These are demonstrated using ROC curves in Figures 5.8 and 5.9 below: 
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Figure 5.8 – Visual comparison of the Clinical risk score with and without POCT BNP variable using 
receiver operator characteristic curves. The black diagonal line is the 50% reference. 
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The two models produced were then compared statistically using NRI analysis.  
When adding BNP to the Clinical model, 6 events moved up category, 7 events moved down 
category, 3 non-events moved up category and 2 non-events moved down category. 
NRI value for the addition of BNP to the Clinical model =-0.013, p=0.54. This is equivalent 
to a 1.3% net reduction in within-patient performance of the model. This is not statistically 
significant. 
When adding BNP to the Clinical & Echo model, 6 events moved up category, 5 events 
moved down category, 7 non-events moved up category and 1 non-event moved down 
category. 
Figure 5.9 – Visual comparison of the Clinical & Echo risk score with and without POCT BNP variable 
using receiver operator characteristic curves. The black diagonal line is the 50% reference. 
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NRI value for the addition of BNP to the Clinical model =-0.012, p=0.69. This is equivalent 
to a 1.2% net reduction in within-patient performance of the model. This effect is not 
statistically significant. 
5.6 Discussion 
This study was performed to assess the ability to produce and use a novel risk scoring tool for 
prognostication in AHF. It was intended to assess the ability to use only those variables and 
data available to the clinician within the acute phase of a patient’s hospital admission, and 
whether with these data alone useful predictions can be made about likely mortality outcomes 
at 6 months post discharge. 
The strength of the study lies in the study design and patient cohort, with prospective 
enrolment, systematic data collection and statistical tests focussed on variables already 
demonstrated to show prognostic value, helping to avoid the common pitfalls of overfitting 
and specious associations. It also uses the data from consecutive patients of all ages and 
aetiologies. 
From the data and results presented above, one can see that not only is it feasible to produce 
such a scoring tool, but that the model produced using these variables is Fair to Good in its 
predictive accuracy, or at least Good when including echocardiographic variables in addition 
to demographic, clinical and biochemical data. The C-statistic of the Clinical model is 0.746 
(0.695-0.798), and the C-statistic of the Clinical & Echo model is 0.804 (0.758-0.849). These 
are both consistent with the reported C-statistics of other similarly produced models in both 
AHF and CHF. It is favourable when compared to the C-statistic of other widely adopted 
predictive models such as the CHADS2 and subsequent CHA2DS2 VaSc scores which 
reported a C-statistic of 0.606 (Lip, Gregory YH, Nieuwlaat et al. 2010). Within the field of 
HF, it compares favourably to standards in CHF mortality prediction such as the Seattle risk 
score in which C-statistics variably ranged from 0.682 to 0.810 depending upon population 
(Levy, W. C., Mozaffarian et al. 2006), and compared to other AHF models, C-statistic 
values have been reported from 0.72 to 0.84 (Scrutinio, Ammirati et al. 2013, O'Connor, 
Hasselblad et al. 2010b, Felker, Leimberger et al. 2004, O'connor, Abraham et al. 2008). 
When initially producing the model, the data from 52 cases were omitted due to the 
assumptions necessary to perform logistic regression. This reduces the size of the dataset but 
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is required to correctly produce logistic regression models of outcome. The patients omitted 
from the data were older, were more likely to have known heart failure and had increased 
levels of previous admissions in the past year. HF is known to progress with age and 
progression of disease leads to increased rates of hospital admission, therefore those with 
repeated admissions in the recruitment period are more likely to be older and have had recent 
admissions.  
From the remaining dataset, forward conditional regression modelling selected 7 variables in 
the Clinical model and 9 in the Clinical & Echo model. Both models used a combination of 
demographic, biochemical and observational data, as well as echocardiographic data in the 
Clinical & Echo model.  The selection of variables was not externally controlled as the 
automated regression model inherently selects all of the most statistically significant 
variables which add to the predictive power of the model. The fact that fewer than 10 
variables were selected is very helpful for the clinician, the ultimate beneficiary of such a 
tool. A risk scoring tool is only as good as it is practical, and so producing a risk scoring tool 
with a relatively small number of variables required for its calculation adds to the practical 
utility of the score. This is in marked contrast with some of the other scores previously 
discussed which require access to a computer-based calculator (Levy, W. C., Mozaffarian et 
al. 2006), regression tree diagram (Fonarow, Adams et al. 2005) or complex mathematical 
calculation (Lee, Austin et al. 2003). 
Calibration of both models is good; both tests add to the predictive ability when compared to 
chance, increasing accurate prediction by more than 5% in each case. Given the intended 
purpose of the test to predict risk of mortality, the pre-model sensitivity of 0% is useless thus 
an increase to 38% in the clinical model and 40% in the clinical & echo model demonstrates 
a substantial and imperative improvement.  
In a similar vein, the pre-model calibration plot demonstrated a non-calculable positive 
predictive value which becomes 63.1% and 62.7% respectively while negative predictive 
value increases from 72.4% to 79.5% and 72.1% and 80.0%. 
Prior to use of a model, the guess of the calibration plot, whilst relatively accurate, is useless 
in terms of predicting mortality as it predicts that all patients will not die in 6-months post 
admission.  
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The models both deliver a substantial improvement in sensitivity, positive and negative 
predictive values, with only a small loss of specificity. This demonstrates the purpose of 
producing such a model, allowing a physician to make better predictions regarding the 
outcome of interest, and the statistics presented above demonstrate the utility of both models. 
Hosmer and Lemeshow tests were not statistically significant which suggests a good 
statistical fit. The Hosmer and Lemeshow test must be interpreted with caution as it can be 
over-reassuring in tests using small sample sizes so typically sample sizes of 400 or greater is 
recommended. In this study the sample size is approximately 400 and the probability 
estimates are not close to being significant therefore the risk of type II error is small. 
The variables included within the model are, necessarily, consistent with variables selected 
by other groups due to the manner in which they were selected. The ORs are also illustrative; 
several groups have previously described age as an important predictive factor, and in both 
models it is the variable that accounts for the greatest proportion of variance in mortality. 
Arrhythmias have been described as detrimental in the CHF and AHF population, 
contributing greatly to the mortality burden (Nattel, Maguy et al. 2007, Ehrlich, Nattel et al. 
2002). In both predictive models arrhythmogenic HF is found to be prognostically protective 
when compared to other forms of decompensation. This is unlikely to suggest that 
arrhythmogenic heart failure is benign, but that decompensation by other cause is simply 
even more damaging. It may also reflect a proportion of patients admitted with transient 
arrhythmias as the sole driver of their presentation and minimal structural or vascular 
abnormalities, so that if/when the arrhythmia is appropriately controlled their risk profile is 
substantially reduced. 
When adding echocardiographic variables, the calibration of the model improved as 
demonstrated by improvements in C-statistic and Nagelkerke R2 values. In addition, NRI 
analysis suggested a large, statistically significant improvement of the Clinical & Echo model 
in comparison to the Clinical model when comparing the models within individual patients. 
One surprise omission from the Clinical & Echo model is left ventricular ejection fraction. 
Many other groups have created models which included LVEF as a prognostic indicator in 
their risk scores (Lupón, de Antonio et al. 2013, Xanthopoulos, Giamouzis et al. 2017, Levy, 
W. C., Mozaffarian et al. 2006), but LVEF was not included in the Clinical & Echo model 
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described above. Falling LVEF is widely recognised as a poor marker of prognosis but was 
not found to add significant prognostic value in combination with the variables included in 
the model. This may simply be a function of the logistic regression model, but may reflect the 
fact that in the acute decompensated phase of HF LVEF may be enhanced by volume 
overload and consequent elevation of preload. This may give a falsely high value which does 
not reflect the true severity of systolic dysfunction which in term may not be of additional 
prognostic value in comparison to other clinical, biochemical and echocardiographic features. 
Alternatively, the MRAHF cohort had a relatively high mean and median LVEF. Lower 
LVEF is known to confer poorer prognosis in comparison to higher LVEF throughout the 
entire range but the effect size may be smaller at higher LVEF which could render LVEF less 
statistically relevant than other variables in this cohort. 
In contrast, RVFAC and SPAP were selected when including echocardiographic data. Both 
are correlates of right ventricular function, and, as such, it is not surprising that impaired right 
ventricular function should confer a prognostic disadvantage. It is, perhaps, unexpected that 
in this modelling the effect was larger than that of LVEF and remained statistically 
significant. The reasoning behind this is not entirely clear, but it may be that in the acute 
phase markers of right ventricular function act as more useful prognostic variables. Other 
common echocardiographic parameters were omitted from the model. As with LVEF, this 
does not suggest that parameters such as severity of valvular disease or TAPSE are devoid of 
prognostic use. As discussed above, all of these have been demonstrated to be of use when 
considering prognosis, however regression modelling selects only those variables which add 
the greatest discriminatory power in the derivation cohort. Within this cohort, markers of 
right ventricular function were found to be particularly predictive of prognosis, and perhaps 
require more attention than is currently being afforded. The discovery of medications to 
ameliorate LV morphology and clinical outcome has led to a substantial focus on the LV in 
the previous decades, but there is an increasing focus on parameters of right ventricular 
function and the benefit RV specific therapy which may prove of great importance given the 
ventricular interdependence discussed in the introduction (Harjola, Mebazaa et al. 2016).  
Recategorisation of risk scores for both models was performed to achieve good 
discrimination between patients at low, medium and high risk of mortality at 6-months post 
discharge. In addition, it is easier for clinicians to both remember the information and convey 
it to their patients. The Kaplan-Meier curve for mortality in each risk group demonstrates that 
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actual mortality correlates well with risk group assignment. The 6-month mortality 
differences between risk categories in each model are statistically significant and the Kaplan-
Meier survival curves demonstrate the trend well, showing the large differences in mortality 
between each group. This is useful for the clinician as it demonstrates good discriminatory 
power to the terms Low, Medium and High risk used to further stratify AHF patients.  
BNP level has been demonstrated by many contemporary studies to be a useful guide to 
clinical status, response to therapy and mortality risk and has been included in risk prediction 
models by other groups (Lupón, de Antonio et al. 2013). Due to the fact that point of care 
testing B natriuretic peptide (POCT BNP) levels were measured in this study rather than 
laboratory serum BNP levels, this was omitted from the original models; the majority of 
hospitals will not have access to similar equipment and thus its inclusion is potentially 
counterproductive. Despite this, an assessment of its impact on the predictive models was 
made for intellectual interest. When POCT BNP ≥1000 pg/ml was added as a variable to both 
models it has significantly and substantially increased the discriminatory power of both 
models. Model calibration, the total Nagelkerke R2 value and C-statistic all improved for both 
models, suggesting benefit of its use in such a model but NRI analysis did not suggest a 
significant change to either model when applied in this cohort. POCT BNP levels are known 
to correlate well with formal laboratory values (Shah, Terracciano et al. 2010), and certainly 
may play a role, but there is substantial variation in values derived from different vendors of 
POCT. As a result, absolute values from the POCT BNP device used in this study are 
unlikely to be generalisable to other POCT devices. If POCT BNP devices become more 
widely available and a reduction in variability of BNP results between devices is seen then it 
is likely that their use in prognostic risk scores would be beneficial. Alternatively, the use of 
formal laboratory BNP or NT-pro-BNP levels is likely to be of additional value, in line with 
the improvements to the models seen secondary to the inclusion of POCT BNP.  
NRI analysis should be interpreted with caution. NRI is not a measure of model calibration 
but rather compares the old and new risk values within individual patients (Kerr, Wang et al. 
2014). In the first instance NRI demonstrates substantial and significant improvement from 
the Clinical to the Clinical & Echo model which is in line with the improvement in indices of 
model performance such as C-statistic and Nagelkerke R2 value. When used later to compare 
the effect of adding the POCT BNP variable to both models it shows non-significant net 
worsening of the model despite C-statistic and Nagelkerke R2 both demonstrating 
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improvements. Whilst a useful guide to model comparison, its results should be interpreted in 
context (Kerr, Wang et al. 2014). NRI analysis is also particularly sensitive to an increasing 
number of risk categories and tends to increase in line with this number. Its use in a study 
with only two categories – death or non-death – is less constrained by this but this inherent 
flaw should be noted (Pickering, Endre 2012). 
The results presented above demonstrate the feasibility of producing risk scoring models 
using data available to the clinician during the early stages of hospital admission. Valid risk 
scoring models can be produced using clinical data, and potentially improved by the addition 
of echocardiographic variables where these are available. 
The models produced here are derived from a real-life AHF cohort. Other larger AHF and 
CHF risk prediction models use data acquired from randomised case-control studies with 
selection criteria that inevitably restrict patient involvement. This introduces selection bias, 
whereas the prospective consecutive cohort study design used here is recognised as the best 
model for studying prognosis due to the ability to control and measure predictors and 
outcomes (Han, Song et al. 2016). It also restricts the numbers lost to follow up, and 
particularly reduces the quantity of information missing which is a common problem in larger 
retrospective registry studies.  
Both models also use only those variables that are available to the clinician within hours of 
presentation to hospital, enabling calculation and decision making at an early juncture within 
the patient journey. Use of this information to more accurately risk-stratify patients may have 
important beneficial consequences for patient management, admission, discharge and follow-
up. 
5.6.1 Limitations 
As has been discussed in the general limitations of previous results chapters, this study is 
limited by the nature of its population. Due to the demographic makeup of the local area in 
which the study was conducted, it has an older, predominantly Caucasian population and 
these demographics are not generalizable to either the nationwide or global AHF population. 
Patients of different ages, genders and ethnicities have different outcomes in AHF thus it is 
difficult to generalise these findings to a larger more diverse population without extensive 
external validation in alternate populations with varying demographic makeup. 
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In addition, when comparing sample size to other studies of a similar nature, one can see that 
typical cohort sizes range from 500-5000, so the MRAHF patient cohort is notably smaller 
which may reduce reliability and generalisability of the findings. 
Though POCT BNP has been discussed as a useful additional discriminatory variable in this 
cohort, the gradual increase in the use of angiotensin-receptor neprolysin inhibitors (ARNIs) 
may influence the interpretation of BNP levels, both POCT and formal laboratory values. As 
discussed in the introduction, BNP is degraded by neprolysin, the action of which is directly 
targeted by ARNIs for therapeutic effect. The use of ARNIs leads to a rise in circulating BNP 
levels (McMurray, John JV, Packer et al. 2014, Solomon, Scott D., Zile et al. 2012), thus 
their use as a marker of worsening overload or indeed as part of a prognostic risk score 
appears hampered by this iatrogenic rise. As discussed earlier, further investigation as to the 
utility of NT-pro BNP in this setting may be of greater benefit. 
In terms of the statistical analysis itself, when conducting binary logistic regression there is a 
risk of a statistical error termed overfitting. If the complexity of the statistical model is too 
great for the quantity of data collected, the variables included in the model can represent 
statistical noise rather than statistically significant relationships between the variable and the 
outcome (Peduzzi, Concato et al. 1996). Typically, a rule of 10 or 15 is applied to logistic 
regression analyses in which 10 or 15 events must occur per variable included in the model. 
After the exclusions required for logistic regression, 109 patients had died at 6 months, with 
283 alive. In this case 109 events had occurred so using the rule of 10, 10 variables could be 
included into the model without risking overfitting but in this case up to 33 variables were 
included in the Clinical & Echo model. The risk of overfitting the data can be mollified by 
selection of variables with a known link to the outcome and this study has aimed to reduce 
the risk of statistical overfitting by selecting only those clinical and echocardiographic 
variables with evidence of prognostic value provided by previous studies. Nevertheless, it is 
still possible that, though the results are interesting, due to the relatively small sample size 
these results may not replicate well with a larger dataset. This adds weight to the need for 
these results to be assessed in a larger cohort. 
Including variables in linear regression models that are correlated, such as creatinine and 
history of CKD, may lead to multicollinearity. This can reduce clarity regarding the precise 
role of each individual variable. In risk prediction modelling, however, this is not necessarily 
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a negative consequence as the model is not concerned with the exact role of each variable, 
but rather which markers can accurately predict the desired outcome. Neither model selected 
clinically correlated variables, but their co-selection in future models should be accompanied 
by consideration of the purpose of the model. 
5.6.2 Further Work 
Due to the relatively small sample size, demographic homogeneity and concern regarding 
overfitting, these models would benefit from external validation using a large external cohort 
with a heterogeneous population.  
Widely adopted risk stratification models such as the CURB-65 and CHA2DS2-VaSc were 
validated using large heterogeneous populations acquired by performing large multi-centre 
prospective cohort studies (Lim, W. S., van der Eerden et al. 2003, Lip, Gregory YH, 
Nieuwlaat et al. 2010). Designing a follow-up large multi-centre study to validate the above 
findings would help reduce concerns regarding the validity of the results acquired above 
when applied to larger more heterogeneous populations. 
An alternative option would be to perform a similar study in which the patient population as 
divided into a derivation cohort and a validation cohort, allowing for internal validation as 
has been performed by other groups (Xanthopoulos, Giamouzis et al. 2017). This allows for 
validation of the model and methods but is perhaps of less use when attempting to 
demonstrate further generalisability of the model to general AHF cohorts with different 
demographic constituents. Studies have demonstrated that the effect of individual risk factors 
on AHF can vary widely across discrete geographical patient populations and therefore large, 
multi-regional validation is often of greater benefit (Wessler, Ruthazer et al. 2017). 
In addition, data regarding cardiac biomarkers such as BNP, NT pro-BNP and ST2 could be 
usefully included in a risk prediction model. Further studies could collect formal laboratory 
biomarker values in addition to the use of POCT BNP values as a rapid screening tool, in 
order to assess the utility of formal laboratory values in a risk stratification model. 
Further work is required to produce similar risk stratifying scores in terms of cardiovascular 
mortality rather than simple all-cause mortality as has been described in this study. All-cause 
mortality is perhaps the most pertinent outcome for the patient, but it would further the 
understanding of the disease and perhaps improve clinical practice if the specific factors that 
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are predictive of cardiovascular mortality in AHF patients could be identified. There are 
inherent difficulties in this task. Cause-of-death in this study has been categorised according 
to data retrieved from death certificates. Death certificates are produced largely without 
access to post-mortem information, and therefore the primary aetiology is often based on 
clinical judgement alone. This is perhaps the best marker available, aside from universal post-
mortems, but is inherently flawed by the fact that often it is based on insufficient or 
incomplete evidence. 
There still remains a dearth of information regarding prediction of readmission which is of 
great importance for both the patient and healthcare provider. For the individual, each 
hospital admission causes incredible upheaval in their life, destabilising personal and family 
life with consequent physical and mental health burdens (Vaccarino, Kasl et al. 2001). For 
the healthcare provider, each hospital admission for AHF is known to worsen prognosis and 
incur substantial additional costs (National Institute for Health and Care Excellence 2014b, 
Gheorghiade, Vaduganathan et al. 2013). If these risks are better predicted, and thus 
mollified, it is likely to serve in the best interests of both parties. 
5.7 Chapter summary 
This chapter has reviewed the existing literature on the subject of risk prediction scores in 
both CHF and AHF. It has then described the methods and materials used to produce two risk 
stratification scores, both in terms of data collection and statistical analyses.  
These scoring systems have then been described and analysed for their predictive value, both 
individually and then compared. 
These predictive tools demonstrate the feasibility of risk stratifying AHF patients using 
information routinely acquired both immediately upon admission and with the addition of 
echocardiographic data, to produce informative risk stratification tools. In addition, both tools 
require <10 variables and risk scores are easily calculated, improving their practicality 
compared to many existing models which are limited by the quantity of variables and/or 
calculations required to accurately predict risk. 
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Chapter 6: Summary and Conclusions 
6.1 Chapter introduction 
This chapter will summarise the important literature regarding heart failure (HF) as discussed 
in the introduction and then restate the hypotheses set within this thesis, with a summary of 
the methods and strategies used to investigate these hypotheses. 
It will then summarise the results of each subsequent chapter, discuss the novel observations 
derived from the results, possible interpretations of these observations and the broader 
implications of these with reference to the practical consequences and suggestions for further 
work. 
6.2 Literature 
Since its recognition as a medical syndrome, HF has been of great interest to the medical 
community due to the large burden of morbidity and mortality, as well as a gradual but 
persistent increase in prevalence. Despite this, until the 1980s very few treatments existed 
with proven efficacy to ameliorate prognosis. Since this time, progress in treating HF patients 
has been mixed, even with the advent of sympathetic nervous system antagonists such as beta 
blockers (Packer, M., Fowler et al. 2002), and inhibitors of the renin-angiotensin-aldosterone 
system such as angiotensin converting enzyme inhibitors (SOLVD Investigators* 1991) and 
mineralocorticoid receptor antagonists (Pitt, Zannad et al. 1999). These medications have 
proven efficacious in patients with HF with reduced ejection fraction (HFrEF) but are of 
unproven value in patients outside of this subcategory who account for up to 50% of all HF 
patients (Bavishi, Chatterjee et al. 2015).  
Due to concerns that the two classic subcategories of HFrEF and HF with preserved ejection 
fraction (HFpEF) were too broad and arbitrary, a third, intermediate subcategory of HF with 
mid-range ejection fraction (HFmrEF) was introduced to stimulate research into phenotypic 
and pathological differences between patients with intermediate left ventricular ejection 
fractions (LVEF), defined as 40-49% (Ponikowski, P., Voors et al. 2016). 
Subsequent to guidelines recognising this additional subcategory, evidence has emerged that 
HFmrEF acts as an intermediate category in many respects, certainly in terms of demographic 
profile, haemodynamic status and comorbidity burden (Tsuji, Sakata et al. 2017). Perhaps due 
to the difficulty in obtaining sufficient data suitable for analysis, data regarding potential 
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differences in myocardial deformation parameters between these three subcategories have not 
been published in any depth. Myocardial deformation imaging is an emerging component 
within echocardiography which is able to detect subtler systolic dysfunction and may offer an 
easily accessible preload-independent marker of systolic function. This could be useful in 
more accurately delineating between subcategories and may have broader implications for 
identification of systolic dysfunction and therapeutic intervention. 
Aside from looking at gaps in the evidence regarding novel subcategorisations, prediction of 
mortality risk in acute HF(AHF) remains hindered by issues of complexity and calculation. 
Risk stratification is important in medicine as it allows us to effectively concentrate 
therapeutic effort on those most in need, and those most likely to benefit. Widely used, well-
validated scoring systems exist for risk stratification of patients presenting acutely with many 
medical conditions; CURB 65 is used in patients presenting acutely with community acquired 
pneumonia and the Blatchford score is used in upper gastrointestinal bleeds to name but two 
of the most commonly used (Blatchford, Murray et al. 2000, Lim, W. S., van der Eerden et al. 
2003). Many risk scores exist for the prediction of risk in chronic heart failure (CHF), and 
online tools are available which can use a combination of demographic, clinical, biochemical 
and echocardiographic data to provide useful prognostic information (Lupón, de Antonio et al. 
2013, Levy, W. C., Mozaffarian et al. 2006). There is a lack of simple, easily applicable tools in 
AHF to effectively risk-stratify patients upon admission to hospital which is a critical period 
in the patient journey. Of the tools that do currently exist in the context of AHF, some are 
complicated to use (Okazaki, Shirakabe et al. 2014, O'connor, Abraham et al. 2008) while 
others require information not readily available to the acute physician (Salah, Kok et al. 2014, 
O'Connor, Hasselblad et al. 2010) and thus they become either too cumbersome or infeasible 
to use at the point of admission. 
6.3 Hypotheses 
The main hypotheses of this thesis were stated in relation to two key areas, myocardial 
deformation parameters in HF subcategories and prognostication in AHF. 
These were stated thus: 
Firstly, left ventricular strain and strain rate values will vary according to HF subcategory, as 
defined by LVEF, in a statistically significant fashion. 
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Secondly, using only data available to the clinician in the acute phase of admission, a simple, 
valid risk stratification tool can be produced to predict risk of 6-month mortality in patients 
admitted with AHF. 
6.4 Strategy 
The data required for the above tasks were acquired as part of the mitral regurgitation in acute 
heart failure (MRAHF) study. The MRAHF study is a prospective cohort study of 
consecutive AHF patients admitted to a single district general hospital. 
It was designed to recruit all patients admitted to the study site with AHF and assess the 
burden of mitral regurgitation (MR) in this population, with a specific focus on the financial, 
morbidity and mortality burden of the disease, as well as tracking the journey of patients with 
AHF and MR to tertiary centres for mitral valve intervention.  
Patients were approached for recruitment into the study if they had: 
1) Clinical signs and symptoms consistent with AHF as the primary cause for admission 
2) Been an inpatient for <7 days by the time of recruitment to the study 
3) The ability to give informed consent 
After consenting for phlebotomy and echocardiography, patients were subsequently excluded 
from the study if they had: 
1) Point-of-care test (POCT) B natriuretic peptide (BNP) level <100 pg/ml 
2) Echocardiography inconsistent with a diagnosis of HF 
The target for patient recruitment was 500, selected as the likely burden of AHF patients in 
the hospital in a year. Patients were recruited from July 2016 until September 2017.  
616 patients were screened from the hospital admissions of which 500 patients were recruited 
to the study. 53 patients were subsequently excluded due to B natriuretic peptide (BNP) level 
or echocardiography not diagnostic of heart failure. The final patient cohort numbered 447. 
Baseline demographic, clinical, biochemical and radiographical data were collected at the 
time of recruitment and echocardiography was performed within 48 hours. 
Offline analysis of echocardiographic data was subsequently performed including cardiac 
geometry, function and, latterly, myocardial deformation parameters. 
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Patients outcomes were monitored in terms of readmission or mortality at 6 months post 
discharge, and cause of both admission and mortality were recorded within the dataset.  
The data from all patients recruited into the MRAHF study were used for the production of 
this thesis.   
6.5 Chapter Three – Baseline characteristics and comparison of 
the MRAHF & EHS II cohorts 
The baseline characteristics of the MRAHF cohort were first stratified according to LVEF 
subcategory. These subcategories were compared to assess for consistency or discrepancy 
with the growing literature on characteristic differences between HFrEF, the novel category 
of HFmrEF and HFpEF. 
Patients categorised as HFrEF were more likely to be male, more likely to have a history of 
ischaemic heart disease and had significantly higher BNP levels upon admission. Left 
ventricular (LV) volumes were larger in these patients and QRS duration was also increased 
compared to the other subcategories. 
Patients categorised as HFpEF were more likely to be female, had a significantly higher BMI 
than patients with HFrEF and BNP values were significantly lower. LV volumes were lowest 
in this group. 
Patients categorised as HFmrEF had intermediate values in terms of gender breakdown, BNP 
values, ECG rate and QRS duration.  Left ventricular volumes were intermediate between 
HFrEF and HFpEF, as were systolic pulmonary artery pressures. History of ischaemic heart 
disease (IHD) was statistically similar to that of the HFpEF patients, not HFrEF. 
These results are in keeping with much of the current research regarding the characteristics of 
HFmrEF patients. In most parameters measured, HFmrEF acts as an intermediate category 
(Tsuji, Sakata et al. 2017). The only substantial difference to reported literature was the 
statistical similarity of HFmrEF to HFpEF in terms of the prevalence of IHD as a 
comorbidity. Patients with HFmrEF are commonly described as having a similar IHD burden 
to patients with HFrEF (Tsuji, Sakata et al. 2017), but this is not the case in the cohort of 
patients recruited for the MRAHF study.  
 168 
 
The MRAHF study was subsequently compared to the EuroHeart survey II (EHS II), a large 
multi-centre prospective registry study of AHF patients conducted in Europe. 
Compared to the EHS II cohort, the MRAHF cohort was older, had a higher proportion of 
female patients, had a lower rate of hospitalisation in the previous 12 months and a lesser 
comorbidity burden. Community prescription of prognostic medications was more common 
in the EHS II cohort with the exception of beta blocker usage, likely related to the higher 
burden of atrial fibrillation seen in the MRAHF cohort. LVEF was statistically higher in the 
MRAHF group and LV volumes were comparably higher. Despite the demographic 
differences, in-patient mortality burden was similar between the two groups. 
The MRAHF and EHS II cohorts are notably different in many respects. This may be due to 
the larger geographic area from which their patients were recruited, but also likely due to the 
less stringent selection criteria used in EHS II and lack of formal exclusion criteria. As a 
result, they are likely to have included many patients in whom a HF was either a concomitant 
diagnosis or a diagnosis of dubious accuracy. Drawing conclusions as to the generalisability 
of findings derived from the MRAHF cohort is rendered somewhat difficult by these facts 
but, given the selection criteria of the MRAHF study and consecutive cohort study design, it 
is likely that the MRAHF cohort represents the typical AHF cohort in the local area.  
The purpose of this comparison is to establish the baseline characteristics of the MRAHF 
cohort, aid assessment of the generalisability of the results and to demonstrate the benefits of 
the study design in comparison to previous projects. The differences shown between the two 
cohorts may in part be due to the recruitment criteria of the EHS II, but also serve as a 
reminder that results derived from a single population in a single geographical location 
require validation from larger datasets. Ideally, external validation would occur using patients 
from a variety of geographical areas and demographic backgrounds to ensure generalisability 
of the conclusions drawn. 
6.6 Chapter Four – Myocardial deformation parameters in heart 
failure subcategories 
In this chapter, an assessment was made of differences in myocardial deformation 
parameters, stratifying the MRAHF cohort by LVEF subcategory. 
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Both longitudinal strain and longitudinal strain rate values were found to be highest (most 
negative) in the HFpEF group and lowest (least negative) in the HFrEF group. Patients in the 
HFmrEF group represented an intermediate category. These findings were statistically 
significant, both in analysis of individual myocardial segments, and when considering the 
averaged values, global longitudinal strain (GLS) and global longitudinal strain rate (GLSR). 
There were large differences seen when comparing the medians of each subcategory, all of 
which were statistically significant. In both strain and strain rate analyses, the deformation 
values of HFpEF were approximately double those in HFrEF. 
In a separate analysis, LVEF was found to be lower in patients recruited ≥2 days after 
admission while GLS and GLSR were statistically comparable in patients recruited both < 
and ≥2 days after admission. Patients recruited ≥2 days after admission were comparable in 
terms of demographic data, comorbidity burden, admission biochemistry and readmission 
rates, but did have a slightly higher mortality rate. 
This study first demonstrates the feasibility of echocardiographic myocardial deformation 
imaging in the acute clinical setting, with clinically and statistically relevant data collected in 
this cohort. 
The results from this cohort summarised above indicate that the difference in median strain 
and strain rate values between HF subcategories is found to be large and statistically 
significant. Myocardial deformation parameters in HFmrEF represent an intermediate 
phenotype, with intermediate levels of contractile function as shown by the strain and strain 
rate values.  
In addition, in those patients recruited ≥2 days since admission, LVEF was substantially and 
significantly lower than those recruited <2 days subsequent to admission. This is in contrast 
to their myocardial deformation values which remained statistically similar across both 
groups. This is unlikely to be a function of an intrinsic phenotypical or pathological 
difference between the groups as they are otherwise statistically comparable in terms of 
demographic characteristics, comorbidity burden, biochemical parameters and readmission 
rate. It is more probable that this finding further demonstrates the relative load-independence 
of myocardial deformation parameters in AHF patients. 
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Strain and strain rate values appear to offer useful information to help delineate and 
subcategorise patients. Given the significant variance in LVEF values seen between 
ultrasonographers, machine types and software, additional information on alternate markers 
contractile function with less inter-user and inter-machine variance may benefit the accurate 
subcategorisation of patients with AHF. This is important as their allocation to a HF 
subcategory can significantly alter their management in terms of pharmacotherapy or device-
based therapies. In this study, inter-observer variability was effectively eliminated as >95% 
of echocardiograms and all basic offline analysis was performed by the same highly 
experienced ultrasonographer. As such, subcategorisation of patients by LVEF value is as 
consistent as possible using standard echocardiographic techniques. 
Deformation parameters are also known to be relatively load-independent (Ferferieva, Van 
den Bergh et al. 2011). Other measures of intrinsic cardiac contractility such as pressure-
volume loops can be impractical to perform, such as pressure-volume loops. As such, 
information from myocardial deformation parameters, particularly GLSR, may offer the 
clinician the ability to better make inferences about intrinsic contractile function of the AHF 
patient’s myocardium. 
The data presented in chapter four indicate that GLS and GLSR values may vary less than 
LVEF in the acute phase. LVEF is known to be preload dependent (Gaasch, Meyer 2008, 
Silke, Verma et al. 1985) and thus will fall in response to therapeutic offloading of the heart 
with diuretics. It is possible that this accounts for the statistical reduction in LVEF values 
seen in patients recruited ≥2 days after admission. In contrast to median LVEF values, 
median GLS and GLSR values remained statistically similar. 
6.6.1 Further Work 
Having already discussed the disadvantages of a single-centre study and the concerns 
regarding generalisability, the results regarding significant variation in deformation 
parameters between HF subcategories would benefit from repetition in alternate sites with 
different patient demographics. Nevertheless, it would seem likely that myocardial 
deformation parameters in HFmrEF are intermediate to HFrEF and HFpEF as this is in 
keeping with current literature and understanding of the biomechanics of HF. 
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A follow up study to ascertain the veracity of the finding regarding variance of LVEF, GLS 
and GLSR values after admission would also be beneficial. Determining whether LVEF is in 
fact a reliably stable marker in the setting of AHF is of great importance given the degree 
upon which it is relied. If deformation parameters offer a more stable indication of systolic 
function in the acute phase, this could greatly add to current practice and patient assessment. 
This could feasibly be assessed by performing a similar study in which AHF patients undergo 
echocardiography at admission and 2 days hence to assess whether the factor likely 
contributing to the apparent change in parameter is in fact time and diuresis.  
The study and use of myocardial deformation parameters have grown hugely in the preceding 
two decades and the enthusiasm with which they are being trialled and implemented in a 
wide range of conditions affecting cardiac function appears unabated. Currently the 
widespread use of deformation imaging for clinical decision making appears relatively 
constrained by a lack of consensus over normal values, particularly between vendors and 
software manufacturers. Nevertheless, this state of affairs appears to be improving, and the 
use of deformation parameters appears destined for greater use in the future (Yang, Marwick 
et al. 2015). This may enable more accurate assessment of contractile function which could 
ultimately revolutionise the way that HF is discussed and subcategorised. 
6.7 Chapter Five – Prediction of 6-month mortality risk in acute 
heart failure 
This chapter describes the production and assessment of a risk score for predicting mortality 
in AHF patients at 6 months post discharge. 
From the 316 variables collected in the MRAHF study, 33 variables were selected for testing 
within a risk prediction model. Variables were considered for inclusion if they were available 
to the clinician within 48 hours of admission and there was literature which indicated their 
utility as variables predictive of mortality in AHF. Seven of these variables were derived 
from echocardiography. Two models were produced, the first (Clinical model) using 
demographic, clinical, biochemical and common investigations only, and the other (Clinical 
& Echo model) also including echocardiographic data. 
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The Clinical and Clinical & Echo models used 7 and 9 variables respectively to predict 6-
month mortality outcomes and were able to predict mortality with accuracy of 76.7% and 
77.1%. 
C-statistic for the models were 0.746 and 0.804, so the models would standardly be assessed 
as ‘Fair’ and ‘Good’ respectively. This compares favourably with other widely-used medical 
prediction models such as CURB-65, and in the context of HF compares favourably with the 
commonly-used Seattle risk score. 
Scores derived from both models were stratified into tertiles to simplify the process for the 
clinician, and these allocated risk groups delineated well between patients at low, medium 
and high risk of mortality in both cases. 
The inclusion of echocardiographic variables appeared to add diagnostic accuracy to the 
models but this difference did not appear statistically significant. 
This study has demonstrated the feasibility of producing a risk score for prediction of 6-
month mortality in AHF using only those variables available to the acute physician. Both risk 
scores produced are of comparably high predictive accuracy and use a relatively limited 
number of variables. Producing two separate scores using similar variables allows for risk 
prediction either in the absence or presence of echocardiographic information. 
These risk scores use a small number of variables enabling both scores to be easily 
remembered and used by clinicians in the acute period of hospital admission. This could aid 
the process of patient risk stratification in the acute phase, and guide decisions regarding 
admission, escalation and intensity of community or outpatient follow-up. 
6.7.1 Further Work 
Evidently this study and the proposed models require external validation. Multi-centre data 
collection from prospective AHF cohorts would be ideal for external validation and would 
allow for confident conclusions to be made about the generalisability of the risk score to the 
general AHF population. 
Further information could be acquired from this trial regarding need for escalated medical 
care and involvement of intensive care unit support. This additional data would help to 
 173 
 
support decision making regarding escalation of individual care, as has been successfully 
implemented with the CURB-65 scoring model. 
In summary, the risk stratification models produced offer novel, easily usable risk 
stratification tools for the acute physician in the early stages of patient admission. They 
appear to work well in the derivation population but for more widespread use they require 
validation with an external cohort. This will either confirm or refute the feasibility of usage 
outside of the derivation population.  
6.8 Thesis summary 
The work described in this thesis contributes new evidence to the field of AHF. Specifically, 
this thesis has demonstrated the feasibility, utility and potential future applications of 
myocardial deformation imaging, and established the potential for novel risk scoring methods 
to enhance early risk stratification of patients with AHF. 
Amelioration of the mortality and morbidity burden is required in HF, which is rapidly 
becoming a global epidemic as populations live longer in the presence of multiple cardiac 
risk factors. Improving the accurate assessment of AHF patients, both in terms of their 
systolic function and prognostic risk, will enable us to better identify patients requiring 
therapeutic intervention and improve patient outcomes.  
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Appendices 
 
Appendix 1.1 POCT BNP Assay and Instrument Calibration Data 
 
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION 
DECISION SUMMARY 
ASSAY AND INSTRUMENT COMBINATION TEMPLATE 
 
A. 510(k) Number: 
k053597 
 
B. Purpose for Submission: 
New device 
 
C. Measurand: 
B-type natriuretic peptide 
 
D. Type of Test: 
Quantitative 
 
E. Applicant: 
i-STAT Corporation 
 
F. Proprietary and Established Names: 
i-STAT BNP test 
i-STAT Control Level 1 
i-STAT Control Level 2 
i-STAT Control Level 3 
i-STAT BNP Calibration Verification Control Set 
 
G. Regulatory Information: 
1. Regulation section: 
862.1117, B-type natriuretic peptide test system 
862.1660, Single (specified) analyte controls (assayed and unassayed) 
2. Classification: 
Class II, Class I 
3. Product code: 
NBC, JJX 
4. Panel: 
75 Chemistry 
 
H. Intended Use: 
1. Intended use(s): 
The i-STAT BNP test is an in vitro diagnostic test for the quantitative measurement of Btype 
natriuretic peptide (BNP) in whole blood or plasma samples using EDTA as the 
anticoagulant. BNP measurements can be used as an aid in the diagnosis and assessment 
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of severity of congestive heart failure. 
The i-STAT Controls are assayed liquid plasma used to verify the integrity of newly 
received i-STAT BNP cartridges. 
The i-STAT BNP Calibration Verification Controls are assayed liquid plasma used to 
verify the calibration of i-STAT BNP cartridges throughout the reportable range. 
2. Indication(s) for use: 
See Intended use(s) above. 
3. Special conditions for use statement(s): 
Prescription use only 
4. Special instrument requirements: 
i-STAT 1 Analyzer 
 
I. Device Description: 
Each i-STAT BNP cartridge provides a sample inlet, sensors to detect the BNP, and all the 
necessary reagents needed to perform the test. The cartridge contains a buffer and 
preservatives. A list of reactive ingredients is indicated below: 
 
 
 
The i-STAT BNP Controls are supplied as assayed frozen liquid plasma at 3 levels, 
Control Level 1, Control Level 2 and Control Level 3. The human sera used in the 
preparation of this product has been tested by FDA approved test methods and found 
negative/non-reactive for HIV-1, HIV-2, HBsAg, HCV, HTLV-1 and HTLV-2. 
 
The i-STAT Verification Control Set is supplied as 3 levels of assayed frozen liquid 
plasma at 3 levels, Level 1, Level 2 and Level 3. The human sera used in the preparation 
of this product has been tested by FDA approved test methods and found 
negative/nonreactive 
for HIV-1, HIV-2, HBsAg, HCV, HTLV-1 and HTLV-2. 
 
J. Substantial Equivalence Information: 
1. Predicate device name(s): 
Biosite Triage BNP Test 
2. Predicate 510(k) number(s): 
k021317 
3. Comparison with predicate: 
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K. Standard/Guidance Document Referenced (if applicable): 
CLSI Guideline EP7-A; CLSI Guideline EP9-A2; CLSI Guideline C-28-A2 
 
L. Test Principle: 
The i-STAT BNP test cartridge uses a two-site enzyme-linked immunosorbant assay 
(ELISA) method. Antibodies specific for BNP are located on an electrochemical sensor 
fabricated on a silicon chip. Also deposited in another location on the sensor silicon chip is 
an antibody/alkaline phosphatase enzyme conjugate specific to a separate portion of the BNP 
molecule. The whole blood or plasma sample is brought into contact with the sensors 
allowing the enzyme conjugate to dissolve into the sample. The BNP within the sample 
becomes labeled with alkaline phosphatase and is captured onto the surface of the 
electrochemical sensor during an incubation period of approximately seven minutes. The 
sample is washed off the sensors, as well as excess enzyme conjugate. Within the wash fluid 
is a substrate for the alkaline phosphatase enzyme. The enzyme bound to the 
antibody/antigen/antibody sandwich cleaves the substrate releasing an electrochemically 
detectable product. The electrochemical (amperometric) sensor measures this enzyme 
product which is proportional to the concentration of BNP within the sample. 
 
M. Performance Characteristics (if/when applicable): 
1. Analytical performance: 
a. Precision/Reproducibility: 
Precision data were collected as follows: duplicates of each control were tested daily 
for a period of 20 days for each of 3 lots of cartridges, resulting in a total of 434 
replicates. The average statistics are presented below. 
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Whole blood imprecision data were collected as follows: whole blood samples from 5 
healthy donors were spiked to low, intermediate and high BNP concentrations 
affording 15 samples, each of which was measured in 10 i-STAT BNP cartridges 
from a single cartridge lot; three lots of cartridges were employed. The mean withinsample 
BNP concentration ranged from 84 – 3925 pg/mL and the within-sample 
imprecision (%CV) ranged from 3.4 to 9.4%; the average BNP concentration and 
imprecision were 1464 pg/mL and 6.5% respectively. The individual results are 
presented in the table below: 
 
 
 
 
b. Linearity/assay reportable range: 
The dilution linearity of the i-STAT BNP test was studied using EDTA whole blood 
and plasma samples derived from 3 separate donors. For each donor, the original 
BNP negative sample and a BNP spiked sample were prepared. This process yielded 
three BNP positive whole blood samples that were then assayed in duplicate for each 
of 3 separate i-STAT BNP cartridge lots. These whole blood samples were then 
diluted using an equal mass of the original unspiked whole blood and assayed in 
duplicate. From this whole blood data, the BNP recovery was calculated. 
 
 
 
The plasma derived from these three donors was combined in all pair-wise 
combinations in equal volumes. These combinations were then assayed in duplicate 
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for each of 3 separate i-STAT BNP cartridge lots. The BNP recovery for each pair 
was calculated using the average of the 6 results. 
 
 
 
A plasma sample was spiked with BNP to a value of approximately 5000 pg/mL. This 
sample was subjected to a series of dilutions with fresh, un-spiked plasma in order to 
prepare a range of concentrations. The concentration of each sample/dilution was 
calculated based on the measured concentration of the initial solution and the 
dilutions performed. The diluted samples were then measured in i-STAT BNP test 
cartridges (N = 6-10). The procedure was repeated with a whole blood sample. The 
results of these experiments are summarized in the following table: 
 
 
c. Traceability, Stability, Expected values (controls, calibrators, or methods): 
The i-STAT BNP calibrators are traceable to an internal reference standard that has 
been prepared gravimetrically with synthetic BNP. The internal reference standard 
underwent a one-time value assignment to align with the ARCHITECT BNP assay 
with a decision threshold of 100 pg/mL. Manufacturers working calibrators are 
prepared by gravimetric manipulation of the standard and incorporate a one-time 
value assignment for alignment of methods. The i–STAT, AxSYM and ARCHITECT 
assays have been designed, by virtue of their calibration, to report comparable values. 
The i-STAT vs. ARCHITECT method comparison data exhibits a correlation slope of 
0.97 (see method comparison section). Similar data for the ARCHITECT vs. 
AxSYM exhibited a slope of 1.03. 
 
Stability studies were performed to evaluate the intended storage (open and closed 
vial) for the i-STAT controls and calibration verification materials. The real-time 
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frozen stability of BNP control/calibration verification materials was established for 3 
lots of material, each comprised of 3 levels. Stability was judged to be acceptable 
provided that the mean BNP concentration measured at each test event be within ± 20 
% of the original mean concentration. The stability was acceptable over 5 months 
frozen storage. The stability studies are ongoing. 
 
The labeling for the i-STAT controls and calibration verification materials states that, 
after thawing, the opened or unopened vial is stable for 4 hours when capped and 
stored at 2 – 8 º. Stability studies performed support the 4 hour time limit. 
 
d. Detection limit: 
The limit of the blank for the BNP method is 15 pg/mL, which is the lowest BNP 
level that can be distinguished from zero. The value was estimated using a control 
material with < 5 pg/mL BNP during a 20 day precision study in which 3 separate 
lots of BNP test cartridges were tested in duplicate using a pool of 6 i-STAT 1 
analyzers for a total of 147 test results. 
 
e. Analytical specificity: 
The following muscle proteins were tested at both 1000 pg/mL and 20,000 pg/mL 
concentrations and found to have no detectable cross-reactivity for BNP: ANP, CNP, 
and N-terminal pro-BNP. 
 
The i-STAT BNP assay employs electrochemical rather than optical detection. An 
electrogenic substrate is cleaved by an enzyme label giving rise to an electroactive 
product that can be oxidized at a sensor electrode generating a signal comprised of 
electrical current, therefore optical interferents, including hemoglobin, bilirubin, and 
chylomicrons, do not interfere with this mode of detection. 
 
The following substances were found to have no significant effect (less than 10%) on 
the BNP method, when added to a plasma pool containing approximately 1000 pg/mL 
of B-type natriuretic peptide at the concentrations indicated: 
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f. Assay cut-off: 
BNP results less than or equal to 100 pg/mL are representative of normal values in 
patients without CHF. See Clinical cut-off section below. 
 
2. Comparison studies: 
 
a. Method comparison with predicate device: 
Method comparison data were collected using CLSI guideline EP9-A2. Venous blood 
samples were collected in EDTA evacuated tubes and analyzed in duplicate on the i- 
STAT System. A portion of the specimen was centrifuged and the separated plasma 
was analyzed in duplicate on the i-STAT 1 System and on the comparative method, 
the Abbott ARCHITECT BNP assay, within 1 hour of collection. Deming regression 
analysis was performed on the first replicate of each sample. In the method 
comparison table, n is the number of specimens in the first data set, Sxx and Syy refer 
to estimates of imprecision based on the duplicates of the comparative and the i- 
STAT methods respectively. Sy.x is the standard error of the estimate, and r is the 
correlation coefficient. The samples had BNP values ranging from 5-5000 mg/dL. 
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b. Matrix comparison: 
EDTA plasma is the only sample type indicated. The labeling states that performance 
characteristics have not been established for samples taken from capillary tubes and 
direct skin punctures (e.g. fingersticks) so these sample types should not be used with 
the BNP cartridge. 
 
3. Clinical studies: 
 
Clinical studies performed with the Abbott AxSYM BNP assay are included in the 
labeling for the i-STAT BNP assay. The applicant provided the following to support the 
transfer of reference ranges: 
 
• The AxSYM, ARCHITECT and i-STAT BNP assays employ an identical 
antibody set. The average imprecision is similar for the 3 assays as follows: 
AxSYM average %CV = 7.9 %; ARCHITECT average %CV = 5.2 %; i-STAT 
average %CV = 9.7 %. 
• The i–STAT, AxSYM and ARCHITECT assays have been designed, by virtue of 
their calibration, to report comparable values. 
• The CLSI document C28-A2, How to Define and Determine Reference Intervals 
in the Clinical Laboratory, provides guidance concerning the transferability of 
reference ranges from one measurement system to another. The i-STAT vs. 
ARCHITECT method comparison data exhibits a correlation slope of 0.97 (see 
method comparison section above). Also, similar data for the ARCHITECT vs. 
AxSYM exhibited a slope of 1.03 (see k060964). 
 
a. Clinical Sensitivity: 
In studies performed with the AxSYM BNP Assay, age-matched analysis of the heart 
failure and non-heart failure populations was performed based on the data published 
by the American Heart Association in the 2000 Heart and Stroke Statistical Update 
and according to the age structure of the United States population. The age 
distributions in the intended use population are approximately as follows: individuals 
less than 45 years old comprise 9%, individuals 45-54 years old comprise 11%, 
individuals 55-64 years old comprise 22%, individuals 65-74 years old comprise 
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26%, and individuals 75 years and older comprise 32%. The resulting combined AUC 
is 0.87 (0.85 to 0.90, 95%CI). The clinical sensitivity and specificity using a decision 
threshold of 100 pg/mL is presented in the table below. 
 
 
 
b. Clinical specificity: 
See Clinical Sensitivity section above. 
 
c. Other clinical supportive data (when a. and b. are not applicable): 
 
4. Clinical cut-off: 
Data from the clinical studies performed with the AxSYM BNP assay were used to 
generate The Receiver Operating Characteristic (ROC) curve of BNP decision thresholds 
versus clinical sensitivity and clinical specificity. At a decision threshold of 100 pg/mL, 
the BNP assay demonstrated a clinical sensitivity and specificity of 74.2% and 91.5% 
respectively. The area under the curve is 0.90 (0.86 to 0.92, 95% CI). 
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5. Expected values/Reference range: 
Plasma samples from 890 individuals (465 females, 425 males) who had not been 
diagnosed with heart failure were tested with the AxSYM BNP assay. This population 
included non-hospitalized patients with renal disease (not on dialysis), diabetes, 
hypertension and chronic obstructive pulmonary disease. BNP levels for these patients 
were not statistically different from the population of apparently healthy individuals. The 
data are summarized below. 
 
 
 
 215 
 
 
 
Plasma samples from 693 patients with diagnosed heart failure (231 females, 462 males) 
were tested with the AxSYM BNP assay. All patients in this population were categorized 
according to the functional classification system published by the New York Heart 
Association (NYHA). This system divides heart failure patients into one of four 
categories of increasing disease progression (classes I to IV) based upon a subjective 
assessment of the patient’s clinical signs and symptoms. The data from this study are 
summarized below. 
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N. Instrument Name: 
i-STAT 1 Analyzer 
 
O. System Descriptions: 
1. Modes of Operation: 
 
Single use cartridge 
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2. Software: 
FDA has reviewed applicant’s Hazard Analysis and software development processes for 
this line of product types: 
Yes ___X_____ or No ________ 
 
3. Specimen Identification: 
Bar code reader is incorporated into the system 
 
4. Specimen Sampling and Handling: 
Whole blood samples are applied directly into the sample well of the cartridge 
 
5. Calibration: 
Factory set 
 
6. Quality Control: 
The reliability of the results is maintained through a combination of user testing and 
instrument self-checks. The self checks occur with every cartridge run and verify 
performance of the analyzer and cartridge sub-systems. This includes checks on the 
individual sensor’s performance, the integrity of the calibrant fluid, the response of the 
pressure and thermal transducers, and the flow of calibrant and sample within the 
cartridge. Any values that are statistically deviant from the factory established 
expectation values would cause the test results to be suppressed. Daily monitoring is 
through the use of internal and external electronic simulators. Liquid controls are 
provided for the verification of cartridge lot performance for all newly received cartridge 
lots. 
 
P. Other Supportive Instrument Performance Characteristics Data Not Covered In The 
“Performance Characteristics” Section above: 
 
Q. Proposed Labeling: 
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10. 
 
R. Conclusion: 
The submitted information in this premarket notification is complete and supports a 
substantial equivalence decision. 
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Appendix 1.2 Patient Information Sheet 1.1 25th April 2016 for 
MRAHF study 
 
 
Study Title: Incidence of significant mitral regurgitation in patients presenting with acute heart 
failure. Journey to Tertiary Centre (MRAHF).   
 
Patient Information Sheet 
Dear Patient, 
 
We would like to ask you to take part in our clinical investigation study. Before you decide whether 
you would like to take part it is important that you understand why this research is being done and what 
it will involve. One of our team will go through this information sheet with you and answer any 
questions or concerns you may have. Please ask us if there is anything that is not clear or if you would 
like more information and talk to others if you wish. You will have to decide on the first day of your 
admission to the hospital whether you would like to take part in this study. This information sheet will 
explain the purpose of the study and what will happen to you if you take part.  
Thank you for taking the time to read this. 
 
Part 1 
What is the purpose of the study? 
The purpose of this study is to assess the prevalence of moderate-to-severe Mitral Regurgitation 
(MR), also known as leaky valves in patients presenting to hospital in acute Heart Failure (HF). 
Patients requiring hospital admission. 
 
Why have I been invited? 
You have been asked to participate in this study because you have been admitted to hospital with 
symptoms of heart failure.  
 
Do I have to take part? 
Your participation in this study is completely voluntary.  You do not have to take part. Please take the 
time to read this information sheet carefully and discuss it with relatives, friends. 
 
It is up to you to decide whether or not to take part in this clinical study. If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent form. You will be free 
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to withdraw at any time and without giving a reason. A decision to withdraw at any time, or a decision 
not to take part, will not affect the standard of care you receive. 
 
If you have any questions or concerns about this study, or if you do not fully understand any part of it, 
please ask your research doctor. 
 
What will happen to me if I take part? 
If you agree to take part in this clinical study you will be asked to have a recording of heart sounds with 
a special stethoscope, have a heart scan and a bedside B-type Natriuretic Peptide Blood Test (BNP). 
The level of BNP will be checked using a small device (i-STAT BNP) at the bedside. The BNP test 
results will determine your eligibility for inclusion into this study.  
If your test results indicate elevated BNP level of (≥100 pg/ml) you will undergo special procedure 
called Transthoracic Echocardiography (TTE) for grading of MR severity within 2 days of your 
hospitalisation.  
A transthoracic echocardiogram (TTE) is the most common type of echocardiogram, which is a still or 
moving image of the internal parts of the heart using ultrasound. In this case, the probe (or ultrasonic 
transducer) is placed on the chest or abdomen of the patient to get various views of the heart. 
 
Will expenses be paid? 
We are not anticipating expenses to incur as all the investigations will be completed within current 
hospital admission.   
 
What do I have to do? 
Your participation in the study will last for the time you are in hospital. 
 
You will not be eligible to participate in the study if you have other causes of breathlessness or 
palpitations.  
 
What are the possible disadvantages and risks of taking part? 
Participation involves having a heart scan whilst in hospital and additional skin prick to take blood for 
BNP test. 
 
What are the possible benefits of taking part? 
 
Your participation will be important as it will help us establish whether hospital admissions with heart 
failure are caused with leaky valves. We will also be in a position to find out if assessment of heart 
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sounds on auscultation is good enough to detect valvular problems as well as value of bedside 
assessment of BNP. These tests are not routinely available in current clinical settings. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm you might 
suffer will be addressed. 
 
What will happen if I don’t want to continue in the study? 
You are free to withdraw your participation at any time with no prejudice to your standard of care. We 
will need to use the data collected on you up until the time of your withdrawal.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers who 
will do their best to answer your questions. If you remain unhappy and wish to complain formally, you 
can do this by contacting Patient Advice and Liaison Service (PALS) within the hospital: 
Telephone: 01932 723553 
Email: pals@asph.nhs.uk 
 
Will my taking part in the study be kept confidential? 
Yes. If you consent to take part in the clinical study, any of your medical records may be inspected by 
the company sponsoring the research for purposes of analysing the results. They may also be looked at 
by people from the company and from regulatory authorities to check that the study is being carried out 
correctly. Your name, however, will not be disclosed outside the hospital. The Trust Information 
Governance Policy and Data Protection Act 1998 will be strictly followed. 
We will follow ethical and legal practice and all information which is collected about you during the 
course of the research will be kept strictly confidential. Any information about you which leaves the 
hospital/surgery will have your name and address removed so that you cannot be recognised from it. 
 
What will happen to the results of the research study? 
After the end of this clinical study the results will be analyzed and published in medical scientific 
journals. As all information that is available from you is collected anonymously you will of course not 
be identified in any report or publication.  
The study outcome will be posted on the Trust research and development website, which is located at: 
http://www.ashfordstpeters.nhs.uk/quality/research . Participants will be provided with the web link to 
access the information. 
 
Who is organising and funding the study? 
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This study has been funded by Abbott Vascular Company, and sponsored by Metanoic Health Ltd.  
 
Who has reviewed the study? 
The formal review by R&D committee took place on 15.10.2015. Similar detailed review took place at 
ABBOTT Laboratories Abbott Vascular. Both panels have come to a conclusion that this is an 
innovative and interesting research project. This study will also be reviewed and approved by Research 
Ethics Committee (REC) [REC Name: North of Scotland 2]. 
  
Contact for Further Information 
Please feel free to ask any question you have about this study. If you have a concern about any aspect 
of this study, you should ask to speak to the researchers who will do their best to answer your questions.  
Contact Details: 
Name: Dr A. Baltabaeva 
Email: Aigul.Baltabaeva@asph.nhs.uk  
Tel No.: 01932723534 
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Appendix 1.3 Abbott POCT BNP user guide 
 
 
 Intended Use  
The i-STAT® BNP test is an in vitro diagnostic test for the quantitative measurement of B-type 
natriuretic peptide (BNP) in whole blood or plasma samples using EDTA as the anticoagulant. BNP 
measurements can be used as an aid in the diagnosis and assessment of the severity of congestive 
heart failure.  
Method Explanation  
The i-STAT BNP test cartridge uses a two-site enzyme-linked immunosorbant assay (ELISA) 
method. Antibodies specific for BNP are located on an electrochemical sensor fabricated on a silicon 
chip. Also deposited in another location on the sensor silicon chip is an antibody/alkaline phosphatase 
enzyme conjugate specific to a separate portion of the BNP molecule. The whole blood or plasma 
sample is brought into contact with the sensors allowing the enzyme conjugate to dissolve into the 
sample. The BNP within the sample becomes labeled with alkaline phosphatase and is captured onto 
the surface of the electrochemical sensor during an incubation period of approximately seven minutes. 
The sample is washed off the sensors, as well as excess enzyme conjugate. Within the wash fluid is a 
substrate for the alkaline phosphatase enzyme. The enzyme bound to the antibody/antigen/antibody 
sandwich cleaves the substrate releasing an electrochemically detectable product. The electrochemical 
(amperometric) sensor measures this enzyme product which is proportional to the concentration of 
BNP within the sample.  
Contents  
Each i-STAT BNP cartridge provides a sample inlet, sensors to detect the BNP as described above, 
and all the necessary reagents needed to perform the test. The cartridge contains a buffer and 
preservatives. A list of reactive ingredients is indicated below:  
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Metrological Traceability 
The i-STAT System test for B-type natriuretic peptide (BNP) measures BNP amount-of-substance 
concentration in plasma or the plasma fraction of EDTA anticoagulated whole blood (units of measure: 
pg/mL or ng/L) for in vitro diagnostic use. BNP values assigned to i-STAT’s controls and calibration 
verification materials are traceable to i-STAT’s working calibrator prepared from synthetic BNP 
(Peptide International, Louisville, KY, Cat# 4212v). i-STAT System controls and calibration 
verification materials are validated for use only with the i-STAT System and assigned values may not 
be commutable with other methods. Further information regarding metrological traceability is available 
from Abbott Point of Care Inc. 
Reportable Range  
The i-STAT BNP test will report 15 to 5000 pg/mL (ng/L). Samples below the reportable range will 
yield “ <15 pg/mL” on the analyzer display screen. Samples above the reportable range will yield 
“>5000 pg/mL”.  
Reference Range 
Whole blood and plasma samples from 165 apparently healthy donors were assayed. The upper 95% 
reference range was determined to be 50 pg/mL (ng/L).  
Clinical Significance 
Congestive heart failure (CHF) is a complex clinical syndrome resulting in decreased cardiac output 
that is insufficient to meet the body’s metabolic needs.1 It may result from dysfunction of either 
ventricle in systole (contraction), diastole (relaxation) or both.2 The most common underlying cause of 
CHF is coronary artery disease. Other causes include: hypertension, myocarditis, valvular heart disease 
and idiopathic (unknown).3  
Common symptoms include: paroxysmal nocturnal dyspnea (PND), orthopnea, dyspnea on exertion 
(DOE), nocturnal cough and peripheral edema.2 Clinical signs include elevated jugular venous 
pressure, rales on lung auscultation, the presence of a third heart sound and peripheral edema.2 
Unfortunately, these signs and symptoms are variable, and when present, non-specific as other clinical 
entities such as chronic obstructive pulmonary disease can produce a similar clinical picture.4 
B-type natriuretic peptide (BNP) is one of a family of structurally similar peptide neurohormones that 
also includes atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) whose function is to 
regulate blood pressure, electrolyte balances, and fluid volume. ANP is stored in granules within the 
atria and released rapidly in response to atrial stretch. In contrast, BNP is synthesized, stored, and 
released primarily by the ventricular myocardium in response to volume expansion and pressure 
overload.1 Pre-pro-BNP (134 amino acids) is synthesized in the cardiac myocytes and is processed to 
a pro-BNP (108 amino acids) precursor molecule. The pro-BNP is then subsequently cleaved into the 
physiologically active BNP (32 amino acids) and an N-terminal fragment referred to as N-Terminal 
pro-BNP (76 amino acids).3 
Numerous clinical trials suggest the potential clinical usefulness of plasma BNP in: 
1. the diagnosis of dyspnea and CHF4,5  
2. the detection of left ventricular systolic and diastolic dysfunction6,7  
3. the prognosis of patients with CHF and acute coronary syndromes8,9 and  
4. therapy monitoring for CHF patients10,11  
Multiple studies establish the value of BNP for facilitating the diagnosis of CHF in patients presenting 
with dyspnea.12 Davis et al. measured levels of ANP and BNP in 52 patients presenting with acute 
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dyspnea.12,13 They found that admission plasma BNP concentrations more accurately reflected the 
final diagnosis than did ejection fraction (EF) levels or ANP plasma concentrations. Morrison et al. also 
showed that rapid testing of BNP could help differentiate pulmonary from cardiac etiologies of 
dyspnea.4 Furthermore, the Task Force of the European Society of Cardiology for the Diagnosis and 
Treatment of Chronic HF has included the use of natriuretic peptide (e.g., BNP) testing along with 
electrocardiography and chest x-rays in their guidelines for the diagnosis or rule out of HF.14 
The Breathing Not Properly study, a 1586 patient multinational prospective study, validated the clinical 
utility of rapid measurement of BNP, used in conjunction with other clinical information, for the 
diagnosis or exclusion of CHF in the emergency department.15 BNP levels were much higher in 
patients with subsequent CHF than in those with non-cardiac dyspnea (675 pg/mL vs 110 pg/mL). A 
BNP cutoff value of 110 pg/mL had a sensitivity of 90% and a specificity of 76% for differentiating 
CHF from other causes of dyspnea, and a cutoff value of 50 pg/mL had a negative predicative value of 
96%. There was a 43% indecision rate among physicians in the ED trying to make a diagnosis in patients 
with dyspnea. Had BNP levels been available to those physicians, the indecision rate would have been 
reduced to 11%. In multivariate analysis, BNP levels always contributed to the diagnosis, even after 
consideration of the history and physical exam.  
BNP levels are also raised in patients with left ventricular dysfunction, and the values can be used to 
assess the severity of CHF, as they correlate with both New York Heart Association (NYHA) functional 
class and patient prognosis.16  
Steg et al. indicated in 2005 that BNP measurement is consistently superior to a single 
echocardiographic determination of left ventricular EF in identifying patients with CHF, regardless of 
the threshold value.16 Two-dimensional echocardiography was less sensitive than a single 
determination of BNP in diagnosing CHF. However, the two variables have marked additive diagnostic 
value and when combined have a much improved accuracy compared to either method alone. This 
strongly suggests that, where applicable, they should be used together.16 
Studies also indicate that BNP also has a burgeoning role in the prognostic assessment of patients with 
heart failure.17 BNP is a powerful prognostic indicator for patients with CHF at all stages of the disease 
and seems to be a better predictor of survival than many traditional prognostic indicators, such as New 
York Heart Association class, serum creatinine values, and possibly left ventricular ejection fraction.18 
The relative risk of death increases by about 35% for each 100 pg/mL increase in BNP in patients with 
CHF.18 Raised BNP values also predict the survival in patients not known to have CHF, with the risk 
doubled in patients with a BNP value >20 pg/mL.18  
BNP has also been shown to predict morbidity and mortality in other cardiovascular conditions, such 
as acute coronary syndromes and acute myocardial infarction.19 ACS patients with increased BNP 
levels have a higher rate of cardiac complications and higher mortality post myocardical infarction. 
When a panel of neurohormones (including BNP and catecholemines) was measured one to four days 
after acute infarction, BNP was the only independent predictor of late ejection fraction (EF <40%) 
and was the most powerful predictor of death within four months after infarction.20 In 2,525 AMI 
patients, the magnitude of BNP elevation correlated with mortality, heart failure, and recurrent 
infarction at both 30 days and 10 months.8 A strategy of combining EF and BNP improved risk 
stratification beyond using either alone.21 
EXPECTED VALUES 
Non-heart Failure Population 
Plasma samples from 890 individuals (465 females, 425 males) who had not been diagnosed with heart 
failure were tested with the AxSYM® BNP assay. This population included non-hospitalized patients 
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with renal disease (not on dialysis), diabetes, hypertension and chronic obstructive pulmonary disease. 
BNP levels for the patients with renal disease, diabetes, hypertension and chronic obstructive 
pulmonary disease were not statistically different from the population of apparently healthy individuals. 
The data from this study are summarized in the following table.* 
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Heart Failure Population 
Plasma samples from 693 patients with diagnosed heart failure (231 females, 462 males) were tested 
with the AxSYM BNP assay. All patients in this population were categorized according to the 
functional classification system published by the New York Heart Association (NYHA).22 This system 
divides heart failure patients into one of four categories of increasing disease progression (classes I to 
IV) based upon a subjective assessment of the patient’s clinical signs and symptoms. The data from 
this study are summarized in the following table.* 
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A box and whiskers plot of the clinical study population, broken down by NYHA classification, is 
presented in the following graph. The dashed line represents 100 pg/mL, the suggested decision 
threshold for the AxSYM BNP assay. In support of previous literature reports,23 these data show a 
progressive increase in BNP concentrations with increases in NYHA classifications. This analysis 
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indicates that BNP measurements provide objective information for use in the assessment of the severity 
of heart failure. 
 
Data from the above clinical study were used to generate the Receiver Operating Characteristic 
(ROC) curve of BNP decision thresholds versus clinical sensitivity and clinical specificity as shown 
in the following graph. At a decision threshold of 100 pg/mL, the BNP assay demonstrated a clinical 
sensitivity and specificity of 74.2% and 91.5%, respectively, in this study. The area under the curve 
(AUC) is 0.90 (0.86 to 0.92, 95% CI). 
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The i-STAT BNP Calibrators are traceable to an internal reference standard that has been prepared 
gravimetrically with synthetic BNP. The internal reference standard underwent a one-time value 
assignment to align with the ARCHITECT BNP assay with a decision threshold of 100 pg/mL. 
An age-matched analysis of the heart failure and non-heart failure populations was performed based on 
the data published by the American Heart Association in the 2000 Heart and Stroke Statistical Update24 
and according to the age structure of the United States population.25 The age distributions in the 
intended use population are approximately as follows: individuals less than 45 years old comprise 9%, 
individuals 45-54 years old comprise 11%, individuals 55-64 years old comprise 22%, individuals 65-
74 years old comprise 26%, and individuals 75 years and older comprise 32%. The resulting combined 
AUC is 0.87 (0.85 to 0.90, 95% CI). 
The clinical sensitivity and specificity using a decision threshold of 100 pg/mL is presented in the 
following table. 
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Performance Characteristics 
Precision data were collected as follows: Duplicates of each control were tested daily for a period of 20 
days for each of 3 lots of cartridges, resulting in a total of 434 replicates. The average statistics are 
presented below. 
Whole blood imprecision data were collected as follows: whole blood samples from 5 healthy donors 
were spiked to low, intermediate and high BNP concentrations affording 15 samples, each of which 
was measured in 10 i-STAT BNP cartridges from a single cartridge lot; three lots of cartridges were 
employed. The mean within-sample BNP concentration ranged from 84 – 3925 pg/mL and the within-
sample imprecision (%CV) ranged from 3.4 to 9.4%; the average BNP concentration and imprecision 
were 1464 pg/mL and 6.5% respectively.  
Method comparison data were collected using CLSI guideline EP9-A2.26 Venous blood samples were 
collected in EDTA evacuated tubes and analyzed in duplicate on the i-STAT System. A portion of the 
specimen was centrifuged and the separated plasma was analyzed in duplicate on the i-STAT System 
and on the comparative method within 1 hour of collection. Deming regression analysis27 was 
performed on the first replicate of each sample. In the method comparison table, n is the number of 
specimens in the first data set, Sxx and Syy refer to estimates of imprecision based on the duplicates of 
the comparative and the i-STAT methods respectively. Sy.x is the standard error of the estimate, and r 
is the correlation coefficient.* Method comparisons may vary from site to site due to differences in 
sample handling, comparative method calibration and other site specific variables. 
The i-STAT BNP assay is designed for quantitation of BNP in whole blood or plasma samples. A series 
of samples for comparison of whole blood and plasma results was prepared from blood drawn from 25 
nominally healthy donors. For each donor, whole blood (unspiked) and plasma obtained via 
centrifugation were first run simultaneously in duplicate i-STAT BNP test cartridges. A whole blood 
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sample was then spiked with BNP and, following a short equilibration period, a plasma sample was 
prepared by centrifugation and the whole blood and plasma samples were run simultaneously in 
duplicate. Three lots of i-STAT BNP test cartridges were employed with a single lot being used for 
each donor. The results of Deming regression of whole blood vs plasma (x-axis) correlation data are 
summarized below for all samples ( [BNP] < 5000 pg/mL) and separately for samples with [BNP] < 
1000 pg/mL. 
*The usual warning relating to the use of regression analysis is summarized here as a reminder. For 
any analyte, “if the data is a narrow range, the estimate of the regression parameters are relatively 
imprecise and may be biased. Therefore, predictions made from estimates may be invalid”.
26 
The 
correlation coefficient, r, can be used as a guide to assess the adequacy of the comparative method 
range in overcoming the problem. As a guide, the range of data can be considered adequate if r>0.975. 
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Analytical Sensitivity 
The limit of blank (commonly termed analytical sensitivity) was estimated at 14 pg/mL by calculating 
two times the total imprecision determined using a BNP-depleted plasma material (measured to be <5 
pg/mL BNP) over a 20-day imprecision study using three separate lots of BNP cartridges and six i-
STAT 1 analyzers. 
Analytical Specificity 
The BNP method is specific for the B-type natriuretic peptide. The following muscle proteins were 
tested at both 1000 pg/mL and 20000 pg/mL concentrations and found to have no detectable 
crossreactivity for BNP: ANP, CNP, and N-terminal pro-BNP. 
Recovery 
The dilution linearity of the i-STAT BNP test was investigated using EDTA whole blood and plasma 
samples derived from three separate donors. For each donor, the original BNP negative sample and a 
BNP spiked sample were prepared. This process yielded three BNP positive whole blood samples that 
were then assayed in duplicate for each of three separate i-STAT BNP cartridge lots. These whole 
blood samples were then diluted using an equal mass of the original unspiked whole blood and 
assayed in duplicate. From this whole blood data, the BNP recovery was calculated. 
 
The plasma derived from these three donors was combined in all pairwise combinations in equal 
volumes. These combinations were then assayed in duplicate for each of three separate i-STAT BNP 
cartridge lots. The BNP recovery for each pair was calculated using the average of the six results. 
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A plasma sample was spiked with BNP to a value of approximately 5000 pg/mL and the 
concentration was determined by duplicate measurements with i-STAT BNP test cartridges; the result 
was found to be within 200 pg/mL of the intended target. This sample was subjected to a series of 
dilutions with fresh, unspiked plasma in order to prepare a range of concentrations. The concentration 
of each sample/dilution was calculated based on the measured concentration of the initial solution and 
the dilutions performed. The diluted samples were then measured in i-STAT BNP test cartridges (N = 
6-10). The procedure was repeated with a whole blood sample. The results of these experiments are 
summarized in the following table. 
 
Test Limitations 
The frequency of suppressed results is affected by atmospheric pressure. Suppressed result rates may 
increase with higher elevations (decreased barometric pressure) and may become persistent if testing is 
performed at more than 7500 feet above sea level. Where unavailability of results is unacceptable, i-
STAT recommends having an alternate test method available.  
Samples from patients who have been exposed to animals or who have received therapeutic or 
diagnostic procedures employing immunoglobulins or reagents derived from immunoglobulins may 
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contain antibodies, e.g., HAMA or other heterophile antibodies, which may interfere with 
immunoassays and produce erroneous results.28-34 The generation of potentially interfering antibodies 
in response to bacterial infections has been reported.28 While this product contains reagents that 
minimize the effect of these interferents and QC algorithms designed to detect their effects, the 
possibility of interference causing erroneous results should be evaluated carefully in cases where there 
are inconsistencies in the clinical information. 
Partially clotted samples can result in elevated BNP readings above the reference range, as well as 
quality check codes. To prevent this from occurring, upon drawing the whole blood sample into an 
EDTA collection tube, the sample should be inverted gently at least 10 times to ensure even dissolution 
of the anticoagulant.  
Grossly hemolyzed samples can cause a decreased alkaline phosphatase activity, resulting in decreased 
detection of BNP, increased assay backgrounds, and/or quality check codes. 
Hematocrits in the range of 0-60% PCV have been demonstrated not to affect results. Samples with 
hematocrit levels above this range have demonstrated increases in the test imprecision and quality check 
codes. 
The analyzer must remain on a flat surface with the display facing up during testing. Motion of the 
analyzer during testing can increase the frequency of suppressed results or quality check codes. A level 
surface includes running the handheld in the downloader/recharger. 
Measurements of BNP should occur prior to nesiritide (Natrecor) recombinant BNP treatment, or 2 
hours post-treatment.35 
Interference Testing 
The following substances were found to have no significant effect (less than 10%) on the BNP method, 
when added to a plasma pool containing approximately 1000 pg/mL of B-type natriuretic peptide at the 
concentrations indicated: 
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Interference studies were based on CLSI guideline EP7-A.36 
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Appendix 1.4 Transthoracic Echocardiography Image 
Acquisition Protocol 
 
Echo image acquisition protocol: Parasternal long axis (PLAX) view: 
▪ 2d loop at 50-70/second frame rate. 
▪ 2d loop with colour Doppler. 
▪ 2d loop with colour tissue Doppler at >120/sec frame rate. 
▪ M mode of aortic root/left atrium. 
▪ M mode of left ventricle. 
▪ 2d loop of aortic root for left ventricular outflow tract dimension. 
▪ 2d loop RV inflow view. 
▪ 2d loop RV inflow view with continuous wave Doppler. 
 
Parasternal short axis (PSAX) view: 
 
▪ 2d loop at aortic valve level. 
▪ Pulsed wave of right ventricular outflow tract. 
▪ 2d loop of mitral valve. 
▪ 2d loop with colour Doppler at mitral valve level >120/second frame rate. 
▪ 2d loop at papillary muscle level at 50-70/second frame rate. 
▪ 2d loop at mid left ventricular level. 
▪ 2d loop at apical left ventricular level. 
 
Apical four chamber (A4C) view: 
 
▪ 2d loop at 50-70/second frame rate focusing on all 4 chambers. 
▪ 2d loop with colour flow Doppler on all 4 chambers. 
▪ 2d loop zoom at 50-70/second frame rate focusing on left and right ventricles. 
▪ 2d loop zoom with colour tissue Doppler at >120/sec frame rate focusing on left and 
right ventricles. 
▪ Pulsed tissue Doppler of the lateral mitral annulus. 
▪ Pulsed tissue Doppler of the septal mitral annulus. 
▪ Pulsed tissue Doppler of the right ventricular free wall annulus. 
▪ 2d with colour flow Doppler focusing on mitral regurgitation – assess proximal 
isovelocity surface area, vena contracta and colour jet in left atrium. 
▪ Zoomed 2d loop with colour flow Doppler focusing on mitral regurgitation - assess 
proximal isovelocity surface area, vena contracta and colour jet in left atrium. 
▪ 2d loop with colour flow Doppler focusing on tricuspid regurgitation. 
▪ 2d loop at >120/sec frame rate including both atria and pulmonary veins. 
▪ Pulsed Doppler of the mitral inflow. 
▪ Pulsed wave Doppler of the right upper pulmonary vein. 
▪ Continuous wave Doppler of the mitral regurgitation jet. 
▪ Pulsed Doppler of the left ventricular outflow. 
▪ Continuous wave Doppler of the aortic outflow. 
▪ Pulsed Doppler of the tricuspid inflow. 
▪ Continuous wave Doppler of the tricuspid regurgitation jet. 
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Apical two chamber (A2C) view: 
 
▪ 2d loop at 50-70/second frame rate looking at left atrium and left ventricle. 
▪ 2d loop with colour flow Doppler. 
▪ 2d loop at 50-70/second frame rate focusing on left ventricle. 
▪ 2d loop with colour tissue Doppler at high frame rate focusing on left ventricle. 
▪ 2d loop zoom at high frame rate on left atrium and pulmonary veins. 
▪ 2d loop with colour flow Doppler focusing on mitral regurgitation – focus on 
proximal isovelocity surface area, vena contracta and colour jet in left atrium. 
▪ Zoomed 2d loop with colour flow Doppler focusing on mitral regurgitation – focus on 
proximal isovelocity surface area, vena contracta and colour jet in left atrium. 
 
Apical long axis (ALAX) (or three chamber) view: 
 
▪ 2d loop at 50-70/second frame rate. 
▪ 2d loop at 50-70/second rate focusing on left ventricle. 
▪ 2d loop with colour tissue Doppler. 
▪ 2d loop with colour flow Doppler focusing on mitral regurgitation - focus on proximal 
isovelocity surface area, vena contracta and colour jet in left atrium. 
▪ Zoomed 2d loop with colour flow Doppler focusing on mitral regurgitation - focus on 
proximal isovelocity surface area, vena contracta and colour jet in the left atrium. 
 
Subcostal (SC) view: 
 
▪ IVC dimension and sniff test with M-mode. 
▪ 2d loop of subcostal long axis view. 
▪ 2d loop of subcostal short axis view at papillary muscle level. 
▪ 2d loop of subcostal short axis view at aortic valve level. 
 
 
Qualitative assessment of primary vs secondary aetiology of mitral regurgitation if present. 
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Appendix 1.5 Cardiac Marker Quality Control Information 
 
Cardiac Marker & Endocrinology 
 
Quality Controls 
 
cTnl Control Level 1 06P1709 
cTnl Control Level 2 06P1710 
cTnl Control Level 3 06P1711 
BNP Control Level 1 06P1705 
BNP Control Level 2 06P1706 
BNP Control Level 3 06P1707 
BhCG Control Level 1 05P5901 
BhCG Control Level 2 05P5902 
BhCG Control Level 3 05P5903 
 
Storage: Fridge 2-8C or Room Temperature 4 Hours unopened/recapped.  
Equibriation before Use: 15 Minutes at room temperature.  
 
1. Set up the Analyser – Turn the Analyser on, press the Menu key for the Administration menu, 
then select number 3 for Quality Tests, then 1 for Control, then scan or enter your Operator ID 
(you can just enter through this), scan the bar code on the vial of the QC for the control lot 
number, the scan the bar code on the cartridge pouch for the cartridge lot number.  
 
2. Thoroughly mix by gently swirling the bottle, avoid foaming the sample.  
 
3. Dispense a drop of the sample directly from the vial into the cartridge  
 
4. Insert cartridge into the i-STAT.  
 
5. Check values against Value Assignment Sheet for Control Lot Number.  
 
Value Assignment Sheets located:  
https://www.abbottpointofcare.com/support/value-assignment-sheets 
 
